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Non-Q Myocardial Infarction (NQMI) is considered to be an unstable 
condition with increased risk of recurrent infarction. Thus 
aggressive approaches in management have been recommended. How-
ever, there is no firm evidence that this strategy influences the 
course of NQMI patients favourably. 
To determine the experience at Groote Schuur Hospital all patients 
admitted to CCU from 1990 to 1993 with NQMI were analysed 
retrospectively especially with regard to management and outcome. 
One-hundred and eighty-one patients were admitted with NQMI. 
Seventy-eight percent (141) remained cardiovascularly stable in the 
early period after the index event; 51% (93) underwent cardiac 
catheterisation during that hospital admission and revascu-
larization was performed in 29% (52). 
There were 2 deaths during the initial hospital admission, both 
after surgical revascularisation . 
At one year the cardiac mortality was 7%. There were 23 cardiac 
deaths in all. Early readmission for symptomatic recurrence of 
ischaemia was identified as a risk factor (p=0.004). 
By one year 51% of patients had developed recurrence of symptomatic 
ischaemia, the majority (62%) in the first 3 months after the 
primary admission. There was a significantly reduced recurrence in 
those patients managed actively (i . e. cardiac catheterisation 




CONCLUSION: NQMI managed in the Groote Schuur Hospital CCU showed 
low mortality rates (both early and at one year). Retrospective 
analysis appear to relate active interventional management with a 
reduction in overall recurrence of symptomatic ischaemia, the 
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II PROLOGUE 
NON-Q WAVE MYOCARDIAL INFARCTION IN PERSPECTIVE 
Acute myocardial infarction (AMI) is important as a major common 
cause of death and disability in the Western world. In South 
Africa, mortality due to ischaemic heart disease (!HD) forms the 
highest proportion of all death due to natural causes 
(Figure 1). (l) The majority of these deaths due to IHD are as a 
result of AMI (51% in 1992). (2 ) 
Statistics from 1985 to 1992 show a decline in mortality rates from 
IHD in South Africa, in keeping with a world-wide tendency. (3 ) (4 ) 
The decline, however, has not been seen amongst Blacks. 
Percentage decline in mortality rates from IBD* 1985-1989(3): 
* 
** 





IHD mortality= sum of ICD codes 410-414 (9th Edition) i.e. 
AMI, other acute and subacute forms of IHD, old myocardial 
infarction, angina pectoris, other forms ·of chronic IHD. 
As from 1991, statistical information regarding recorded 
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Figure No.1: Principal causes of death in 1992 in males 
and females. (Central Statistical Service)<1> 
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In absolute numbers, over the period 1983 to 1988 there has been a 
38.8% increase in the number of reported IHD deaths amongst 
Blacks. (S) (G) This trend probably still persists as it reflects 
the considerable increases in IHD-risk e.g. hypertension and stress 
that are known to occur with the process of urbanisation.(?) 
Western Cape mortality data shows that IHD ranks first, with 11.8% 
of all deaths. This is the highest percentage of death in this 
category for all the provinces. (8) 
Non-Q wave myocardial infarction (NQMI) forms about 20-40% of all 
infarcts. (9 ) (lO) Thus, as a major group, NQMI is important and 
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This includes a thorough literature review of non-Q myocardial 
infarction detailing the origin of the term, its value and 
validity, pathogenesis. 
1. TRANSMtJRAL / NONTRANSMtJRAL MYOCARDIAL INFARCTIONS 
Modern, evidence-based medicine is based on patho-physiological 
principles. Since the advent of these, attempts have been made to 
describe or give a sound basis to various observations in every 
field of medicine. 
Likewise with myocardial infarction (MI), an obviously non-uniform 
or inhomogeneous condition with various causes, presentation and 
possible lethal outcomes, currently available pathological and 
physiological tools were used to account and to predict for this 
observed inhomogeneity. Thus, it is not surprising that the two 
most solid and objective modes or types of findings then available 
viz. 1) postmortem/pathological, and 2) electrophysiological data 
were used in the earlier part of this century and that some link 
between these two types of data would be made. 
Pathology (postmortem studies) showed that MI could be divided into 
transmural and nontransmural (or subendocardial). This division 
was strengthened by findings that nontransmural infarcts occurred 
frequently in severely narrowed, but still patent coronary arteries 
or resulted from total thrombotic occlusion that had undergone 
early spontaneous thrombolysis(ll) (l2 ). On the other hand, 
electrocardiographic (ECG) observation noted that some myocardial 
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infarcts were associated with pathological Q waves and others not. 
The now discounted incorrect concept of the subendocardium being 
electrically silent was used as evidence for nontransmural or 
subendocardial infarcts not displaying Q waves. (l3} Thus a link 
had been made. Numerous studies resulted, all differentiating 
between transmural and nontransmural MI on the basis of ECG data 
that did not in fact acurately reflect the pathological facts. 
Over-reliance and over-interpretation (and perhaps false claims} 
followed this mistaken belief that the ECG, the most easily 
reproducible test then available, reflected the anatomy of the 
myocardial infarct. 
2. Q AND NON-Q =f= TRANSMURAL AND NONTRANSMURAL MI 
The term, Q-wave myocardial infarction (QMI} has been used with the 
implication that Q waves represent through-and-through endocardial 
to epicardial necrosis. QMI was shown to be associated with larger 
infarcts and was assumed by some therefore, to be transmural. 
However, numerous studies show that a poor correlation exists 
between the extent of necrosis into the thickness of the 
ventricular wall and the presence or absence of Q waves. (l3} (l4 } 
Despite this, the terms Q wave and non-Q wave myocardial infarction 
(NQMI}, first coined in a letter, (l5} were taken up rapidly and 
preferentially by clinicians and investigators. 
Although Q and NQMI are often used to refer to a transmural and 
nontransmural MI, there is no anatomic evidence to justify this 
distinction. A correlation study of ECG and pathological findings 
in 100 cases of Q and NQMI was performed by Antaloczy et al. (16) 
At autopsy, 55 cases were transmural and 45 subendocardial. 
18 
Pathological Q waves appeared in 67% of the cases of transmural 
infarct and 30% of subendocardial MI. In transmural infarcts, the 
ratio of QMI to NQMI was 2:1. In subendocardial infarcts just the 
opposite was observed. Therefore, it is not possible to 
distinguish with certainty between subendocardial and transmural MI 
on the basis of the ECG. QMI as 'transmural' and NQMI as 
'subendocardial', do not correspond to pathological evidence. 
Although it may be inappropriate to assess the validity of ECG 
findings by means of postmortem anatomy (which represents an 
extreme stage of Ischaemic Heart Disease (IHD) with old or recent 
MI), other studies support the view that as markers of transmural 
extent of infarction, Q waves are neither sensitive nor specific. 
Furthermore, mapping studies of depolarisation sequences in the 
human heart show late activation of the lateral and posterobasal 
walls (<70ms after the earliest ventricular sites of excitation) . 
Thus transmural acute myocardial infarction (AMI) may result in no 
Q wave genesis owing to the late activation sequence. This was 
shown in a study, by Landzberg, of 51 patients with total occlusion 
of the circumflex coronary artery, where only 14 developed Q waves 
or ECG. (l?) 
As will be shown in the next section, significant differences exist 
between QMI and NQMI. It is of little consequence to the physician 
managing patients, whether the ECG description also accurately 
defines groups that differ anatomically with regard to the 
thickness of the injured myocardial wall. (lB) Terms such as 
transmural, nontransmural and subendocardial, should be left to the 
pathologist. Thus, it has been suggested that the description of· 
19 
MI based on ECG findings, be confined to what is actually observed 
on the ECG - i.e . • Q wave or non-Q wave MI. (l9 ) 
Review of past studies have shown that the differences between what 
was then called transmural and nontransmural MI are similar to 
those between Q and NQMI. (20) The criteria for the 2 groups, 
transmural and nontransmural, closely resemble modern day criteria 
for Q and NQMI. Thus, many studies on subendocardial MI are 
extrapolated now to include or be equivalent to NQMI. 
3. DIFFERENCES BETWEEN Q AND NON-Q MYOCARDIAL INFARCTION 
Since pathological Q waves on ECG are poor markers for transmural 
myocardial infarction (being neither sensitive nor specific), the 
usefulness of classification of infarcts by ECG into NQ and Q is 
therefore dependent on other differences. 
Awareness of these differences is important because they determine 
ultimate management of patients with NQMI who form a not 
insubstantial proportion of all infarcts (20-40%). (9) (lO) 
Differences between NQMI and QMI are: 
A. pre-infarct 
B. related to infarct 
B. post-infarct 
(Apparent discrepancy among results of studies analysing those 
differences may be related to the inclusion of patients with 
multiple MI. The occurrences of NQMI as a first cardiac event 
20 
differs prognostically from its occurrence as a recurrent cardiac 
event, as reported by Nicod et al. (2l) When assessing differences 
between NQ and QMI, one must determine whether these refer to first 
MI and also the methods of enrolling NQMI patients (inclusion 
criteria) e.g. : 
i) all those who do not develop Q waves by discharge; 
versus 
ii) those on presentation who have ECG changes limited to 
showing ST segment depression or T wave abnormalities. 
3A. PRE-INFARCT DIFFERENCES 
QKI NQMI 
Gender :!~~~~sp1~~?1~~?~4) 
Age Older Younger(25) (13) (26) 
Previous MI Infrequent Frequent (43-46%) (27) (21) (22-224%) 
Preceding 
(27) (29) angina Less frequent More frequent 
Preceding medi- Atrial arrhythmias and 
cal conditions ~~~~:~t1~~t~~s)1~fr 
Presenting Discrete onset Indis1j5fe/intermittent symptoms onset 
Presentation: 
Absent( 3l) Circadian Present 
rhythm 
21 

































Lower levels( 27 ) 
Earlier peaks(33) 
Smaller (27 ) (34 ) (35 ) 






depression(l3 ) (37 ) 
ST segment elevation 
T inversion 
Patent (33) (38) (39) 





The subanalysis of the TIMI II Study, which included only 
patients with ST segment elevation, showed there were less 
anterior MI amongst patients with first NQMI, as compared to 
first QMI (p<0.01). (22 ) This is in contrast to studies 
including all types of infarcts which suggested that the 
anterior area seems to be the predilection site of NQMI where 
it could be localised. (l3 ) 
Serum Enzymes - CPIC 
In NQMI, the creatine phosphokinase (CPK) levels are 
lower. (27 ) Also, peak CPK levels are attained earlier in 
NQMI: 
NQMI (15 hours after the event) versus QMI (27 hours). (33) 
This may represent earlier reperfusion and/or greater 
collateral supply. 
3) Infarct Size 
Based on peak CPK( 27 > and CPK-MB isoenzyme/body mass 
index( 34 >, NQMI infarcts appear to be smaller than QMI. In 
QMI, the volume of necrosis is usually greater than NQMI. The 
previous assumption that OMI, being larger, was therefore 
transmural, should be changed. Rather, it should be 
considered more extensive in any 3-dimensional way. The 
appearance of Q waves on the ECG is probably dependent on the 
amount and site of myocardial necrosis. The amount of 
myocardium destroyed in NQMI is presumably insufficient for 
abnormal Q waves to evolve. (35) 
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4) 
A smaller area of acute infarction damage is also suggested by 
lower wall motion abnormality scores. (42 ) 
Left Ventricular Function 
Higher LVEF is seen among patients with NQMI than amongst 
those with QMI. 
For example: NQMI 50.6% versus QMI 43.7% (p<0.001) (34 ) 
In the TIMI II Study subanalysis of patients with infarcts 
pre-discharge resting LVEF was more likely to be normal in the 
NQMI patients (p<0.01). (22) 
5) Biochemical Differences: - TPA and PPAI 
In a study examining the plasma levels of tissue plasminogen 
activor (TPA) antigen and plasminogen activator inhibitor 
activity in NQ and QMI patients before thrombolytic therapy, 
the mean plasma TPA antigen was similarly elevated in both 
types of infarcts. The mean level of plasma plasminogen 
activator inhibitor (PPAI) activity was lower in patients with 
NQMI: 
NQMI 7.3IU/ml versus QM! 17.lIU/ml (p<0.01) (36 ) 
This may be related to the higher patency rate of infarct 
related arteries (IRA) in NQMI. 
6) Histology 
Freifeld et al. reported a higher incidence of histologic 
evidence of prior infarction among patients with a fatal NQMI 
24 
than among those with a fatal QMI. (43 ) Contraction band 




Initial ECG differences between Q and NQMI exist. (l3 ) 
Analysis of initial ECGs of 440 patients( 37 ) showed: 
NQMI QMI 
ST segment elevation 38% 72% (p<0.001) 
T inversion 36% 17% (p=0.03) 
Signal Averaged ECG 
Late potentials noted on signal averaged ECG may adversely 
affect prognosis following acute MI. Kuchar showed that NQMI 
was a predictor of loss of these late potentials if they 
developed post AMI. (44 ) 
9) Cardiac Catheterisation 
A study showing patients with NQMI to have lower LV end 
diastolic pressures: 
NQMI 11.7 ± 2.7rnmHg versus QMI 16.1 ± 5.9rnmHg (p<0.02) (l8), 
is in keeping with the smaller infarct size and better LVEF in 
NQMI noted previously. 
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10) Coronary Anqioqraphic Differences Between O and NOMI 
a) Multi-vessel involvement: 
b) 
Ogawa's study of the clinical and angiographic features of 119 
patients with NQMI and 354 with QMI concluded that: 
73% of NQMI patients had multiple vessel stenosis on 
angiography versus 51% of QMI patients. {p<0.05) <27 > 
Other studies have shown equal numbers of diseased vessels in 
both NQ and QMI patients. (33) (22) 
Infarct-related artery (IRA) occlusion/patency: 
Complete occlusion of IRA varies in studies: 
NQMI 19-51% versus QMI 79-80%. (33) (38) (39) 
Occlusion rates also increase significantly and progressively 
with time. Comparison of coronary angiographic findings 
during the first 6 hours of either NQ or QMI showed complete 
occlusion of the IRA: 
NQMI 11% versus QMI 91% {p0.0001). <40) 
Whereas, angiography up to 3 months after the index event 
showed: 
NQMI 23% versus QMI 54% {p<0.05). (45) 
Thus, even without thrombolysis, there is a high incidence of 
patent IRA in patients with NQMI. (46) 
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c ) 
Analysis of IRA patency after thrombolysis was performed in 
the TIMI II Study in which patients with ST segment elevation 
were given TPA. IRA patency (TIMI flow grade 2 or 3) occurred 
in: 
NQMI 88.8% versus QMI 83.8% (p0.002), 
and complete IRA reperfusion (TIMI flow grade 3) occurred in: 
NQMI 72.2% versus QMI 62.6% (p<0.01). (22 ) 
Collaterals: 
In the angiographic study within 6 hours of either NQ or QMI, 
collaterals were found in: 
NQMI 45% versus QMI 19% (p=0.06), 
but more significantly residual perfusion of the IRA by either 
antegrade or collateral flow occurred in: 
NQMI 79% versus QMI 26% (p=0.0001). (40) 
Another study limited to first infarcts showed a significant 
difference in incidence of collaterals present: 
NQMI 47% versus QMI 3% (p<0.001). (4l) 
d) Myocardial jeopardy: 
Jeopardised myocardium is defined as normal or mildly 
hypokinetic wall motion, as identified on ventriculograrn, in 
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e ) 
segments distal to a coronary artery lesion causing a stenosis 
of >50%. (lO) Ogawa compared the residual myocardial jeopardy 
in patients symptomatically stable, 6 months after a first QMI 
or NQMI. Patients with NQMI had a significant increase in 
frequency of jeopardised myocardium compared to QMI . (47 ) (The 
combination of coronary narrowing with retained wall motion 
may contribute to the increased frequency of re-infarction 
seen in NQMI.) 
Stenotic/culprit lesions: 
The 6-hour coronary angiographic study showed a lower 
incidence of thrombus in patients with NQMI: 
NQMI 39% versus 91% (p=0 . 0002). (40) 
A study of first MI (32 patients with NQMI and 38 with QMI), 
who had coronary angiography both before and after MI without 
interval procedures, showed, in the angiograms done before 
infarction: (4l) 
- mean stenosis severity at the site causing future MI: 
NQMI 23% ± 35 versus QMI 44% ± 25 (p<0.01) 
- eccentric and irregular plaques: 
NQMI 13 % versus QMI 56% (p<0 . 001) 
Review of the pre-infarct angiograms showed that, NQMI 
patients tended to fall into 2 categories - either minimal or 
no stenosis (<20%) or else a severe stenosis (>70%). 
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This study therefore suggested that the atheromatous plaque 
substrate was different in QMI and NQMI. NQMI occurred 
typically at a site shown by pre-MI angiography to be usually 
non-ulcerated and either minimally or severely stenosed before 
the MI. QMI, by comparison, occurred where stenosis was 
moderate with plaque eccentricity and ulceration. Such 
differences may be responsible for differences in thrombus 
lability and collateral development and consequently in 
different clinical profiles. (4l) 
f) Aneurysm formation: 
An angiographic study showed that apical aneurysms occurred 
exclusively in patients with QMI. (49 ) The association of 
death due to cardiac rupture and QMI was similar. (27 ) 
11) Thallium/Sestamibi perfusion scans 
Fixed thallium perfusion scan defects are less frequent in 
NQMI: 
NQMI 64% versus QMI 98% (p<0.002) (18) 
indicating that larger areas of myocardium are ·irreversibly 
damaged in QMI and perhaps suggesting more reversible 
ischaemia and remnants of viable myocardium ("incomplete" 
infarction) in NQMI. (Perfusion defects will be picked up 
only if a certain critical mass of myocardium is involved. 
This may not be achieved in NQMI.) 
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12) LV remodelling 
The functional impact of LV remodeling during healing after NQ 
and Q anterior MI has been studied in the dog. NQ wave 
infarcts were caused by ligating the left anterior descending 
artery (LAD) and Q infarcts by ligation of the LAD plus 
collateral obliteration. At 6 weeks, the Q wave group had 
significantly: 
greater infarct size 
greater transmurality 
more thinning 
greater cavity dilation 
lower global ejection fraction 
higher incidence of aneurysm and LV thrombus. (49) 
3C. DIFFERENCES BETWEEN NO AND OMI RELATED TO THE POST INFARCT 
• PERIOD 
QMI NQMI 
Early mortality ± 20% ± 10% (42) (24) 
Late mortality Equivalent to MI (42) (34) (50) (51) 
Sudden death 5% 1%(52)(53) 
Recurrence ischaemia ± 20% ± 50% (27) (54) (9) (55) 
Re-infarction ± 5 ± 20%(42) 





Short-term/Immediate Survival, or In-hospital Mortality: 
It is generally reported in numerous studies that the 
immediate mortality rate among patients with NQMI is about 
half that with QMI. (34) (42) 
Two meta analyses of in-hospital mortality show a significant 
difference(42 ) (24 ) 
NQMI 10-12% versus QMI 17-19% 
Some studies, however, show no difference. (2 7 ) (21) For 
example: A study of a large patient population (n=2024) on 
the short- and long-term clinical outcome after NQ and QMI 
showed that in-hospital mortality was only lower in patients 
older than 70 years. (2l) The discrepancies in results may be 
related to types of infarct patients included. The Framingham 
Heart Study analysing NQ versus QMI, included first infarcts 
only. This distinct subset had approximately half the early 
mortality rates of those with prior MI. (lO) 
Studies undertaken before the advent of antithrombotic therapy 
show a significant difference in early mortality between NQMI 
and QM. However, the TIMI II subanalysis showed no 
significant difference in deaths at 21 days after TPA in 
patients who presented with ST segment elevation, whether they 




Long-term survival/Delayed mortality: 
There is general consensus amongst studies that long-term 
mortality rates in patients with NQMI are similar to those 
with QMI. (42) (34) This has been shown in the placebo arms of 
large drug studies e.g. the Multicenter Diltiazem Post-Infarct 
Trial (MDPIT) (SO) and the Beta-blocker Heart Attack Trial 
(BHAT) (Sl) which provided an opportunity to study the natural 
history of first NQMI. 
This lack of significant difference in long-term survival 
rates is valid up to 8 years after the index event. (S4 ) Other 
factors used in subanalysis are e.g. first myocardial 
infarction, (SO) previous IHD, CCF, diabetes mellitus (D.M.) or 
age >75 years, make no difference to these findings. (25 ) 
Thus, unlike early or in-hospital mortality which is 
significantly lower in patients with NQMI, subsequent 
mortality is higher in NQMI patient than in QMI patients, 
resulting in a 1-year mortality similar in both groups. The 
initial advantage in NQMI patients is soon lost and long-term 
prognosis is not related to the development of Q waves. 
Maisel et al showed that 1-year mortality rates after 
reinfarction were significantly higher in the NQMI 
patients. (SG) 
Sudden Death 
In the placebo group in the Cardiac Arrhythmia Suppression 
Trial (CAST), NQMI patients had a significantly lower rate of 
sudden death and cardiac arrest than QMI patients: 
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NMQI 1% versus QMI 4.6% (p=O. 04) 
However, the non-fatal ischaemic events in the placebo group 
were paralleled by an increase in sudden death in the 
encainide and flecainide groups: for QMI, the relative risk 
was 1.7, but for NQMI it was 8.2. (52) (53) 
3) Recurrence of ischaemia 
Since Q wave myocardial infarcts are often considered 
completed infarcts, they should be "curative" of angina 
pectoris. Ogawa et al showed that post-infarct angina 
occurred more frequently in patients after NQMI: 
NQMI 55% versus QMI 21% (p<O. 05) ( 27 ) 
This is in keeping with other studies taking all types of NQMI 
into account. (54 > ( 9) (55 > 
In the selected group of first NQMI and QMI presenting with ST 
segment elevation and treated with TPA (TIMI II Study), no 
significant difference in recurrence of ischaemia by 6 weeks 
was found between the two groups. (22 ) In comparison, the 
Framingham Heart Study analysis of long-term prognosis after 
first infarct with a follow-up of 5.1 ± 4.9 years, showed that 
NQMI patients had a significantly higher rate of unstable 







A review of 5 studies by Montagne et al showed that re-
infarction occurred: 
NQMI 21% versus QMI 6% (p<O. 05) (42 ) 
Retrospective pooled data of 14 studies by Gibson et al of 
NQMI and QMI with one or more prior infarcts showed a similar 
significant difference. (57 ) In patients presenting with a 
first MI, discrepancy exists: the Framingham Heart Study 
shows that NQMI had a significantly higher rate of 
reinfarction than QMI. However, when analysed separately by 
age and sex, differences in reinfarction rates were only noted 
in men and those under 65 years. (lO) 
Re-hospitalisation 
Gibson et al, in the prospective evaluation of 241 patients 
with NQMI and QMI, noted a higher rate of re-hospitalisation 
in the former: 
NQMI 36% versus QMI 22% (p=0.034), 
during 27 months of follow-up. The NQMI group also had a 
greater likelihood of subsequent bypass surgery or angioplasty 
(p=O. 018). (55 ) 
Exercise Stress Testing/Ambulatory ECG Monitoring 
A study by Mickly et al, assessing residual ischaemia in 
patients with first NQ or QMI by means of exercise stress 
testing (EST) and ambulatory ST segment monitoring, showed 
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that during early post-discharge daily activities, there was 
only a trend towards more patients with NQMI demonstrating 
transient episodes of ST segment depression. However, 
ischaemic episodes were significantly longer (p<0.001) and 
ischaemic thresholds significantly lower in NQMI (p<O.O). (59 ) 
Another study showed that objective evidence of exercise 
induced ischaemia was seen more commonly in NQMI patients: 
NQMI 68% versus QMI 32% (p<0.01). (18) 
Despite the EST, in the study by Mickley et at, significantly 
predicting development of future angina pectoris, (59 ) long-
term infarct-free survival has been shown to be similar in 
both NQMI and QMI patients where results are positive, (59 ) as 
re-infarction is probably related more to the presence and 
severity of coronary artery disease than to the presence or 
absence of Q waves. 
7) Arrhythmias 
8) 
Although an 8-year observational study revealed that 
arrhythmias in general were more frequent in patients after 
NQMI than after QMI, (GO) late ventricular arrhythmias were 
not, as reported elsewhere. (l8) The Worcester Study showed 
conclusively that NQMI patients had a lower complication rate 
in the acute phase with less hypotension, ventricular 
tachycardia, ventricular fibrillation and cardiac arrest. (54 ) 
Clinical Course 
Stone et al studied 471 patients with first infarcts and found 
that patients with QMI had a worse in-hospital course compared 
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9) 
with NQMI patients, with more cardiac failure (paralleling the 
lower LV ejection fraction and larger infarct size). (34 ) This 
lower rate of cardiac failure in NQMI patients persists into 
late follow-up. (27 ) (lO) 
Gilpin showed in a large population of patients (n=3665) with 
all types of acute MI followed up for 1 year that non-fatal 
recurrence of infarction occurred more often if there was a 
history of previous MI, cardiac failure, diabetes mellitus, 
previous angina and a NQMI as index MI, as compared to the 
infarct-free survivors. (61) 
Other clinical factors may influence the outcome. In elderly 
patients (>70 years), QMI is associated with more in-hospital 
complications including death, when compared to NQMI (p<0.05), 
but post-discharge mortality is higher in elderly patients 
with NQMI so that mortality is similar in the 2 groups at 1 
year. (26 ) 
Secondary Prevention 
Numerous drug trials with beta-blockers and calcium 
antagonists have shown different benefits in NQMI as opposed 
to QMI (see section on Management). 
Thus, differences between NQMI and QMI have been related to: 
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A . Pre-infarct: 








enzymes and other biochemical parameters 
histology and pathogenesis 
ECG 
angiography 
prognosis (early survival) 
recurrence of ischaemia 
re infarction 
re-hospitalisation 
exercise stress testing 
clinical parameters and course 
secondary prevention 
Most differences in biological and clinical variables between the 
t wo types of acute infarction can be related to 3 factors found in 
NQMI {42) (62): 
1 . smaller infarct size possibly due to early reperfusion as a 
result of spontaneous thrombolysis, relief of spasm or both; 
2 . more frequent patency of infarct-related arteries; 
3 . a larger residual mass of viable, but jeopardised myocardium 
within the perfusion zone of the infarct-related artery, in 
part due to a better collateral supply. 
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Thus, NQMI appears to be a relatively unstable condition with lower 
initial mortality and a higher risk of later infarction. These 
cancel each other out so that by 3 years, or even earlier, 
mortality rates in NQ and QMI are equal. (l9) 
The challenge for clinicians is to utilise the early window of 
opportunity to identify patients with NQMI at risk of subsequent 
events and to intervene in an attempt to prevent the mortality 
"catch up". 
4. INVALID: DIFFERENCE BETWEEN NQ AND QMI 
The ECG dichotomisation of infarction into Q and NQMI is not 
universally favoured. Moss feels that it is an oversimplification 
of a complex disease process with limited prognostic and 
therapeutic utility. The categorisation does not provide 
sufficient sensitivity, specificity or predictive accuracy about 
the subsequent clinical cause of patients with first myocardial 
infarct, to use as reliable data. (6 3 ) 
The terms 'QMI' or 'NQMI' have even been criticised as representing 
a "halfway house of the intellect", since the presence or absence 
of Q waves accompanying MI does not delineate or differentiate any 
pathological or clinical subset. (64 ) 
The dichotomy of Q versus non-Q may have produced unwarranted 
lumping of the large number of ECG permutations and combinations of 
wave-form that occur over time, unrelated to the presence of Q 
waves. (6S) Nor are these categories absolutely distinct or 
defined. Some patients with acute ST segment elevation will 
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rapidly develop Q waves; others will evolve Q waves over days, and 
others will never develop them. (66) Therefore, the admission ECG, 
for purpose of classification, is unreliable. It may therefore be 
more appropriate to regard acute MI as "electrocardiographically 
undifferentiated 11 ( 35 ) during the first several hours after the 
index event, until enough time (24-48 hours) is given for the ECG 
to evolve. ST segment shifts are unreliable predictors of 
subsequent Q development after infarction. The 12-lead ECG is 
restrictive and misses Q waves. It has been shown that Q waves may 
be inconsistent, even over relatively short periods of time, e.g. 
during a particular phase of respiration. (65 ) 
The ECG is also too blunt an instrument to differentiate, with 
precision, the state of reperfusion after thrombolysis. The ECG is 
not helpful in identifying patients with initially incomplete 
coronary occlusion who may not require thrombolysis. Although the 
ECG can demonstrate successful reperfusion when applied to large 
groups of patients, the value in the individual patient is 
minimal. (35 ) 
What about the differences attributed to Q and NQMI? Spodick 
noting numerous similarities between these two groups, warned that 
these terms are inadequate for clinicopathological and prognostic 
classification of acute MI. (67 ) Fox, in comparing prognosis of NQ 
and QMI, showed that at one year the mortality, reinfarction and 
angina rates were similar in the two groups and on this basis 
suggested that the distinctions between them need not influence 
management decisions. (45 ) This argument is flawed as the 
equivalent long-term prognosis is due to the catch-up of events in 
NQMI. 
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Thus, the similarities between QMI and NQMI are: (l4 ) (25 ) (45 ) 
1 . Both may be pathologically transmural or not 
2 . Number of diseased coronary vessels 
3 . Grade of coronary artery stenosis 
4 . Long-term reinfarction 
5 . Long-term mortality. 
Taking into account that any binary classification system may fail 
to take into account the heterogeneous manifestations of acute MI, 
and may result in oversimplification, the balance of the evidence 
still suggests that, provided one is aware of the shortcomings in 
ECG classification and the possible heterogeneity of NQMI in 
particular, significant differences do exist between NQMI and QMI, 
especially at the time of infarctions and in the early period 
thereafter. 
5. NQMI - A HETEROGENEOUS GROUP 
That NQMI is a non-uniform group has already been alluded to. This 
refers not only to classification, but also to mechanism, inclusion 
criteria and prognostic implications. At present, Q wave MI forms 
about 60-80% of all infarcts, (l3 ) (9 ) (lO) and the rest, by 
definition, may be described as being non-Q. 
Studies, eg TIMI IIIB in UAP and NQMI have restricted inclusion to 
patients only with ST segment depression . (68 ) ST segment elevation 
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during the early hours of evolving infarction however, is not an 
invariable harbinger of subsequent Q development( 69 >. 
Natural history studies of patients with acute MI who present only 
with ST segment elevation have shown that up to 37% will 
subsequently develop a NQMI. (4G) A study has shown that ST segment 
elevation <2mm on admission is an independent predictor of 
subsequent development of NQMI, whereas only 26% of patients with 
>2mm ST segment elevation on admission developed NQMI . (28 > It is 
generally believed (but not very well substantiated), that if acute 
myocardial infarction presents with ST segment elevation and Q 
waves have not developed, this may be considered to mean some 
salvage of myocardium has been achieved. These are the aborted Q 
wave infarcts. 
The NQ infarcts with ST segment depression and T inversion are also 
non-uniform. In a study(?O) on the different clinical implications 
for ST depression and T inversion in NQMI patients, ST elevation 
was shown to precede T wave inversion in the same leads in 80% of 
the T 'group'. Marked differences in cardiac status were noted: 
Cardiac Status ST+ (n=22) T + (n=20) 
Killip Class II-IV 59% 20% (p<0.5) 
1 month mortality 41% 0% (p<0.05) 
No. of coronaries 
diseased multiple single 
T wave inversion thus implied recovery phase of infarction within a 
presumed one-vessel territory. ST segment depression suggested 
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extensive ischaemia in the subendocardium of multi-vessel 
territory. Another study analysing ST segment deviation in two or 
more leads on the admission ECG of NQMI patients showed a positive 
predictive value of 79% for recurrence of ischaemia or myocardial 
infarction within three months and a negative predictive value of 
64%. (71) 
Features of incomplete infarction are shared by NQMI and reperfused 
acute myocardial infarction after thrombolysis: (35 ) 
subtotal coronary occlusion 
early CPK wash-out 
preservation of global and regional LV function 
high incidence of reinfarction and post-infarct angina 
high incidence of residual myocardial ischaemia during non-
invasive testing. 
The incidence of the so-called NQMI after successful reperfusion 
with thrombolysis (± 40-45%) (35 ) (28 ) appears to increase the number 
of aborted QMI which are expected to occur by means of spontaneous 
natural thrombolysis to occur in some patients presenting with ST 
elevation. (46 ) 
Acute MI with R wave regression is distinct from acute QMI as shown 
by clinical features in keeping with typical NQMI (lower CPK, lower 
incidence of cardiac failure and in-hospital mortality) and 
angiographic features of a higher rate of spontaneous opening of 
infarct-related arteries within 48 hours. (72 ) 
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Patients presenting with acute MI and left bundle branch block 
(LBBB) on ECG, strictly speaking, may be lumped into the NQMI 
group. They should be considered an indeterminate type of acute 
MI. ( 26) 
Using various ECG definitions for MI (Minnesota Code, WHO Code, 
etc.), the concept of NQ posterior MI does not exist because it is 
characterised by indirect "mirror" signs. However, routine 
recording of leads v8 and V9 has shown that this entity of NQ 
posterior MI exists. (l3 ) The fact that the anterior area seems to 
be the predilection site of NQMI may be partly due to the general 
recognition only of the Q wave variant of posterior MI (i.e. R/S 
ratio >1 in Vi - V2). 
Electrocardiographically silent infarcts occur. Lateral and 
basolateral MI in particular, may be silent, even if they are 
transmural as shown by postmortem studies. (l7 ) 
As a result of all these variables, no set of defining criteria for 
Q and NQMI is used in trials: 
1) variable times of ECG categorisation; 
most studies perform this at hospital discharge; 
in the TIMI II Study, this was based on the Day 2 ECG 
(since it was considered the time that most physicians 
made a decision regarding catheterisation in stable 
patients). (22 ) Eisenberg et al, showed that only 1.5% of 
patients with NQMI after thrombolysis progressed to QMI in 
the period after 24 hours to hospital discharge. (73); 
in TIMI IIIB this was based on the admission ECG(68); 
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to confound the issue, a study of NQMI only showed that in 
55%, transient Q waves occurred. (70) 
2) Variable interpretations of ECG; 
some NQMI studies include all those that do not develop Q 
waves and others only those with ST segment depression or 
T changes on the admission ECG; 
some use specific criteria which may not be generally 
acceptable e.g. the Multicenter Post-Infarction Program 
code calls any anterior infarct a NQMI if there are no Q 
waves and only ' ST/T changes, yet the loss of R wave 
amplitude in v5 and V6 is regarded as Q wave equivalent 
infarction. (74 ) 
It is thus quite obvious that ECG changes in NQMI are not 
specific for this entity. They are also found in 
subendocardial ischaemia, rapid heart rates, electrolyte 
abnormalities, intraventricular conduction abnormalities and 
with certain medications (e.g. digoxin). Unlike QMI which is 
likely to arise in a patient presenting with ST segment 
elevation, and acute management can be based on ECG with 
relative certainty, NQMI may occur in a variety of ECG's which 
are non-specific and may be associated with other 
abnormalities. Perhaps there is a place for quick, early 
enzyme analysis if it is shown that acute management would 
play a role in changing the acute outcomes for various 
subcategories of the acute coronary syndrome. 
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3) Variable enzyme criteria 
The definition for CPK-enzyme rise to secure a diagnosis of 
NQMI also varies. Most studies require this to be twice the 
upper nonnal value for their laboratory according to the WHO 
definition for AMI. However, some, for example, the widely 
quoted cross-sectional analysis of coronary angiographic 
findings soon after NQMI by De Wood et al, included those 
patients with CPK 150% of their top laboratory nonnal value 
before intervention. (75 > With the availability of very 
sensitive myocardial enzyme detection techniques, previously 
categorised anginal episodes are now being diagnosed as enzyme 
positive NQMI. (63 ) The problem with their inclusion is that 
mild CPK-MB increases have also been detected in 20% of 
patients within 24 hours after successful PTCA. (76) CPK may 
be released into coronary blood by transient, severe ischaemia 
without associated cellular myocardial necrosis. (77 ) 
Thus, the heterogeneous NQ group of myocardial infarcts includes: 
1) Subendocardial infarction with transient ST-T changes 
2) Intramural infarctions with giant negative T waves( 63 ) 
3) True NQ posterior infarcts 
4) Silent infarcts (may include transmural posterior, lateral or 
basolateral MI) 






6) Variably interpreted infarcts (by ECG) e.g. "pathological R" 
infarcts. 
6. SIMILARITIES BETWEEN NQKI AND UAP 
There is considerable overlap in literature between unstable angina 
pectoris (UAP) and NQMI, both falling under acute myocardial 
ischaemia rather than myocardial infarction. Frequently, for 
purposes of study, NQMI and UAP are lumped together as "unstable 
coronary artery disease" or "acute coronary syndrome", e.g. the 
aspirin study in unstable coronary artery disease;( 78 ) the platelet 
receptor blocker (GPIIB/IIA) trials. (79) (80) 
There appears to be some justification for this: 
1) Some studies have shown small areas of micro-infarction 
(without evolution of an ECG infarct) in some cases of UAP. 
These variants of UAP, with early washout of CPK-MB, represent 
a link to NQMI. (77 ) This has prompted trials assessing the 
use of thrombolytics in UAP (e.g . TIMI IIIB( 68 )). 
2) If one extends the role of the obstructive atherosclerotic 
plaque to include a dynamic component to explain the unstable 
state, the classification of unstable angina can indeed be 
extended to include groups of patients recognised at high risk 
of subsequent infarction, i.e. patients with NQMI and those 
with early post-infarction ischaemia. Recognised dynamic 
components are: rapid progression of disease, active 
vasomotion, plaque fissuring and thrombus formation with 
activation of platelets . (8l) 
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3) Evidence from studies: 
In a study of 911 patients with NQMI and UAP looking for risk 
stratification factors, cardiac enzyme levels had no 
predictive value. (82 ) Clinical morphological comparison of 
the infarct-related artery of NQMI and stenotic lesions in UAP 
have shown similar eccentric atherosclerotic lesions. (93 ) 
Reversible defects on Thallium perfusion scanning are 
characteristic of both UAP and NQMI. 
7. DISSIMILARITIES BETWEEN NQMI AND OAP 
There is difficulty in interpreting management reconnnendations of 
trials that consider NQMI and UAP together, because although the 
aetiology of these two syndromes appears to be similar, the 
clinical course and prognosis are quite distinct, with NQMI 
patients having a higher rate of death and subsequent infarction 
than patients with UAP. (84 ) (85) 
In the TIMI IIIB Study, NQMI patients had a 70% higher risk of 
death or subsequent MI by 6 weeks: 
NQMI 8.6% versus UAP 5.0% (p=0.05) (G 8 ) 
Cohen et al observed that risk of death or subsequent MI by 12 
weeks was similarly significant: 
NQMI 16% versus UAP 7% (p=0.01) (94 ) 
Within the spectrum of conditions caused by ischaemic heart 
disease, NQMI is found near the middle (Figure No. 2). At the time 
47 
48 









The continuum of lschaemic Heart Disease: 
Unstable angina pectoris, NQMI and QMI. 
of MI and early thereafter, NQMI is closely related to UAP (in 
fact, they usually cannot be differentiated at the time of presen-
tation(B3)). Yet, later (in the post-hospital discharge phase) 
NQMI is more like QMI with similar mortality and long-term outcome. 
8. PATHOGENESIS/ MECHANISMS INVOLVED IN NQMI 
It is important to consider the pathogenetic mechanisms specific 
for NQMI in order to understand why it remains an unstable 
condition (more so than in QMI) and where potential strategies of 
management are possible) (Figure No. 3). 
A. PERI-INFARCT 
B. POST-INFARCT COURSE 
MECHANISMS IN THE SPECTRUM OF 
ISCHAEMIC HEART DISEASE 
ATHEROSCLEROTIC PLAQUE 
Stable·----·- Unstable 
Mild stenosis Severe Rupture 
(Matrix ~gfading ~t(nases) 
"' ' "' ' "' ' 
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NQMI, as in common with other manifestations of the acute coronary 
syndrome, e.g. UAP or QMI, frequently appears to be triggered by 
rupture of an unstable atherosclerotic plaque in a coronary artery. 
This itself is the result of complex inflammatory changes(SG) that 
occur in the plaque which precipitate loss of integrity of the 
extracellular matrix of the plaque fibrotic cap. (S?) The outcome 
of plaque rupture is dependent on an interacting triad of 
thrombosis, fibrinolysis and matrix degrading proteinase. The 
result of this is varying severity of occlusion (partial to total) 
of variable duration, the effect of which is modified by the 
myocardial oxygen demand and particularly by the underlying 
substrate. This may be dynamic, e.g. vasomotion or structural, 
e.g. collaterals. The final outcome is the spectrum of acute 
coronary disease. 
What is the evidence? A high proportion of NQMI on histological 
examination has contraction band necrosis, a pattern highly 
suggestive of transient decrease in perfusion or non-perfusion 
followed by reperfusion or of reperfusion via well developed 
collaterals, i.e. a reperfusion injury . (l3 ) NQMI have long been 
considered to represent aborted QMI with an incomplete necrotic 
event and a variable degree of sub-epicardial salvage. Non-
sustained coronary occlusion may be due to two proposed 
mechanisms: (35 ) 
1 . Early spontaneous reperfusion of a total thrombotic coronary 
occlusion resulting in an 'altered reflow' phenomenon. 
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2 . Presence of focal vasospasm superimposed on a severely 
stenotic infarct related artery which abates abruptly 
resulting in partial restoration of antegrade flow. 
The degree to which each contributes remains unresolved. In all 
probability elements of both mechanisms occur. A transient 
reduction in coronary blood flow without a permanent and completely 
obstructing coronary thrombus is probably perpetuated by the 
underlying substrate, causing vasoconstriction. Endothelial injury 
at the site of coronary stenosis is associated with platelet 
aggregation and release of platelet-derived mediators (thromboxane 
A2 , serotonin) which cause further platelet aggregation and dynamic 
increases in coronary vascular resistance and reduction in coronary 
blood flow. White blood cells, and mast cell infiltration of the 
injured endothelial region, release other mediators (platelet-
derived growth factor, platelet activating factor, prostaglandin 
D2, endothelin). (88 ) This sequence causes further platelet 
aggregation. The small micro-aggregates and platelets, which are 
beneath the resolution of coronary angiography, are washed 
downstream(?S) and may interact with other mechanisms of reduced 
flow: abnormal vasomotion (See Figure No. 4). Thus the occurrence 
of NQMI in multi-vessel coronary artery disease with severe 
stenoses can be tied in, since dynamic vasoconstriction may be 
exaggerated if the distal coronary artery has diseased endothelium 
which has less ability to vasodilate (because of low concentration 
of endothelial-derived relaxing factor, tissue plasminogen 
activator and/or prostacyclin). 
These mechanisms with the addition of the time variable may thus be 
responsible for the continuum of the acute ischaemic spectrum: 
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VASOMOTION IN NOMI 
Narrowing due 
to plaque 
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A schematic diagram of the possible mechanisms by which aggregating platelets release thromboxane ~ 
and serotonin, at the site of luminal narrowing, which cause further platelet aggregation downstream 
and dynamic reductions in coronary luminal diameter.(88l 
UAP: short spans of severe ischaernia, but no (or only very 
limited) focal myocardial necrosis 
NQMI: pathophysiological processes causing ischaemia to 
reduce coronary blood flow for periods of 20 minutes to 
2 hours 
QMI: critical reduction of coronary blood flow >2 hours. 
Other variables in substrate also play a role: 
a ) Collaterals: 
Studies have shown that patients with prior coronary stenosis 
~70% had a lower prevalence of NQMI, possibly due to chronic 
stenoses less likely having plaque rupture and the more 
frequent development of collaterals. (39 ) 
If NQMI does occur in severe coronary stenosis, it is associated 
with collaterals. Rentrop et al have shown that sudden coronary 
occlusion in patients with severe coronary stenosis causes the 
collateral channel filling to improve rapidly, (within 1-11/2 
minutes). (89) Thus, partial perfusion is still possible with 
limitation of infarct size. 
b ) Major complications of rotational atherectomy include 
infarction. NQMI occurs in approximately 3.8% of patients and 
is significantly associated with the female gender and a 
history of previous MI. (90) It appears that it is not only 
the mechanism or the pathological process, but also the 
underlying substrate that is responsible for NQMI. 
The complex dynamic interaction of plaque, thrombosis and 
collateral supply that results in NQMI( 42 ) indicates sites of 
possible therapeutic intervention: e.g. antithrombotic agents, 
antiplatelet agents, inhibitors of platelet aggregation, 
antiserotonin agents, endothelium-derived relaxing factor 
promoters, anti-inflammatory agents and matrix proteinase 
inhibitors (that may render atherosclerotic plaques more 
stable), (97 ) etc . 
Other mechanisms of NQMI: 
severe increase in myocardial oxygen demand; 
severe generalised impairment of coronary perfusion. 
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SB. POST-INFARCT COURSE 
Mechanisms involved in the unstable post-infarct course of NQMI are 
essentially a perpetuation of those involved in the acute 
infarction. It is well-known that reinfarction and angina are more 
frequent after NQMI. The post-infarct instability may be due 
to: (13) (91) 
1) peri-infarct residual ischaemia; 
2) sustained by high grade stenosis; 
3) inadequate collateral circulation with the supervening of 
additional pathophysiological events; (92 ) 
4) progressive stenosis in the infarct-related artery; 
5) further coronary thrombosis; 
6) platelet aggregation; 
7) coronary vasospasm. 
The dynamic component of the atherosclerotic plaque may be 
responsible for the unstable state. (Sl) This is in keeping with 
the findings that early reinfarction (within 6 months) has been 
shown to occur in the same ECG region in which initial infarction 
had occurred. (93 ) (Late infarction is randomly distributed.) 
Some evolution does occur after the index NQMI. Total coronary 
occlusion of the infarct-related artery is infrequently observed 
(26%) in the early hours of NQMI, but increases moderately in 
frequency (42%) over the next several days. This is paralleled by 
an increase in the presence of visible collateral vessels. (75 ) 
In addition, it appears that activated substrate (including lesion 
hyperactivity) requires some time to return to baseline. The only 
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significant predictor of clinical restenosis after percutaneous 
transluminal coronary angioplasty (PTCA) following NQMI, is the 
interval duration between myocardial infarction and the PTCA. In a 
study assessing the usefulness of PTCA after NQMI, the interval 
among patients with recurrence of symptoms was 4 to 5 weeks and 
among those without recurrence 12 to 18 weeks (p<0.04). (92 ) 
Furthermore, in patients with unstable angina, intracoronary 
thrombus formation is associated with a hypercoagulable state as 
shown by elevated levels of thrombin-antithrombin III (TAT) 
complexes and fibrin degradation products. (94 ) (95 ) The persistence 
of this state, together with disturbed fibrinolysis, may increase 
the risk for further coronary events. 
9. MANAGEMENT RECOMMENDATIONS 
Should the subset of patients with NQMI be treated any differently 
to other infarct patients? 
The minimal rise in CPK, absence of cardiac failure or shock, may 
lull one into believing that NQMI is benign. However, the 
conclusions from NQMI versus QMI studies must be taken into 
account. 
1 . NQMI is generally accepted to represent an aborted QMI 
resulting in an 'incomplete' necrotic event. It is thus 
believed that: 
- there are areas still at risk of further ischaemia 
- salvage of still viable myocardium is possible. 
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2 . NQMI is believed to be a relatively unstable condition with 
increased risk of recurrent infarction (NQMI may constitute 
the highest risk subset of post-infarct patients. <96 )). 
3 . Extensive damage from recurrent myocardial necrosis has a 
considerable deleterious effect on long-term survival. (9?) 
Therefore, patients with NQMI would be expected to benefit from 
prophylactic treatment that prevents reinfarction (possibly even 
more than patients with QM!). 
9A. MEDICAL 
In addition to the generally applied principles of medical 
management of patients with manifestations of the acute coronary 















Firstly, because of the high incidence of early recurrence, 
NQMI patients may merit intense and prolong monitoring for 
detection of ECG changes and enzyme elevation. Greater 
awareness of recurrence of ischaemia and need for management 
must be encouraged. This increased vigilance is required not 
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only for the initial period of hospitalisation. Patients with 
NQMI pass through a highly vulnerable period for the first 6-
12 weeks after the index event and the propensity for further 
complications probably extends throughout most of the first 
year after the infarct. (83~ 
2) Antithrombotic / Antiplatelet Therapy 
A combination of antithrombotic therapy (heparin, warfarin) 
with aspirin in UAP and NQMI has shown a significant reduction 
in recurrent ischaemic events by 14 days. (98 ) The Persantin-
Aspirin Reinfarction Study (PARIS-2) showed a 48% reduction in 
cumulative incidence of coronary events (mortality and 
reinfarction) in patients with NQMI who received active 
treatment. (99 ) Low dose aspirin, 75mg/d, has been shown by 
the RISC group in a prospective trial of 796 men with unstable 
coronary disease (UAP and NQMI) to reduce the risk of MI and 
death and severity of angina by 3 months. (79 ) This was most 
significant with the NQMI group of patients (p<0.0001). (lOO) 
The risk reduction was maintained at one year. (78) This group 
found no protective effect of intravenous (IV) heparin alone 
against recurrence of MI. On the other hand the combination 
of IV heparin and aspirin was the only regimen that 
significantly reduced the risk of MI during the first 5 days 
in hospital. (lOO) 
Other treatment strategies with newer platelet inhibitors 
(e.g. GPIIb/IIIa inhibitors( 79 ) (9o)) and antithrombotic agents 
(e.g. direct thrombin inhibitors such as hirudin) i.e. 
substances more effective than the combination of heparin and 
aspirin in inhibiting rethrombosis while endogenous 
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fibrinolysis occurs may be useful, provided NQMI can be 
identified more accurately. (3 9) 
3) Beta-Blockers 
As there are multiple differences between Q and NQMI it is not 
illogical to assume that secondary prophylaxis post MI could 
also differ. Gheorghiade et al observed no benefit of 
propranolol among the 601 patients with NQMI in the beta-
blocker Heart Attack Trial (BHAT). (lOl) It has therefore been 
hypothesized that beta-blockers are ineffective in NQMI 
patients. (l0 2 ) (l03 ) 
Yusuf argues that this hypothesis of beta-blockers' 
ineffectiveness is likely to be spurious because the 
statistical power of sub-group analysis in the BHAT Study was 
poor. (l04 ) Furthermore, the results are directly contradicted 
by the Norwegian Timolol Trial. This trial showed that 
timolol showed a significant decrease in mortality among those 
with NQMI (14% in the placebo group versus 7% among treated 
patients). (lOS) (l0 6 ) No significant reduction in reinfarction 
in NQMI patients was noted. Therefore, with all available 
information and recognising the limitations of sub-group 
analysis, Yusuf suggests that beta-blockers are likely to 
benefit patients with NQMI. The size of the benefit is not 







Evidence exists that NQMI patients are prone to reinfarction 
in the same area as the original injury i.e. after a NQMI 
there remains viable, but jeopardised myocardium within the 
perfusion zone of the infarct-related artery (IRA). (24 ) 
Prophylactic therapy aimed at this IRA may protect this highly 
vulnerable tissue from further ischaemic insults. Vasospasm 
has been shown to be an important component of the 
pathogenesis of the acute event and perpetuation of the 
ischaemia. In addition, since angiographic findings (as shown 
by De Wood et al) support the concept of progression to total 
occlusion, short-term therapies aimed at maintaining antegrade 
blood flow may help. (75 ) This may justify the attempted use 
of calcium antagonists (calcium channel blockers) for their 
vasodilatory or anti-vasospastic actions. 
A double-blind randomised study (the Diltiazem Reinfarction 
Study, DRS) (90mg 6 hourly) on reinfarction after a NQMI 
starting treatment within 72 hours after the infarct and 
continuing for 14 days, showed 51.2% reduction in reinfarction 
(p=0.03) and a 49.7% reduction in frequency of refractory 
post-infarct angina (p=0.04). However, 2-week mortality was 
unchanged. This study therefore concluded that diltiazem was 
effective in the prevention of early reinfarction and of 
severe angina after NQMI. (S 3 ) However, the beneficial effect 
must be tempered in that the definition of extension of 
infarction/reinfarction in the DRS Study was based purely on 
re-elevation of CPK-MB levels (i.e. biochemical and not 
clinical grounds). This led to an over-estimation of this 
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b) 
complication(l3 ) and therefore, an over-optimistic beneficial 
4 effect of diltiazem. 
Late use of calcium antagonists 
Wong et al analysed a cohort from the Multicenter Diltiazem 
Post Infarction Trial (MDPIT) in which 235 NQMI patients with 
first MI were randomised to diltiazem, and 279 patients to 
placebo. Reinfarction within 6 months, occurred in 2 of the 
diltiazem group, versus 17 in the placebo group (p=0.001). 
Late reinfarction (after 6 months) and mortality were similar 
in both groups. (93 > This did not confirm the original report 
of MDPIT which included all acute infarcts and suggested a 
significant reduction in 1-year cardiac events (cardiac death 
~ 
or non-fatal MI) in patients on diltiazem, which appeared to 
be especially beneficial in patients with a first 
NQMI. (l0 7) (35 > The possible mechanisms proposed by Wong et al 
for the beneficial effect of diltiazem on reinfarction within 
6 months, include: 
i) reduction in vascular spasm 
ii) reduction in heart rate and blood pressure 
iii) possible antiplatelet effect which may help stabilise 
the lesion in the infarct-related artery. 
However, again the acceptance of these positive results can 
only be made with strong reservations. The MDPIT Study 
enrolled patients from day 3-15 after the NQMI and therefore 
excluded many of the most unstable patients with the highest 
early mortality. Also excluded were those felt to have a high 
likelihood of undergoing cardiac surgery. The long-term 
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incidence of reinfarction was not affected by diltiazem and 
therefore is possibly due to late reinfarctions representing 
progression of atherosclerotic disease. This was supported by 
the random distribution of the location of late as compared to 
the ea~ly reinfarctions. (93 ) Furthermore, the MDPIT Study 
revealed that the group of patients (after NQMI or QMI) with 
left ventricular dysfunction who received diltiazem, had a 
worse long-term outcome. There was a 41% higher cumulative 
cardiac event rate (including mortality) compared with placebo 
in the 20% of patients showing pulmonary congestion on chest 
x-ray (CXR) done during admission with the index MI. (l08) 
Using the MDPIT data base again, it was shown that first NQMI 
and first inferior QMI have a 48% reduction in event rates, 
whereas first anterior QMI had a 25-30% excess event rate when 
treated with diltiazem. This appeared to reflect the degree 
of LV dysfunction since NQMI and inferior QMI had essentially 
normal LVEF. Possible mechanisms for the worse prognosis in 
LV dysfunction include the negative inotropic effect or 
neurohormonal activation of diltiazem. Further subset 
analysis of the MDPIT showed that in patients with NQMI, the 
overall frequency of CXR pulmonary congestion was low (13%). 
This group when treated with diltiazem, had paradoxically 0% 
cardiac mortality and a 6% cardiac event rate compared to the 
20% event rate for placebo. (l08 ) This sharp contrast, 
especially when compared to anterior QMI, suggests different 
mechanisms of pulmonary congestion: in NQMI this may be a 
'stunned myocardium' i.e. reversible diastolic LV dysfunction 
in viable myocardium; in QMI congestion of the lungs reflects 
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reduced LV systolic function. Diltiazem is beneficial to the 
former, and harmful to the latter. (l08) 
Meta-analysis of therapy with various calcium antagonists 
after MI has revealed a disturbing excess mortality averaging 
6% among patients taking active agents . (l0 9) However, when 
revised to include only trials with diltiazem and verapamil, 
(DAVIT-II, the second Danish Verapamil Infarction Trial) i.e. 
the non-dihydropyridine group of calcium antagonists, meta-
analysis suggested an overall risk reduction in cardiac events 
in NQMI which may be as high as 35% when compared to 
placebo. (l0 8 ) 
Therefore, in summary, the following are the known effects of 
calcium antagonists after NQMI: (110) 
i) Nifedipine has no beneficial effects; may be harmful 
ii) Verapamil has shown no preventative effect on death, 
reinfarction or post-infarct angina. 
iii) Diltiazem is the only agent shown to have short and 
long-term benefits on clinical outcome (reinfarction 
<6 months), but not on survival . 
The American College of Cardiology/ American Heart 
Association Joint Task Forces' guidelines, regard diltiazem as 
possibly effective for use in patients after NQMI and 
recommend its use. (lll) 
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The question as to whether diltiazem should be given for the 
'at risk period' and then withdrawn, as it has no positive 
effect in the long-term, has never been addressed. 
5) ACE-Inhibitors 
There is no reason to believe that angiotensin converting 
enzyme inhibitors should be less effective in NQMI than in QMI 
patients with LV dysfunction. A study using captopril in NQMI 
has shown therapeutic effects not only on LV dysfunction, but 
also on ischaemia with a significant reduction in the duration 
of ambulatory ST depression 6 months after the index MI. (ll2) 
9B. MANAGEMENT RECOMMENDATIONS: TBROMBOLYSIS 
Thrombolysis in QMI has been proven to be beneficial in terms of 
survival in numerous well-conducted trials. The simplistic 
arguments of restoring perfusion to an ischaemic segment of 
myocardium, thus limiting the infarct size, may however, not be 
directly transferable to the case of thrombolysis in NQMI. This is 
particularly so in view of the underlying pathogenetic mechanisms 
involved in NQMI which may not involve complete occlusion of the 
infarct-related artery, but may result from dynamic processes that 
perpetuate under-perfusion in the face of a mechanical obstruction 
that itself may not be critically flow-limiting. 
Based on good evidence, there is not much debate about the use of 
thrombolytics in NQMI patients presenting with ST segment 
elevation. The term NQMI is usually applied retrospectively. 
Knowing that up to 37% of patients presenting with ST segment 
elevation will not go on to have QMI even without thrombo-
lytics(69) should not alter management as awaiting the development 
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of Q waves defeats the objective in giving thrombolytics in the 
first instance. 
The dire consequences of loss of myocardium and compromised LV 
function in acute ischaemic syndromes have encouraged the use of 
thrombolytics even when clinical indications are unclear. Such 
attempts have been made with acute MI patients presenting with ST 
segment depression, NQMI and even UAP (all of which overlap to a 
certain extent). 
Numerous studies have included ST segment depression in the 
assessment of thrombolytic therapy. Even though coronary arterial 
thrombi play an important role in the acute event, subgroup 
analysis of patients with MI, who present with ST depression and 
usually evolved NQMI, in trials such as the GISSI-l(ll3 ) and the 
ISIS 2(ll4 ) has shown no survival benefit with streptokinase (SK) 
therapy compared with placebo. In fact, the vast majority of 
studies, using all types of thrombolytic/fibrinolytic agent, have 
shown no statistically significant reduction in mortality during 
days 0-35, even though such patients were at high risk of 
deaths. (ll5 ) 
Furthermore, the general findings applicable to all infarcts may be 
even more significant in NQMI. Thrombolytic therapy for acute MI 
does not reduce the incidence of recurrent ischaemia or infarction 
as is evident from the 18-26% incidence of recurrent ischaemia 
reported in the Thrombolysis and Angioplasty in Myocardial 
Infarction (TAMI) and TIMI trials. In the GISSI study, the 
incidence of reinfarction in NQMI patients was documented as 4% in 
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the streptokinase group which was actually significantly greater 
than in the placebo group (2%). (9l) 
Thus the results of the TIMI IIIB (Thrombolysis in Myocardial 
Ischaemia) specifically designed to look at this dilenuna, and not 
by subgroup analysis, is significant. (68 ) The trial's primary 
objectives were twofold: 
1) to determine the effects of thrombolytic therapy in UAP and 
NQMI; and 
2) to determine the role of routine early coronary angioplasty 
followed by revasculation versus conservative treatment. 
One-thousand four-hundred and seventy-three patients were 
randomised, with the primary endpoint for the tissue plasminogen 
activator (TPA) - placebo comparison being death, MI or failure of 
initial therapy at 6 weeks. The endpoint was reached in: 
54.2% of the TPA patients versus 55.5% of the placebo-treated 
patients (p=NS) 
Furthermore, reinfarction in NQMI patients occurred more frequently 
in the TPA-treated patients: 
7.4% of "TPA" patients versus 4.9% in "placebo" patients 
(p=0.04) 
Intracranial haemorrhage occurred in 4 of the TPA-treated group 
(p=O. 06). 
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Thus, the conclusion of this study was that the addition of a 
thrombolytic agent is not beneficial and may be harmful. 
Reasons for the lack of benefit of thrombolytic therapy in this 
TIMI IIIB trial, possibly include: 
i) The low dose of TPA used (63mg on average). This was to 
reduce complications in a group with known low mortality 
rate. (GS) 
ii) The simultaneous clot dissolving and procoagulant actions of 
thrombolytic agents. Thrombolysis may expose the fibrin-
bound thrombin which is a potent stimulus for rethrombosis. 
iii) Platelet thrombi (which are more resistant to lysis than 
erythrocyte composed thrombi) are the type that predominate 
in the unstable acute coronary syndromes. In addition, 
thrombolytics may activate platelets directly. 
There are numerous reservations about the general recommendation of 
this TIMI IIIB trial that thrombolytic therapy not be used 
routinely in patients with UAP or NQMI: 
i) As mentioned before, concerning UAP and NQMI being "lumped" 
together, often under the title "acute coronary syndrome", 
these two conditions although having similar aetiology, have 
a different clinical course and prognosis. Thus, a general 
recommendation may not be applicable (if these two conditions 
could be differentiated prospectively). 
ii) This trial studied only a subset of the total heterogeneous 
non-Q wave group of myocardial infarcts, enrolling only 
patients with ST segment depression and T wave changes, but 
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excluding ST segment elevation longer than 30 minutes. This 
group forms up to 40% of all NQMI . Also excluded were 
patients in pulmonary oedema, systolic BP> 180mmHg and 
diastolic BP> lOOmmHg. Thus, recommendations regarding NQMI 
presenting with ST segment elevation remain unaltered. 
iii) Not all the patients were comparable. Up to 12% were 
receiving heparin at the time of the qualifying episode i.e. 
they did not present with NQMI and may therefore have been in 
a different risk category. 
iv) The use of TPA as opposed to SK may not be equivalent. 
Studies have shown differences where thrombolytics are used 
conventionally. 
v) All the patients were given a calcium antagonist (diltiazem 
30mg 6 hourly) which may have confounded the issue or blurred 
differences in outcome of UAP versus NQMI. 
Even so, the current recommendations with regard to thrombolytics 
in NQMI can only be to restrict their use to those patients 
presenting with acute ischaemia and ECG evidence of ST segment 
elevation. 
9C. MANAGEMENT RECOMMENDATIONS: ACTIVE 
1 . Stress Testing 
2 . Invasive Investigation 
3 . Active Intervention - Revascularisation 
Recognising the differences between QMI and NQMI, aggressive 
approaches in management with active intervention have been 
recommended in the latter. The basic argument is that with an 
incomplete myocardial infarction, more salvage is possible. The 
67 
suggested more aggressive diagnostic approach may include a careful 
non-invasive search for ischaemia and/or coronary angiography, even 
in the asymptomatic, but selected patient. However, there is no 
firm evidence that this active management strategy influences the 
course of NQMI favourably. 
1) Stress Testing 
The rationale behind exercise stress testing (EST) is to 
identify residual ischaemia and thereby identify and better 
direct invasive investigation in such a heterogeneous group as 
NQMI patients. 
The question raised is whether EST is a good discriminator for 
predicting NQMI patients at risk and its comparison to the use 
in QMI patients. Most studies have shown that the absence or 
presence of pathological Q waves had no significant effect on 
the ability of the EST to identify risk subset of survivors of 
acute MI. (45 ) (ll6 ) 
Within the NQMI group of patients, the timing of the EST may 
also be significant. Since much of the recurrence of 
ischaemia in NQMI patients occurs in the immediate post-index 
MI period, early EST done pre-discharge, is preferable to EST 
done 4-6 weeks later at the first outpatients visit. In a 
Swedish study evaluating the use of pre-discharge EST in 
patients with NQMI, it was confirmed that ST segment 
depression, occurrence of angina and low peak load at exercise 
were independent predictors of future severe angina that 
necessitated rehospitalisation and investigation. (ll?) Not 
only positive results are useful; Sia et al showed that 
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2) 
negative results in the early EST after NQMI predicted absence 
of triple vessel coronary artery disease or critical stenosis 
of one vessel with an accuracy of 92%. (ll8) 
However, the use of EST as ultimate risk stratifier with NQMI 
must be cautious. The Multicenter Post-Infarction Research 
Group showed that early low level EST is of limited value. In 
studying patients with first NQMI who were able to exercise, 
ST depression during exercise identified patients with a 71% 
incidence of cardiac events within 1 year versus 5.3% for 
those without ST segment depression (p=0 . 002). Yet, even with 
this statistically significant result (odds ratio of 45), on 
subgroup analysis of patients without presence of pulmonary 
congestion, the exercise test had no discriminatory value. 
They concluded that low level exercise testing has a limited 
role after uncomplicated NQMI, but is useful in patients with 
clinical markers of higher risk. (ll9) 
When considering performing this test in all NQMI patients 
pre-discharge, knowing the frequency of positive results may 
be useful, especially if it is to be followed by active 
intervention. Gibson, in studying the clinical and functional 
differences between Q and NQMI reported that 55% of the NQMI 
patients had either angina or ST segment depression during 
pre-discharge EST (versus 40% of QMI patients [p<0.03]). (55 ) 
Invasive Investigation 
Coronary artery bypass grafting (CABG) has been shown to 
improve prognosis (survival) in patients with left mainstern 
stenosis or triple vessel disease (TVD) and impaired left 
69 
ventricular function. (l20) (l2l) (122 ) Patients with single 
vessel disease may also benefit from revascularisation, CABG 
or percutaneous transluminal coronary angioplasty (PTCA), not 
so much for prognosis/mortality, but for symptoms or further 
recurrence of ischaemia. 
Armed with this powerful argument and without research/trial-
based limitations, pursuit of the knowledge of coronary 
anatomy becomes an overwhelming or irresistible goal once 
triggered off by the patients experience, however transient, 
of chest pain. 
The data concerning the value and applicability of cardiac 
catheterisation, which is always done with a view to 
revascularisation, needs to be re-evaluated for NQMI. 
Hence the importance of the two studies: TIMI II, with 
specific regard to sub-analysis for NQMI, and the second part 
of TIMI IIIB both of which addressed the role of routine early 
coronary angiography followed by revascularisation when 
anatomy was suitable, versus early conservative strategy 
(coronary angiography followed by revascularisation if initial 
medical treatment failed). 
In the 6 weeks of follow-up in TIMI IIIB, which enrolled 
patients with ST segment depression (and included UAP and 
NQMI) and randomised them on admission to either invasive or 
conservative strategies, the results were: (68 ) 
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Catheteri- Revascu- Death1 Endpoint 
sation larisation MI or in patients 
Poaitive i!: 65 years 
EST 
Early Invasive 
Group 98% 61% 16.2% 7.9% 
(p<0.01) (p<0.001) (p=NS) (p=0.02) 
Early Conserva-
tive Group 64% 49% 18.1% 14.8% 
Thus, in general, equivalent results (occurrence of the 
primary endpoint of death, MI or positive EST by 6 weeks) 
could be achieved by using either early conservative or early 
invasive strategy. (In the NQMI subset, excluding the UAP 
patients, only a trend could be demonstrated towards an 
improved 6-week outcome in the invasive group.) 
Additional observations were made: 
1. In patients~ 65 years, the primary endpoint was reached 
in 7.9% of the invasive group; significantly lower than 
14.8% in the conservative group. 
2. There was also a lower incidence of re-hospitalisation, 
days of hospitalisation and use of anti-anginal drugs in 
the early invasive group. 
The TIMI II Study inclusion criteria were ST segment elevation 
with chest pain (>30 minutes, but <4 hours)). In a 
subanalysis to determine whether invasive or conservative 
strategy was favourable, only first infarct patients, all of 
whom had been given TPA, were included and the day 2 ECG 
interpretation was used to differentiate QMI from NQMI. (22) 
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The findings were similar to TIMI IIIB in that, at 6 weeks, 
the occurrences of reinfarction, death or combination were 
equivalent in patients assigned to the invasive or 
conservative post-lytic management strategy - this regardless 
of the presence or absence of Q waves. 
Therefore, in essence, early invasive/active investigative 
management is as good as early conservatism. A number of 
points, however, have to be borne in mind: 
The conservative strategy in these TIMI studies was not 
really conservative, but expectant and actively sought for 
recurrence of ischaemia in the patients (e.g. by EST}. 
The mean time for cardiac catheterisation after the index 
MI in the conservative strategy group in TIMI IIIB was 7.1 
days and since 64% of this group's patients underwent 
catheterisation, it is not entirely surprising the results 
as compared to active management are similar. 
These TIMI studies each included only specific subsets of 
all NQMI infarctions (which is probably the correct way of 
analysing recommendations for such a diverse group at 
NQMI}. The results cannot be generalised and be applied 
to all NQMI. 
Exceptions to the overall recommendations need to be 
noted. Age was shown in TIMI IIIB to be an important 
consideration. This is in keeping with the findings of 
Nicod et al studying NQ and QMI in a large patient 
population that showed higher mortality in NQMI patients 
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only in those >70 years. (28 ) This strengthens the 
argument that a general policy of invasive management may 
not be appropriate in the younger patient population 
(s70 years) without ischaemic events. 
The conservative strategy in TIMI IIIB began on admission 
and thus encompassed the entire initial period of 
instability which is usually during the admission period. 
Therefore, the dilemma of what type of management 
(conservative or investigative) is indicated in the group 
of patients who remained stable or achieved discharge 
without complication is yet to be addressed. 
The follow-up durations in these studies are short (6 
weeks). Longer term follow-up is required to confirm 
these early observations. 
Any reconunendation in favour of catheterisation of 
asymptomatic post-infarct patients still assumes that 
prophylactic revascularisation with CABG or PTCA will 
prolong life and/or prevent reinfarction. Prognostic 
benefit has only been shown, as mentioned before, with 
left mainstem or TVD and impaired LV function. (l20) (121) 
3) Active Intervention - Revascularisation 
a) PTCA 
Percutaneous transluminal coronary angioplasty has been shown 
to be successful in NQMI. A study specifically looking at 
this issue, by Robert et al, showed that PTCA was successful 
in 87% of 68 patients with angina, an average of 2.3 months 
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after NQMI. (92 ) However, this study was uncontrolled and most 
of these patients had single vessel disease with preserved LV 
function, in whom a favourable outcome was expected. It can 
thus not be an endorsement of PTCA in all patients after NQMI, 
particularly in those with complex multivessel disease. 
Furthermore, recurrence of angina in patients who underwent 
PTCA for angina after NQMI varies from 20% to 41%. (24 ) (9 2 ) 
This suggests a relatively high clinical restenosis rate. 
PTCA performed in NQMI patients with recurrence of ischaemia 
appears justifiable and yet, in the TIMI IIIB Study, PTCA was 
performed in the early invasive group even if the patients 
settled down. PTCA was also done to major arteries other than 
the culprit artery - in order "to maximise the relief of 
ischaemia". 
What about the timing of PTCA? In the group of patients that 
receive thrombolytics, there appear to be some answers. 
Routine PTCA in the first 48 hours following thrombolysis, 
offers no benefit and is not recommended. (ll7 ) Immediate 
angioplasty following thrombolysis, as compared to delayed 
PTCA or conservative management, has not been shown to improve 
LV function and is associated with a trend to increased in-
hospital and one-year mortality. (l23 ) Delayed/deferred PTCA 
(i.e. within 48 hours after thrombolysis), compared to a more 
conservative approach, has been associated with increased 
incidence of emergency CABG and no significant reduction in 
rates of reinfarction or mortality. (124 ) On the other hand, 
angioplasty guided clinically (by recurrence of ischaemia) or 
conservative treatment is not associated with any lower 
survival, but is associated with increased incidence of 
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symptomatic post-discharge angina hospital re-admissions and 
possibly costs. (l2S) 
The issue of primary angioplasty also needs to be considered. 
Apart from being another cause of NQMI, by aborting the 
development of QMI, preliminary results suggest that patients 
who .have had primary PTCA have a better prognosis than those 
treated with thrornbolysis, possibly having half the 
reinfarction or mortality at 6 months. (126 ) 
b) CABG 
It was shown, some time ago, that coronary artery bypass 
grafting (CABG) done within 30 days after an acute MI is 
safe. (127 ) Studies assessing the usefulness of CABG in NQMI 
have been few and limited to the assessment of relief of 
symptoms. A prospective study of patients treated with CABG 
within 3 months of NQMI shows on long-term follow-up (16 
months) that there was a 78% incidence of angina-free 
survival. (128) (127) 
In sununarising 'Management Reconunendations', with regard to active 
investigation and intervention, evidence is still lacking in 
support of its general reconunendation in NQMI. Many studies or 
findings suggest aggressive management, but few actually show that 
this translates into improved survival. Routine angiography on all 
NQMI patients before discharge does influence the course of NQMI 
favourably, but this only for symptoms (post-discharge angina and 
re-hospitalisation) and not survival. (124 ) In order to catch all 
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cases where intervention may have benefit, the net has to be cast 
widely . The joint task force of the American College of Cardiology 
and the American Heart Association formulated guidelines for 
coronary angiography and placed NQMI without any qualifications or 
restrictions into Class I - i.e. definite indication for 
angiography . (lOS) The problem with such wide netting is that the 
catch may be unexpected and unwanted. Therefore, if stenosis seen 
on angiography is equivocal, EST (or radionuclide stress testing) 
is then requested and if positive, one may feel compelled to do 
revascularisation even if the patient is stable and his lifestyle 
unrestricted. 
The question remains: how should NQMI be managed? Broadly 
speaking, either as UAP with an aggressive strategy with a view to 
revascularisation, or as an evolved MI with conservative treatment 
supported by investigation if indicated. These are grounds for the 
performance of a study in NQMI, in which the high incidence of 
recurrence may be an advantage in that it is easier to determine 
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II PROJECT OBJECTIVES 
1. PROJECT PURPOSE 
The purpose of this study is to determine and analyse the 
experience of the Coronary Care Unit of Groote Schuur Hospital 
(GSH) with NQMI with specific regard to diagnosis, management, 
investigation and outcome. 
2. PROJECT AIMS 
The aims of this analysis are: 
1) to compare the outcome of patients with NQMI at GSH to that in 
other studies. 
2) to assess the recurrence of myocardial ischaemia in this group 
of patients. 
3) to determine and compare the outcomes of patients managed more 
conservatively as opposed to those who underwent investigation 
and active intervention. 
In achieving these aims, additional conclusions or analyses will be 
possible: 
1) a statistical audit of cardiac catheterisation in NQMI 
(indications, complications, findings, recommendations and 
outcome). 
2) the determination of accuracy of localisation of site of 
myocardial infarction in the absence of localising 
pathological Q waves 
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3. IMPLEMENTATION OBJECTIVES 
Investigation of patients with ischaemic heart disease is 
associated with morbidity, mortality and considerable cost. Thus 
knowledge of the extent of investigation needed in managing 
patients with NQMI may be of great advantage and benefit in 
justifying risks and especially where resources (staff, experience 
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II RESEARCH METHODS 
1. DEFINITION: NON-Q WAVE MYOCARDIAL INFARCTION 
As there is an interest in characterizing the make-up and location 
of NQMI and determining any factors to further risk stratify NQMI, 
a broad definition of NQMI is required to encompass all these 
patients. 
NQMI have previously been equated to:-
* nontransmural infarcts 
* ST segment or T wave infarcts 
* subendocardial infarcts. 
However, these terms are inaccurate and exclusive. 
Thus the criteria for admission into this study henceforth also 
referred to as the Groote Schuur Hospital (GSH) Study, as acute 
NQMI were a triad: 
1 ) 
1) History 
2) ECG changes 
3) CPK enzyme rise. 
History: Suggestive of myocardial ischaemia i.e. typical 
ischaemic chest pain. Obviously this excluded those patients 
with no previous history of ischaemic heart disease and who 
now presented with silent myocardial infarction. It was, 
however, unlikely that such a patient would be admitted to the 
Coronary Care Unit. 
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2) ECG changes - excluding new pathological Q waves (or 
development of them during the hospital admission without 
evidence of recurrent infarction). For the purpose of this 
study the definition of Non-Q MI was used in its broadest 
meaning i.e. absence of new pathological Q waves. Thus, any 
changes in the standardized 12-lead electrocardiographic 
tracing were acceptable except for pathological Q waves 
present in >2 leads which would be defining criteria for a 
NQMI by the Minnesota code and WHO categorization. (74 ) 
Pathological Q waves were defined as: Q waves broader than 
0,04 sec and deeper than 25% of the subsequent R waves. 
Previous Q wave myocardial infarction was not excluded 
provided it was clear that the present index infarct was 
clearly a NQMI, involving a different area and not a 
"reinfarction" in a previous QMI area. Thus it was evident 
that this definition of NQMI would also include: 
a) pathological R-wave infarcts: 
true posterior (Q wave) myocardial infarction (R wave >S 
wave and >30rnS in Vi or V2) which are not considered to 
be true NQMI by some investigators. 
>50% loss of R-wave voltage compared to baseline. 
b) acute myocardial infarction presenting with new LBBB or 
developing LBBB before evolving Q-waves. 
c) subendocardial or 11 ST segment" infarcts. 
d) AMI that are not localisable e.g. LBBB, but these would be 
excluded from analysis of outcome and prognosis as is 
generally accepted in other studies. 
e) Previous Q wave MI. 
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f ) Aborted Q wave MI - by thrombolysis. Subanalysis of the 
results would take these factors into consideration. 
3 . CPK Rise: A diagnostic CPK enzyme rise of acute MI is 
generally considered to be twice the upper normal limit for 
CPK at a particular laboratory excluding other non-cardiac 
sources. (However, some studies have included CPK only 150% 
of their top laboratory normal value. (?S) (9 2 ) Although MB 
iso-enzyrnes are more specific (they may be less sensitive) and 
testing for them is available at GSH, this result was 
available in only a minority of patients. However, it is not 
a requirement for diagnosis, especially if the triad of 
diagnostic features is present, and is used more particularly 
in doubtful cases . The abnormal elevation of CPK had to occur 
before any intervention was performed. 
The triad had to be fulfilled. Hence UAP was excluded. 
2. STUDY DESIGN 
1) Patient recruitment 
2) 
Patients for this study were recruited by retrospective folder 
or admission note analysis of the prim?ry index admission. 
This is facilitated by the keeping of a separate copy, by the 
Cardiac Clinic, of the clerking and admission notes of every 
patient admitted to the GSH Coronary Care Unit. 
Follow-up 
Follow-up and outcome were determined again from folder 
analysis and by telephonic and postal connnunication . 
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3. PATIENT POPULATION 
3A. STUDY POPULATION 
The study population consisted of all patients admitted to the 
Coronary Care Unit (CCU), Groote Schuur Hospital (GSH) between 1st 
January 1990 and 31st December 1993, a period of 4 years. From 
this group were selected all those who fulfilled the triad of 
criteria for the diagnosis of acute NQMI: 181 patients. 
Routine Management: 
Routine management in the CCU consisted of aspirin, IV heparin and the 
introduction of beta-blockers. Calcium antagonists were not given. Thrombolytic 
agents were administered if accepted indications existed:-
1) typical acute chest pain lasting> 30 minutes, unrelieved by nitrates. 
2) ST segment elevation >lmm in 2 contiguous leads. 
3) Total duration of symptoms lasting <6 hours. 
Cardiac catheterisation during the primary admission was not routine practice. 
The aim of cardiac catheterisation was to define coronary artery anatomy. The 
policy of the Cardiac Clinic was to act (i.e. perform revascularisation, either 
PTCA or CABG) on lesions only if accompanied by the occurrence of symptoms (and 
not prophylactically). During the study period, the cardiac catheterization 
laboratory was not very aggressive with PTCA. Stenting or other percutaneous 
revascularisation methods were not available during the time period of this 
study. 
Exercise stress testing or other tests of evoking ischaemia were not routine 
practice at GSH, either pre-discharge or at the first follow-up visit . 
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Follow-up occurred at the Cardiac Clinic, Medical Outpatients or Day Hospitals 
and by Family Practitioners. The policy at GSH was to discharge well and stable 
patients from follow-up clinics to the community. 
Factors or characteristics analysed: 
Each of the 181 NQMI patients was analysed with respect to:-
1) Demographic features (age, gender, race); 
2) Risk factors or previous medical history of angina, myocardial 
infarction or ischaemic heart disease, hypertension, diabetes 
mellitus, hyperlipidaemia, cardiac failure, peripheral 
vascular disease; history of smoking or heavy alcohol intake; 
use of aspirin prior to the index NQM; 
3) Time periods: duration of preceeding angina, duration of 
acute pain, time from pain onset to admission in GSH; 
4) Admission characteristics: blood pressure, evidence of 
cardiovascular instability, ongoing chest pain, arrhythmias; 
5) Laboratory investigations: CPK enzyme peak, CPK-MB iso-enzyme 
positivity, cholesterol level. (CPK enzyme levels were taken 
routinely on admission, at 12 and 24 hours) (MB iso-enzyme was 
considered positive if the CPK-MB isoenzyme level was >6% of 
total CPK level); 
6) ECG findings; 
7) Initial management: thrombolysis, heparin use, inotrope use; 
8) Cardiac catheterisation and angiographic findings 
and definitive in-hospital management: medical or 
revascularisation; 
9) In order to determine what proportion patients with myocardial 
infarction and particularly NQMI formed of the annual work-
load of the coronary care unit, all patients admitted to the 
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GSH CCU in 1993 were analysed as to the reason for admission. 
If this was a myocardial infarction, the following factors 
were determined: 
- QMI or NQMI 
- use of thrombolytics 
- ECG location. 
3B. ELECTROCARDIOGRAPHIC ANALYSIS 
This was based on admission and subsequent daily ECGs which were 
also requested whenever there was a change in the condition of the 
patient. All these were analysed with respect to development of Q 
waves, which if found, resulted in the exclusion of the patient 
from this study. i.e. the non-Q wave diagnostic feature was not 
based on the admission ECG. 
In many instances it is difficult to assess accurately the specific 
infarct subtype (Q vs NQMI) on admission. Some patients develop Q 
waves rapidly and others will evolve Q waves over the course of 
days . (66 ) A natural history study of early NQMI has shown that 20% 
of patients who on admission "had" a NQMI with ST segment elevation 
developed Q waves subsequently and 15% with ST segment depression 
and/or T inversion developed Q waves subsequently. (69) 
All these ECGs were assessed to determine NQMI location. NQMI 
localisation appears to have prognostic implications. Location was 
determined by the leads in which primary ECG changes occurred, as 
based on criteria for infarct location described by Scharnroth( 129 ) 
and Rowlands. (l30) The primary ECG changes in decreasing order of 
importance or validity are: 
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1) ST segment elevation (in 2 contiguous leads), primarily and 
2 ) T wave inversion (in 2 contiguous leads) 
3) ST segment depression in combination with T wave inversion. 
4) R wave changes: 
peaking/dominance in Vi and V2 
loss of R wave height (regression) in anterior chest leads. 
ST segment depression alone was not used as it is considered to be 
a poor localiser. (30) (l3l) 









(above ECG changes in 2 leads of II, III and 
aVF) 
(as for inferior with peaking or dominant R 
wave in v1 or V2) 
(as for inferior with changes in V6, I or aVL) 
(dominant R wave in Vi or V2) 
(equivalent to extensive anterior: changes in 
v1 to v5 or V6) 
(changes in v1 or V2 to V3 or V4) 
(changes in V4 to v6 plus I or aVL) 
(changes in I and aVL) 
Another category termed: "widespread ST segment depression" and 
often labelled as subendocardial location, was identified if there 
was: 
* widespread ST segment depression 
* without inverted T wave localization or NQMI location in 
multiple areas 
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* and these chang·es were persistent. 
Non-localisation: i.e. not localizable to one territory 
(* ST segment depression only i.e. no T inversion or 
* T inversion in 2 territories) 
The admission ECG specifically and prior to any acute management 
e.g. thrombolysis, was assessed for: 
* ST segment elevation 
* ST segment depression 
* T inversion (in the absence of ST segment elevation) 
* ST segment depression (in the absence T inversion) 
as these features have been shown to influence the subsequent 
course in NQMI patients. 
Further analysis of the positive predictive and other statistical 
value of ECG in localisation of NQMI was performed in the group of 
patients who underwent LV angiography in whom specific regional 
wall motion abnormality was considered to be the gold standard for 
defining NQMI location. Angiograms of patients who had had 
previous myocardial infarction were excluded from these 
epidemiological tests. 
3C. CARDIAC CATBETERISATION 
Cardiac catheterisation was performed in 93 patients during the 
primary admission with the index NQMI - this was termed "early 
cardiac catheterisation" (the majority within 96 hours of 
presentation). None of these catheterisations was for a rescue 
angioplasty or a primary angioplasty. 
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Coronary angiography and left ventriculography were performed using 
multiple views of the right and left coronary systems in right and 
left anterior oblique projections to define the coronary anatomy. 
In order to examine whether NQMI patients should be managed with 
active intervention or not, it was important to extract a group of 
patients that was investigated just for the fact that they had 
NQMI. The indications and reasons or justifications/intentions of 
the attending cardiologist, as stated in the written records, for 
this early cardiac catheterisation were analysed. 
Indications for CardiaG Catheterisation: 
1 ) NQMI: Cardiac catheterisation done purely for the presence of 
a non-Q myocardial infarct. 
2) ECG: "ischaemic looking" ECG changes e.g. deep symmetrical T 
inversion in the anterior chest leads suggesting possible 
proximal LAD stenosis; widespread significant ST segment 
depression. 
3 ) NQMI plus "ischaemic-looking ECG": presence of NQMI plus ECG 
which appeared to show persistent ischaemia. 
4 ) Positive EST: A low level (70% of maximum) exercise stress 
test was performed during the primary admission in only 9 
patients to determine inducible ischaemia in "incomplete 
myocardial infarction" . 
5 ) Unstable angina pectoris history: 
pectoris preceding the index NQMI. 
History of severe angina 
The NQMI was considered to 
be a non-final event or a small infarct not resolving the 
u:qd~rl_ying problem. 
6 ) Unstable immediate outcome or ongoing chest pain. 
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7) UAP - post infarct angina. 
8) Dissection of aorta presenting with NQMI. 
Contraindications to cardiac catheterisation were determined: 
1) cardiac catheterisation was indicated for reasons of cardiac 
ischaemia or NQMI, but considered inadvisable because of co-
morbidity e.g. poor lung function, morbid obesity, bedridden, 
poor left ventricular function or cardiomyopathy, 
cerebrovascular disease. 
2) patient refusal. 
Complications as a result of catheterisation were noted. 
The findings at cardiac catheterisation were assessed: 
1) haemodynamic: LV end diastolic pressure 
2) angiographic: a) left ventricular and b) coronary 
All the angiograms (121) performed in this group of NQMI 
patients were analysed. To ensure uniformity of inter-
pretation, they were all reviewed by one investigator and over 
a short period of time (4 days) to maintain consistency. This 
was done blinded to the ECG findings or previous history of 
myocardial infarction. Where marked discrepancies were noted 
-
with the initial angiogram report, re-analysis was performed. 
If the findings were subsequently found to be in keeping with 
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the history or ECG evidence of previous myocardial infarction , 
or if another myocardial infarction was sustained after the 
index NQMI and before cardiac catheterisation was performed, 
these angiograms were considered as being invalid for further 
analysis. 
a) LV Angiography: 
This was assessed for: 
- impaired LV function 
- dilatation of LV 
- regional wall motion abnormality: 




The findings were then used to determine NQMI location by 
angiography. 
b ) Coronary angiography: 
Assessment was made of: 
presence of occlusive coronary artery disease (whether or 
not the considered culprit lesion was occluded or patent); 
vessel involvement (single, double, triple, and/or 
mainstem, vasospasm); 
culprit vessels (primary and if difficulty to ascertain, a 
secondary culprit vessel was noted) 
(The identification of the culprit vessel or Infarct-
Related Artery (IRA) is based on the severity of stenosis 
iri re1.ation to the site of regional·wall motion 
abnormality . Thus, the IRA may be defined as the vessel 
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that was most likely responsible for the abnormalities 
observed on LV angiography.); 
culprit vessel (IRA): occlusion or patency; 
collaterals: these were graded according to Rentrop's 
classification(89). 
Grade O = 
Grade 1 = 
Grade 2 = 
Grade 3 = 
no visible filling of collateral vessels 
collateral filling of branches of the 
occluded or stenosed vessel without any dye 
reaching the epicardial segment of that 
vessel (i.e. very poor collaterals) 
partial collateral filling of the 
epicardial segment of the diseased vessel 
complete filling by collateral vessels of 
the culprit vessel. 
Early catheterisation refers to catheterisation during the primary 
hospital admission (not necessarily during the CCU stay) as a 
result of an indication determined during the CCU admission. 
Late catheterisation refers to those investigations indicated only 
after discharge from CCU following admission with the primary NQMI. 
This was considered as failure of initial conservative management. 
3D. FINAL LOCALISATION OF NOMI: 
In order to determine the final location of the NQMI, results of 
all investigations performed in an individual were considered. 
They were ranked in decreasing order of certainty or validity with 
regard to power -0f localisation: 
92 
LV angiography: regional wall motion abnormality 
echocardiography 
nuclear LV imaging 
coronary angiography (supposed culprit vessel) 
ECG: ST segment elevation 
pathological R wave 
T inversion 
ST segment depression and T inversion 
3E. MANAGEMENT 
The records, particularly of those who underwent early catheteri-
sation, were analysed to determine what recommendations were given 
or what action followed, viz . : 
1) medical treatment; 
2) percutaneous transluminal coronary angioplasty; 
3) coronary bypass grafting; 
and for alternative action if the patients subsequent course 
indicated it (e.g. recurrence of symptoms). 
Early revascularisation was considered to be the total of PTCA and 
CABG as a result of early catheterisation. 
Late revascularisation included all the PTCA and CABG patients in 
whom these procedures were recommended as a result of late 
catheterisation which was performed for failure of initial 
conservative management or where medical (only) treatment had been 
recommended at the earlier procedure. 
93 
4. PROGNOSIS, ANALYSIS AND FOLLOW-UP 
4A. IMMEDIATE OUTCOME 
The immediate course (and status during the first 24-48 hours) of 
admission to the CCU was assessed and the patients were classified 
as stable or unstable. 
The unstable group included: 
1) Cardiovascular instability: 
haemodynamic instability (cardiogenic shock) 
requiring inotropes 
significant pulmonary oedema 
2) Ongoing ischaemic chest pain 
3 ) Arrhythmia 
(life-threatening e.g. - ventricular fibrillation 
- symptomatic ventricular 
tachycardia 
- symptomatic bradycardia 
e.g. CHB) 
This group could be considered to have required intensive care 
management and intervention for subsequent survival. 
4B. FOLLOW-UP 
Follow-up of the patients was essential in order to determine the 
validity of factors in risk stratification of NQMI and its 
management: conservative versus active intervention. A minimum 
follow-up period of one year was striven for. This was achieved in 
166 patients (92%) including accumulated deaths over a period of 
-
one year. Longer periods of follow-up were impractical as there is 
a high incidence of loss of follow-up by Groote Schuur Hospital 
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with attendance at other regional hospitals and general 
practitioners. (Stable patients are routinely discharged from 
further follow-up at GSH.) Those patients about whom less than one 
year of information subsequent to the index NQMI was available by 
folder analysis, were contacted by telephone or post. 
Factors noted in follow-up were: (endpoints in the study) 
1) Recurrence of ischaemia: 
patients with AMI at GSH do not, as is sometimes 
recommended, routinely undergo tests to provoke ischaemia 
e.g. EST, thal_lium or sestamibi stress tests, helter 
monitoring; rather, recurrence of ischaemia is awaited by 
the spontaneous declaration of further symptoms. 
recurrence was defined as being early, following 
recognised definitions, if it occurred within 3 months of 
the index NQMI. 
although recurrence was considered to be a failure of 
either conservative or active management and thus an 
endpoint in this study, the patients were still followed 
up to the minimum period of a year to determine re-
admission or mortality . 
2 ) Re - admission for recurrence of ischaemia; taking into 
account: 
the need for, results and recommendations of late cardiac 
catheterisation 
late revascularisation. 
3 ) Reinfarction 
4 ) Cardiac failure subsequent to discharge after index event. 
5 ) Mortality: 
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a) time interval after index events 
i) in-hospital (early): a generally reported term 
ii) subsequent to discharge 
b) cause: 
i) cardiac - this included all deaths attributed to the 
heart or myocardial infarction, i.e. intra- or 
peri-operative (less than 30 days after cardiac 
surgery [ CABG] ) 
ii) non-cardiac 
as a result of reinfarction, ischaemia or 
cardiac failure. 
5. STATISTICAL METHODS 
Patient data was captured on a personal computer using Paradox 4.0 
(Borland), a relational database management programme. Data was 
analysed using Statgraphics 6.1 (Manugistics) and Epiinfo 5.00 
(Centers for Disease Control, Atlanta/ World Health Organisation, 
Geneva). Continuous data are presented as mean± standard 
deviation. Frequencies and outcomes were examined and compared in 
a fourfold tabular analysis. Categorical variables were analysed 
by Chi-square and . Fischer exact test for small numbers. Continuous 
variables were compared using the Student's T-test. 
Survival curves were determined by Kaplan-Meier survival 
probability methods. The log-rank (Mantel-Haenszel) statistic was 
used for comparing survival rates and time to event variables. 
When analysing risk factors, (l32 ) variables found to be significant 
by univariate analysis were then entered into the model of stepwise 
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logistic regression to identify independent predictors or subsets 
of variables that in combination were good predictors. 
Further multivariate analysis was performed by means of the 
discriminant function analysis model (with stepwise analysis to 
maximise the chi-square value) to evaluate the independent 
importance of prognostic variables. This was done for following 
endpoints: 
1) outcome (immediate) 
2) mortality (specifically cardiac at 12 months) 
3) recurrence 
P values of <0. 05 were. _considered statistically significant. 
(However, in the examination of multiple subgroups where it is 
difficult to interpret a claim of statistical significance at a 
given p value, (l04 ) the Bonferoni argument( 133 ) was considered, and 
the p value for significance was reduced.) 
6. ETHICAL CONSIDERATIONS 
Since this research project is retrospective, ethical consider-
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II FINDINGS AND RESULTS 
1. CCU ADMISSION STATISTICS 
A. 1990 - 1993 
Analysis of population in NQMI study: 
Total number of NQMI patients in 4 years, 1990-1993 (fulfilling 
admission criteria for study) admitted to GSH CCU= 181 
1990 32 NQMI patients 
1991 43 NQMI patients 
1992 52 NQMI patients 
1993 54. NQMI patients 
NQ versus all infarcts (1991) = 43/320 
(1993) = 54/316 
NQ versus total admissions 1990-1993 
Duration of admission to CCU: 









1993 CCU TOTAL ADMISSIONS 
INFARCTS 40% 
PERI CAR DIAL D. 1 % 
MISC. 2% 
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CARDIAC FAILURE 6% 
~..,ERTENSIVE CRISIS 1 % 
POSTPTCA 6% 
UNSTABLE ANGINA 23% 
VALVE PROBLEMS 8% 
AORTIC PROBLEMS 1 % 
ARRHYTHMIAS 13% 
Figure No.5: The frequency of admissions by diagnosis to CCU in 1993. 
B. TOTAL CCU ADMISSIONS IN 1993 
PATIENTS 
DIAGNOSIS/REASON FOR ADMISSION 
UNSTABLE ANGINA PECTORIS 
MYOCARDIAL INFARCTS 
ARRHYTHMIA (incl. for Cardioversion) 
CARDIAC FAILURE 
VALVE PROBLEMS (both Native and Prosthetic) 
PERICARDIAL DISEASE 
AORTIC DISEASE (incl. dissection, aneurysm) 
. 
HYPERTENSIVE CRISIS 















LOCATION OF INFARCT: QMI vs NQMI 
QMI NQMI 
ANTERIOR 48% ANTERIOR 50% 
INFERIOR 51 % INFERIOR 22% 
Figure No.6: Location of Q wave and non-Q wave infarcts in patients admitted in 1993. 
MYOCARDIAL INFARCTS 1993 
TOTAL 
TYPE 
Q WAVE INFARCTS 
NON- Q WAVE INFARCTS 
LOCATION 
a 316 PATIENTS (39.9% OF ALL ADMISSIONS) 
= 262 
= 54 
(82.9% OF ALL INFARCTS) 
(17.1% OF ALL INFARCTS) 
LOCATION (BY ALL MI QMI NQMI 
ECG) 
ANTERIOR 153 (48.4%) 126 (48%) 27 (50%) 
LATERAL 3 (0.9%) · 2 (0 . 8%) 1 ( 1. 9%) 
I NFERIOR 144 (45.6%) 134 (51%) 12 (22%) 
NON-LOCALISED 14 (4.4%) 0 14 ( 26%) 
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Figure No.7: Proportion of QMI and NQMI patients admitted to CCU in 1993 
who received thrombolytics. 







(43.7% OF ALL INFARCTS) 
( 48% OF ALL QMI) 
(p=0.001) 
(24% OF ALL NQMI) 




mean 55.3 ± 10.7 years 
range 28 to 79 years 




57.3 ± 9.7 years 
(p=NS) 
54.2 ± 11.1 years 
RACE/ GENDER GROUPS: (as recorded by the hospital computer) 
White male 21 
female 6 
Coloured: male 94 
female 53 
Indian: male 0 
female 3 




3. RISK FACTORS AND PAST HISTORY 
FACTOR ABSENT PRESENT % PRESENT 
Angina 113 68 37.6 
Previous MI 148 33 18.2 
Previous Il:ID / Cardiac 90 91 50.3 
Hypertension 94 87 48.1 
Diabetes Mellitus 146 35 19.3 
Hypercholesterolaemia 159 22 12.2 
Cardiac Failure 177 4 2.2 
Peripheral vascular disease 166 15 8.3 
Family History 103 78 43.1 
Smoking 64 117 64.6 
Alcohol 169 12 6.6 
Prior aspirin use 154 27 14.9 
Prior beta-blocker use 138 43 23.8 
Subanalysis of risk factors: 
Smoking: Females 33 (51.6%) 
(p=0.0065) 
Males 84 (71.8%) 
Age: Smokers <70 years versus~ 70 years (p<0.0001) 
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4. PRESENTATION: TIME DURATIONS (for NQMI patients in 1993) 
All patients Males Females Signi-
ficance 
Angina (duration 
prior to NQMI) 2.1 ± 2.5 weeks 1.99 ± 2.75 2.5 ± 2.1 (p=NS) 
Chest pain (of 
acute NQMI) 4.0 ± 3.6 hours 4.13 ± 3.98 3.77 ± 2.8 (p=NS) 
Time from pain 
± onset to hospital 7.11 8.8 hours 8.25 ± 10.4 4.73 ± 3.3 (p=NS) 
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= 872 I.U. 
= 200-6961 
Median = 688 
(no significant difference between 
group with thrombolytics versus 
group without) 
Mean = 6.5 ± 1.5 nunol/1 
Range = 2.9 - 12 
Median= 6.4 
MB Fraction result only available in 13. 
BP average: 
ECG: 
100.3 ± 10.1 mmHg 
hypotension in 8 patients 
hypertension in 48 patients 
ST segment elevation = 97 
ST segment depression = 52 
T inversion (excluding 
ST segment elevation) = 62 
ST segment depression 
(excluding T inversion) = 11 





6. NQMI LOCALISATION BY ECG 
Location No. " Territory/Group No. 
Inferior 36 19.9, 
Inferoposterior 5 2.8 ~ Inferior 62 
Inferolateral 21 11. 6_J 
Posterior 3 1. 7 Posterior 3 
Anterior 15 8.3, 
Anteroseptal 19 10.5 ~ Anterior 72 
Anterolateral 38 21 . o_J 
Lateral 4 2.2 Lateral 4 
Left BBB 4* 2.2, 
I 
Widespread ST-depressio~ 
~ "subendocardial" 8 4.4 Non-localised 4 
I 
Unknown 28 15 . 5_J 
Therefore: Localised 141 77 . 9% 
Non-localised 40 22 . 1% 
For purpose of analysis these are usually considered as 







22 . 1 
7. MANAGEMENT 
Thrombolysis: 





1990: 3 32 
1991: 5 43 
1992: 8 52 
1993: 13 54 
Nil 152 
Thrombolysis use: 
Amongst inferior infarct group 
Amongst anterior infarct group 
Amongst posterior infarct group 






Not given in 
Beta-blockers: 
Given in 
Not given in 
Aspirin: 
Given in 

















= 14/ao = 17.5% 
= 15/72 = 20.8% 











Yes 93 patients; cath. rate= 51.4% 
No 88 
Late catheterisation: 28 patients (of these, 12 were repeats) 
(cath. rate= 16.1%) 
Total catheterisation:~ 





Indications for early catheterisation: 
NQ 
ECG 
NQ plus "ischaernic-looking" ECG 
EST positive 
UAP history 
Unstable/ ongoing pain 











(i.e. catheterisation indicated for cardiac ischaernia/NQMI reasons, 





Dissection of aorta 







d) Early catheterisation requirements by ECG determined NOMI 
location/territory: 
NQMI locations No cath Cath Cath % Territory/Group 
Inferior 23 10 30.3 -i 
Inferoposterior 5 19 79.2 1-- 42.9 
Inferolateral 12 1 7.7 ___J 
Posterior 2 10 83.3 
Anterior 12 31 72.1 -i 
Anteroseptal 2 1 33.3 I- 55.6 
Anterolateral 18 8 . 30.8 ___J 
Lateral 1 0 0 
Non-localised 13 3 18.8 
(No significant differences between no catheterisation and 
catheterisation, except for posterior infarcts p=0.012) 




LVEDP mean = 22 ± 8.lmmHg 
(Using one-way analysis of variance, the only factor achieving 
statistical significance with regard to elevation of 
LVEDP is CPK >500 : p=0.004) 
ANGIOGRAPHIC FINDINGS 
LV angiograRhY 
NO YES % 
i) LV impaired 15 86 85 
ii) LV dilated 97 4 4 
iii) LV regional wall motion abnormality: 
- No abnormality 17 
- Hypokinesia / Ak.inesia 74 
- Dyskinesia 6 
- Aneurysm 4* 



















RAO and LAO projections: 
1 Apical = Api 
2 Anterolateral = AL 
3 -· Anterobasal =AB 
4 Inferior = Inf 
5 Posterobasal = PB 
6 Basalseptal = BS 
7 Midseptal = MS 
8 Anteroseptal =AS 
9 Posterior =P 
1 O Apicoposterior =AP 
Figure No.a: Sites of regional wall motion abnormality as defined 
by right anterior oblique (RAO) and left anterior oblique (LAO) 
projections in left ventricular (LV) angiography. 
b) 
iv) LV site of wall motion abnormality: 
LV site No. of Site No. of 
patients combinations patients 
1. Apical 6 4+5 14 
2. Anterolateral 1 4+5+9 7 
3. Anterobasal 0 4+9 3 
4. Inferior 4 5+9 5 
5. Posterobasal 10 1+4+5 4 
6. Basalseptal 0 1+8 10 
7. Midseptal 0 4+10 3 
8 . Anteroseptal 1 4+10+1 3 
9 . Posterior 3 1+2 8 












i) Coronary occlusion: 
(i.e. some vessels occluded, whether or not culprit lesions 







ii) Coronary artery disease by vessels: 
Single vessel disease 
Double vessel disease 
Triple vessel disease 






(No risk factors e.g. DM, smoking, hypertension were 
identified for number of vessels involved.) 
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B. 
iii) Culprit vessels (infarct-related artery): 
Primary culprit Secondary 
lesion culprit 
Circumflex 25 7 
Diagonal 1 1 
LAD 31 8 
Mainstem 2 2 
Obtuse marginal 11 2 
Right Coronary 28 6 
Ramus 4 0 
iv) Culprit vessel occlusion versus time of angiography: 
Early Late 
angiography angiography 
Occluded 56 (60.2%) 9 (32.1%) p=0.009) 
Patent 37 19 
v) Collaterals: 
None 39 39.8% 
Grade 1 14 14.3% -, 
Grade 2 26 26.5% f- 60.2% 
Grade 3 19 19.4% _J 































9. FINAL LOCALISATION OF NQMI 
NQMI location was determined by these factors, where available, which 
are listed in decreasing order of certainty or validity with regard to 
power of localisation: 
* LV angiography - regional wall motion abnormality. 
* Echocardiographic findings 
* Nuclear imaging 
* ECG - ST Segment elevation 
* Coronary angiography - supposed culprit vessel 
* ECG - T wave inversion 
* ECG - ST depression and T wave inversion combination · 
NQMI Location No. % Group/Territory 
Inferior 33 18.2 -, 
Inferoposterior 34 18.8 I- Inferior 
Inferolateral 13 7.2 _J 
Posterior 12 6.6 Posterior 
Anterior 43 23.8 -, 
Anteroseptal 3 1.7 I- Anterior 
Anterolateral 26 14.4 _J 
Lateral 1 0.6 Lateral 








10. ACTIVE MANAGEMENT AND RECOMMENDATIONS 
A. RECOMMENDATIONS 
a) Early Catheterisation (n=93) RecoDDDendation/Action: 
Primary Action Alternative action (eg if 
recurrence of symptoms) 
Medical treatment 43 
PTCA 13 
CABG 37 








































PTCA (rate: 11.0%)~ 




Early - 13 
Late 8 
Early - 39 
Late 7 
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Late revascu- TOTAL 
larisation 
PTCA CABG 
0 2 12 
p<0.001 
5 6 51 
11. EPIDEMIOLOGICAL TESTS ANALYSING ECG VERSUS ANGIOGRAPHY IN LOCALISATION OF NQMI* 
A. PREDICTIVE VALUE OF ECG 
By grouped territories: 
Inferior Group NQMI Anterior Group NQMI 
Angio Angio 
Inf. Other Ant. Other grp (not grp 
inf) 
39 48 34 53 
Inf MI Ant MI ECG 23 20 3 ECG 38 24 14 a b 
Not inf Not ant MI 64 19 45 MI 49 10 39 
C d 
Posterior Group NQMI Non-localised NQMI 
Angio Angio 
Post Other Un- Local-grp deter ised 
mined 
11 76 3 84 
Post MI Non-localis. ECG 3 2 1 ECG 16 3 13 
Not post Localised MI 84 9 75 71 0 71 
* First time MI; i.e. excluding previous MI. 
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B. EPIDEMIOLOGICAL TESTS: ECG VERSUS ANGIOGRAPHY 
Bl. ANALYSIS BY GROUPED TERRITORIES 
Inferiox Anterior Posteriox Non-localised 
Group Group Group Group 
Prevalence= 
(a+c)/(a+b+c+d) 44.8 39.1 12.6 3.4 
Sensitivity = 
a/(a+c) 51.3 70.6 18.2 100 
Specificity = 
d/(b+d) 93.8 73.6 98.7 84.5 
False neg. rate = 
c/(a+c) 48.7 29.4 81.8 0 
False pos. rate = 
b/ (b+d) 6.3 26.4 1.3 15.5 
Positive predictive 
value= a/ (a+b) 87.0 63.2 66.7 18.8 
Negative predictive 
value= d/(c+d) 70.3 79.6 89.3 100 
Overall accuracy = 






B2. ANALYSIS OF SPECIFIC ECG LOCATION VERSUS ANGIOGRAPHY LOCATION: 
Inf. Inf. Inf. Post. Ant. Ant. Ant. Over-
post. lat. sept. lat. all 
Sensitivity% 55 6.9 100 18.2 8 100 75 25.3 
Positive 
predictive value 36 100 10 66.7 60 6 35 29 
* Average specificity in localising NQMI within total NQMI and not 
NQMI versus non-NQMI. 
** Or 69.7% if only considering localisable NQMI. 
B3. ANALYSIS BY INFARCT AREA: 
a) Posterior involvement (as determined by angiography) 
Total = pure posterior MI+ inferoposterior MI 
46 = 12 + 34 
ECG sensitivity in detecting posterior involvement = 
but positive predictive value = 
11.4%, 
100% 
b) ECG non-localisable group (where checked by angiography): 
Of the total of 20 NQMI not localisable by ECG, location by 
angiography is: 
- Inferior 3 
- Inferoposterior 5 
- Posterior 3 
- Anterior 6 
- Remain non-localised 3 
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c) ECG •subendocardial group•: i.e. widespread ST segment depression: 
Total 10 
Angiographic NQMI location is scattered in all territorial groups. 
C. EVALUATION OF COMPONENTS OF ECG RE: LOCALISATION OF NOMI 
Tests evaluated the Positive Predictive value of the following specific 
components of the 12-lead ECG in NQMI (excluding previous MI and LBBB): 
- ST segment elevation 
- ST segment depression 
- ST segment depression alone (excluding T inversion) 
- T wave inversion (not associated with ST segment elevation) 
- T wave inversion alone (excluding ST depression) 
ECG No. Positive Predictive Value: 
ST t ST i ST i T i T i 
alone alone 
Inferior 23 100% 67% 50% 67% 50% 
Anterior 38 72% 36% 50% 41% 50% 




Some follow-up available 176 97.2% 
Lost to all follow-up 5 2.8% 
Follow-up at 1 month 176 therefore rate is 97.2% 
3 months 173 95.6% 
12 months 166 91.7% 
Range of follow-up: 0 - 62 months 
1 
Median follow-up time: 20 months 
Average: 21.0 ± 12.3 months 
13. OUTCOME 









Ongoing ischaemic chest pain 
Arrhythmia (life-threatening) 
(e.g VF 




Of the cardiovascular unstable group: IABP required in 4. 
a) Immediate outcome Subanalysis 
i) Univariate: 
Identifiable risk factors/ factors associated with immediate 
outcome: 
Factor Stable Un- Odds 95% Con- Signifi-
patients stable ratio fidence cance 
limits 
Diabetes Mel. 20 15 3.63 1.5-8.6 p=0.001 
Alcohol use 12 0 0 p=0.043--r* 
Smoking** 97 20 0 .45 0.21-0.98 p=0.03__J 
Age >40 years 126 40 1.07- p=0.02 
Thrombolysis 27 2 0.22 0.02-0.96 p=0.03 
ST segment 
depression 4 7 7.27 1.7 -35.4 p=0.003 
"Subendo-
cardial" on ECG 3 5 6.6 1.2-43.7 p=0.014 
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* Note: Alcohol use and smoking appear to confer a reduction in risk 
of instability. 
** Mean age of non-smokers= 61.4 ± 2.4 years; mean age of smokers= 
52.0 ± 1.8 years. 
No significance was achieved for previous ischaemic heart disease, 
hypertension, cardiac failure, peripheral vascular disease, prior 
aspirin or beta-blocker use or ECG non-localisability. Analysis of 
catheterisation findings showed no significant differences in LVEDP, 
occlusive versus patent coronary artery disease, number of coronary 
arteries involved or culprit lesions. 
ii) Multivariate analysis: 
Discriminant analysis: 
Factor Discriminant function 
coefficient {standardised) 
Diabetes Mellitus 0.668 
Age 0.430 
Alcohol use -0.368 
Smoking -0.199 
chi square = 19.1 significance level = 0.0007 
Stepwise logistic regression analysis: 
Factor Significance level 
Diabetes Mellitus 0.003 
Age 0.03 
Alcohol use NS 
Thrombolysis NS 
Smoking NS 
B. LATE OUTCOME 
Cardiac failure after primary admission: 
- Total number: 24 (excluding previous cardiac failure) 
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i) Univariate analysis of identifiable risk, predictive or associated 
factors for late outcome: 
Factor Odds 95% Limits Signi-
Ratio ficance 
Use of inotropes 10 1.53-71.6 p=0.007 
Unstable immediate outcome 3.95 1.46-10.69 p=0.002 
Hypotension on admission 7.45 1.26-42.6 p=0.013 
Inferior NQMI territory 0.25 0.05-0.92 p=0.022 
Beta-blockers post event 0.27 0.10-0.71 p=0.002 
Ischaemia recurrence s12 months 2.56 0.92-7.78 p=0.046 
No significance was achieved for age, past history e.g. diabetes 
CPK level, thrombolysis, number of vessels involved, early 
revascularisation or early recurrence. 
ii) Multivariate analysis: 
Discriminant analysis: 
Factor Discriminant co-efficient 
(standardised) 
Inotrope use 0.422 
Unstable immediate outcome 0.424 
Ischaemia recurrence sl year 0.473 
Beta-blockers post event -0.437 
chi square = 26.0 Significance level = 0.00003 
Stepwise logistic regression analysis: 
Factor Co-efficient Significance F-Ratio 
level 
Beta-blocker use possible -0.167 0.0056 7.97 
Inotrope use 0.326 0.018 5.70 
Recurrence by 1 year 0.105 0.04 4.16 
14. MORTALITY 
A. TOTALS 
Early In- :s3 :s12 months Total Follow-
hospital months up period 
Total deaths 2 9 16 32 
Cardiac deaths 2 7 13 23 
Non-cardiac deaths 0 2 3 9 
B. CAUSES OF DEATH (Breakdown) : 
C. 
a) 
Cardiac deaths (n=23) - O Early in-hospital (non-peri-
operative) deaths 
- 2 Intra/peri-operative deaths (day 
O + day 1) 
- 21 Cardiac causes (recurrence 
ischaemia, CF) 











MORTALITY RATES (Versus number of patients followed-up at 
particular time) 
Total Deaths: 
Overall mortality rate = 
Three months = 
32; 181 = 
= 
17.7% (with 








/166 = 9.6% (with a 92% 
follow-up rate) 
b) cardiac Deaths: 
Early in-hospital, = 0 = 0% 
but if 2 peri-operative 
2
/101 deaths are included: = = 1.1% 
One month = 4 /176 = 2.3% 
Three months = 7 /173 = 4.0% 
One year = 13; 166 = 7.8% 












4 6 8 10 12 
MONTHS AFTER INDEX NOMI 
Figure No.9: Kaplan-Meier plot of survival probabilities for the total group 
of GSH-study patients in the first year after NQMI. 
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D. MORTALITY SUBANALYSIS 
a) Univariate: 
Risk/assoc. Total Cardiac Deaths Cardiac Deaths at 12 months 
Factors: 
Odds 95% Confi- Signi- OR 95% limits Signi-
Ratio dence limits ficance ficance 
(OR) 
PMH: 
Ischaemia 2.7 (0.97-8.21) p=0.035 NS 
Diabetes 
Mellitus 3.38 (1.14-9.52) p=0.01 5.47 (1.27-24.09) p=0.01 
CF (4.53-a) p=0.0003 44.7 (3.06-2360) p=0.0015 
PVD 5.44 (1.21-22.1) p=0.013 NS 
Age p=0.003 NS 
Hypotension 5.25 (0.71-33.06) p=0.05 8.7 (1.15-51.45) p=0.01 
Hypercholes-
terol p=0.04 NS 
Unstable 
immediate 
outcome 4.36 (1.54-12.1) p=0.002 4.87 (1.28-18.75) p=0.009 
Cath. early NS 0.19 (0.02-0.97) p=0.02 
Cath. Triple 
VD 8.57 (1.01-394) p=0.028 p=0.046 
Culprits: 
LAD/main NS 9.85 (0.89-492) p=0.014 
Collaterals 
present NS 
B. -blockers 0.24 (0.09-0.65) p=0.001 0.29 (0.08-1.09) p=0.035 
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D. MORTALITY SUBANALYSIS - Univariate/cont .... 
* 
Risk/assoc. Total Cardiac Deaths Cardiac Deaths at 12 months 
Factors: 
Odds 95\ Confi- Signi- OR 95\ limits Signi-




3 months} 3.67 (1.08-14.15) p=0.018* 4.57 (1.08-22.18) p=0.019 




three months 2.62 (0.86-7.46) p=0.048 6.87 (1.57 - 30.6) p=0.004** 
Total NS NS 
Univariate analysis shows no significance as risk factors: 
gender, race, past history of angina, myocardial infarction, 
hypertension, hypercholesterolaemia, alcohol, smoking, family 
history, aspirin use, CPK value, ECG ST segment elevation or 
depression, thrombolysis, heparin use, inotrope use, 
catheterisation findings of occlusive coronary artery disease 
and NQMI localisation/non-localisation or specific territory 
group. 







Nine of the 10 cardiac deaths (excluding the 2 intra-operative 
deaths) have a median recurrence of 2 months. 






b) Multivariate analysis 
i) Discriminant analysis of the following factors as risk factors for 
cardiac deaths at 12 months, showed: 
Factor Discriminant function 
coefficient 
(standardised) 
Re-admission by 3 months 0.628 
Past history of cardiac failure 0.833 
Hypotension on admission 0.406 
Immediate outcome 0.296 
with chi square = 53.7 
and predicted groups: no deaths = 94.59% 
deaths = 53.85% 
ii) Stepwise logistic regression analysis - analysing cardiac mortality 
at 12 months as the dependent variable: 
Factor Significance level F-ratio 
Previous cardiac failure 0.00001 37.35 
Hypotension on admission 0.0008 11.7 
Re-admission by 3 months 0.0012 10.9 
Early outcome 3.72 
Recurrence by 3 months 0.80 
Beta-blockers 0.244 
Diabetes 0.128 
Early catheterisation 0.01 
15. RECURRENCE OF ISCBAEMIA 
Recurrence of ischaemia is divided into: 
1) Recurrence of symptomatic ischaemia (refers to earliest symptomatic recurrence i.e. of myocardial ischaemia) (equivalent to event rate) 






median - 3 months 
range - 0.1-37 months 





Recurrence 53 /173 = 30.6% 85; 166 = 51.2% 103; 174 = 59.2% 
Re-admission 33; 173 = 19.1% 49; 166 = 29.5% 60 I . 174 = 34.5% 
Reinfarct 5 /173 = 2.9% 15 /166 = 9.0% 25 /174 = 14.4% 
B) PROPORTION OF ONE-YEAR OCCURRENCES VERSUS TIME: 
Recurrence by Re-admission Reinfarct (15) 
12 months (85) (49) 
At 1 month 39/a5 = 45.9% 27; 49 = 55.1% 4 /15 = 26.7% 
At 2 months 47/a5 = 55.3% 32; 49 = 65.3% 5 /15 = 33.3% 
At 3 months 53/a5 = 62.4% 33/49 = 67.3% 5 /15 = 33.3% 
C) SURVIVAL WITHOUT SIGNIFICANT MORBIDITY: 
Three-month survival 114 /173 = 66% 
Twelve-month survival 76 /166 = 46% 
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NOMI: MONTHLY RATE OF RECURRENCE 
OF ISCHAEMIA 
Cl) 









0 2 4 6 8 10 12 
MONTHS AFTER INDEX NOMI 
Figure No.1 O: Monthly rates of first symptomatic recurrence of ischaemia 




D. SUBANALYSIS OF RECURRENCE OF ISCHAEMIA - RISIC FACTORS 
a) Univariate analysis (single factor study} 
i) Early symptomatic recurrence (i.e. s3 months) 
Risk or Associated Factors 
Odds 95% Signif-
Ratio limits cance 
PMH Hypertension 2.06 1.02-4.22 p=0.03 
PMH Hyperchol 2.88 1.02-8.14 p=0.02 
CPK >440* 0.49 0.24-1.03 p=0.04 
Thrombolysis 2.9 1.07-7.8 p=0.016 
Early Cath i.e. active management 0.51 0.25-1.03 p=0.04 
Early revascularisation 0.09 0.01-0.37 p=0.0001 









0.37 0.15-0.96 p=0.02 
recurrence ischaemia s 3 months 
691.4 
489 
** All risk factors maintain significance if pathological R wave infarcts are excluded (i.e. posterior-infarction on ECG) except inferior location of NQMI. 
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Risk or Associated Factors for Early Recurrence cont/ .... 
Excluding early revascularisation Excluding Thrombolytic 
OR 95% Signifi- Odds 95% Signifi-
cance Ratio cance 
PMH Hypertension 2.28 1.02-5.21 p=0.029 
PMH Hyperchol 2.78 0.91-8.34 p=0.036 
CPK > 440 0.36 ( 0 .15-0) 0.015 0.39 0.17-0.90 p=0.03 
Early revasc. 0.10 0.01-0.44 p=0.0006 
Location of NQMI 0.39 0.16-0.90 p=0.016 
( inferior MI) 
Aspirin use 0.37 0.14-1.02 p=0.026 
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ii) Recurrence (symptomatic) by 12 months: 
Factor OR 95% limits Significance 
Thrombolysis 3.25 (1.13-10.59) p=0.015 
Early cath 0.32 (0.16-0.62) p=0.0003 
Early revascularisation 0.12 (0.04-0.31) p=0.0001 
Smoking 0.28 (0.08-0.89) p=0.016 
Inferior location of 0.47 (0.24-0.92) p=0.016 NQMI 
Analysis for the following factors revealed no significance: 
gender, age, previous angina, previous myocardial infarct, diabetes mellitus, previous cardiac failure, alcohol, family history, prior aspirin use, hypertension on admission, hypercholesterolaemia as measured on admission, use of heparin, use of inotropes, acute outcome, ECG changes: ST segment elevation versus depression versus T inversion, cath findings: number of vessels involved, culprit vessel, occlusive or patent coronary artery disease, presence or absence of collaterals, non-localisation or localisation of NQMI except the inferior group. 
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b) Multivariate analysis for recurrence by 3 months: 
i) Stepwise logistic regression: 
Factor Significance F-Ra tio 
Early revascularisation 0.0003 13.4 6 
PMH hypercholesterolaemia 0.017 5.8 3 
Thrombolysis 0.02 3.5 1 
Aspirin 0.037 4.4 1 
Inferior infarction 0.04* 4.1 0 
CPK 0.045 4.0 7 




















Chi square= 41 . 5 













* Significance increases to 0.0197 if infero-lateral and infero-
posterior infarcts are excluded. 
-
c) Multivariate analysis for recurrence by 12 months 
i) Stepwise logistic regression: 
Factor Significance F-Ratio 
Early revascularisation 0.00 38.34 
Inferior infarction 0.00** 5.66 
Thrombolysis 0.019 3.08 
ii) Discriminant analysis 
Factor Discriminant co-efficient 
(standardised) 
Early revascularisation -0.866 
Thrombolysis +0.285 
Inferior infarct -0.396 
Chi square = 44.7 
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Predicted group percentages: for recurrence by 12 months = 77.6% 
for non- recurrence = 60.7% 
E. REINFARCTION BY 12 MONTHS: StJBANALYSIS 
i) Univariate analysis: 
Risk/Associated Odds 95\ Confidence Significance 
Factors Ratio Limits 
Recurrence by 3 months 3.04 0.93-10.07 p=0.04 
Re-admission by 3 months 3.68 0.97-12 . 79 p=0.028 
Early Catheterisation 0.05 0-0.38 p=0.0003 
Inferior NQMI 0.29 0.05-1.12 p=0.046 
No other significant associations with reinfarction were noted 
including age and past medical history. 
** Significance decreases to 0.0045 if infero-lateral and infero-
posterior infarcts are excluded. 
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16. EARLY CONSERVATIVE TREATMENT VERSUS ACTIVE INTERVENTION 
A. Analysis comparing initial conservative treatment (no early catheterisation, n=88} versus active intervention (catheterisation and appropriate action during the primary admission, n=93}. (No statistically significant differences are noted in demographics of both groups, nor in NQMI location.} 
a} Recurrence 
Conservative Active OR 95% Limits Signifi-(82)* (92)* cance 
Early 
31/92** 22/92 (s 3 months) 0.52 (0.25-1.05) p=0.047 
By 12 months 51 34 0.36 (0.18-0.69) p=0.0009*** 
Total period 
of F/U 58 45 0.40 (0.20-0.78) p=0.0035*** 
b) Re-admission 
By 3 months 21 12 0.43 (0.18-1.00) p=0.03 
By 12 months 34 15 0.12 (0.26-0.55) p=0.0001*** 
Total 38 22 0.36 (0.18-0.73) p=0.0019*** 
c) Reinfarction 
By 3 months 5 0 0 (0-0 . 97) p=0.018 
By 12 months 14 1 0.05 (0-0.38) p=0.0002*** 
Total 18 7 0.32 (0.11-0.86) p=0.012*** 
d) Cardiac Failure NS 
* These are unlike totals because only patients with follow-up were compared statistically. 
** Denominators vary because all statistical analysis takes into account the number of patients followed up to a particular time. *** Significance is maintained even when excluding thrombolysis, LBBB and/or previous myocardial infarction. 
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NOMI MANAGEMENT vs RECURRENCE 
ISCHAEMIA RECURRENCE BY 12 MONTHS 
100 
. 




CONSERVATIVE ACTIVE MANAGEMENT 
p=0.001 
Figure No. 11: Recurrence of symptomatic ischaemia in the first year in patients 
who were managed conservatively versus actively investigated early 
i.e. during the primary admission. 
e) Mortality 
Cardiac deaths 15 8 p=0.055 
Total deaths 21 11 0 . 41 (0.17-0.97) p=0.025 
Note: Of patients who underwent early catheterisation for reasons other than NQMI alone, 41 of the 69 were recommended to have 
revascularisation. 
B. Comparison: no early catheterisation (n=88) 
versus early catheterisation for NQMI only (n=24). 
No statistically significant differences between the two groups were present with respect to: 
demographic factors 
(except age: no early cath 
early cath for NQMI 
use of thrornbolytics 
previous myocardial infarction 
NQMI localisation 
CPK levels 
mean age= 57.3 years 
mean age= 48.5 years 
(p=0.0005) 
a) Recurrence : 
Early 
No early cath. 
cath. for NQMI OR 95% limits Signifi-
(82*) (23*) cance 
Within 3 months 31 7 NS 
Within 12 months 51 11 NS 
b) Re-admission: 
s 3 months 21 4 NS 
s 12 months 34 4 0.27 (0.06-0.94) p=0.023** 
c) Reinfarction: 
s 3 months 5 0 NS 
s 12 months 14 0 0.00 (0.00-0.26) p=0.0001 
d) Mortality: 
Cardiac deaths 15 2 NS 
* Number of patients with follow-up. 




17. SUBGROUP ANALYSIS 
a) •subendocardial group•/ widespread ST segment depression on ECG: 
Compared to the other NQMI groups localised by ECG, there are no significant differences with respect to demographic or risk factors except: 
Diabetes mellitus which approaches significance (p=0.046) 
Immediate outcome is worse (p=0.014) 
No specific angiographic findings were noted. 
b) Mainstem lesions on angiography: 
Number= 4 
Immediate outcome: all 4 unstable - 2 with cardiovascular 
instability 
- 2 with ongoing pain 
c) ECG non-localisable group that underwent angiography (20): 
d) 
e) 





No significant increase in recurrence in non-localisable group. 
Subgroup analysis: Angiographic Findings: 
No correlation was established between occlusive or patent coronary artery disease and specific ECG changes: ST segment elevation/ depression or T inversion. 
Collaterals were found more frequently in groups which had previous ischaemic heart disease (p=0.016). 
Subgroup analysis: Mortality: 
Beta-blockers: 
Prior use of beta-blockers before the index NQMI, did not significantly influence the outcome or subsequent mortality. 
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However, beta-blocker use after the index NQMI was associated with a reduction in: 
Significance Odds 95% Limits 
Ratio 
Total mortality p=0.0001 OR 0.21 10.09-0.50 
Cardiac mortality p=0 . 001 OR 0.24 0.90-0.65 
Cardiac mortality at 
12 months p=0.035 OR O. 29 0.08-1.09 
There was a significant difference in use of beta-blocker between the stable and unstable immediate outcome groups (112/141 versus 15/40 p=0 . 0001) 
In the stable outcome group, there was no significant reduction in mortality amongst thqse on beta-blockers . However, total mortality was significantly less in the group of unstable outcome patients on beta-blockers (p=0.014) (OR 0 . 14 : 0.01-0.87). 
142 
II DISCUSSION II 
1. RESULTS . .................................................. 144 
A. STUDY PRIMARY ENDPOINTS: .............................. 144 
1) Outcome ........ .... ........................... .. .. 144 
a) Immediate outcome 
b) Late outcome - cardiac failure 
2) Mortality ......................................... 149 
a) In-hospital mortality 
b) Post-discharge mortality 
3) Recurrence of Ischaemia ........................... 158 
4) Reinfarction ...................................... 163 
5) Early Conservative Versus Early Active 
Management ........................................ 165 
a) Early ac.tive management 
b) Early conservative 
6) Early Conservative Versus Early Active 
Management in NQMI Alone ............ .... .......... 170 
B. GENERAL RESULTS .... .. ........................ ..... .... 175 
1) Demographic Characteristics ... ..... ............... 175 
a) Age 
b) Gender 
2) Habits: smoking and alcohol intake ............... 180 
3) Cardiac Catheterisation and Coronary 
Angiographic Findings ............................. 182 
4) Thrombolysis and Incidence of NQMI ................ 188 
5) NQMI Location ..................................... 190 
2. ECG LOCALISATION OF NQMI . ................................. 193 
A. ECG FOR LOCALISING NQMI TERRITORY ..................... 194 
B. ECG FOR DETERMINING SPECIFIC NQMI LOCATION ............ 195 
C. SPECIFIC COMPONENTS OF ECG FOR LOCALISATION ........... 196 
D. SIGNIFICANCE OF COMPONENTS OF ECG IN NQMI . ...... ...... 198 
3. COMMENTS ON GSH CCU STATISTICS ............................ 200 
A. NQMI VERSUS QMI RATE .................................. 200 
B. TIME DELAY: ONSET TO TREATMENT ................. ...... 202 
C. ASPIRIN ............................................... 204 
143 
D. BETA-BLOCKERS ......................................... 204 
E. CPK ENZYME ............................................ 2 05 
4. GSH CCU MANAGEMENT OF NQMI ................................ 206 
5 . LIMITATIONS/ SHORTCOMINGS OF THE STUDY ................... 208 
6 . SUGGESTED FUTURE STUDY .................................... 2 0 9 
7. RECOMMENDATION: CONSERVATIVE VERSUS INVASIVE ............. 212 




A. STUDY PRIMARY ENDPOINTS 
B. GENERAL RESULTS 
lA. STUDY PRIMARY ENDPOINTS 
1) Outcome 
a) Inunediate Outcome 
As defined previously, the inunediate course and status during 
the first 24-48 hours of admission to the CCU were assessed 
and classified as stable or unstable. The unstable group 
could have been considered to have required intensive care 
management and intervention for subsequent survival. In 
addition, it was important to assess whether early instability 
was a marker for a subsequent unfavourable outcome with 
increased mortality or recurrence of ischaemia. If this were 
the case, then identifiable risk factors of poor inunediate 
outcome could possibly identify those patients requiring 
earlier or more active intervention. 
Of the study patients, 77.9% (141 patients) were stable 
(Figure No. 12). Of the 22.1% (40 patients) whose inunediate 
course and outcome of acute myocardial infarction was 
unstable, 23 patients were cardiovascularly unstable 
(haemodynamically unstable, in pulmonary oedema or requiring 
inotropes), 17 had ongoing chest pain and 3 had life-
threatening arrhythmias. Four required intra-aortic balloon 








Figure No.12: Immediate outcome following admission with index NQMI. 
patients. Interestingly, none of these unstable patients died 
except for two who died intra- or immediately post-coronary 
artery bypass graft surgery (CABG). This relatively good 
immediate outcome is a credit to the CCU and is also in 
keeping with the better immediate course normally found in 
NQMI. Goldberg in the Worcester Study showed a significantly 
lower complication rate in the acute phase in NQMI as opposed 
to QMI: 19% of patients had hypotension, 3% shock and 2.2% 
had life-threatening arrhythmias. (S4 ) 
In this GSH study, the 17 patients with ongoing ischaernic 
chest pain were included in the unstable group. Other studies 
of NQMI have defined those patients with recurring chest pain 
more specifically as either infarct extension or reinfarction, 
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which have been regarded as evidence of treatment failure. 
The group of unstable patients in this study with ongoing 
pain, was considered to be part of the spectrum of 
presentation of all infarcts, not as treatment failure. 
Rather, it was an indication for urgent active intervention. 
Re-elevation of CPK enzyme levels, in order to confirm 
extension or recurrence of infarction, was not specifically 
sought in this group, unless the ECG suggested ST segment 
elevation or development of Q waves. 
Univariate analysis determined that diabetes mellitus, age 
>40 years and widespread ST ·segment depression on admission 
ECG were probable positive risk factors. That diabetes 
mellitus and increasing age are risk factors, is not 
surprising as both are associated with increased prevalence of 
multivessel coronary artery disease and previous myocardial 
ischaemia which itself did not achieve any statistical 
significance as a risk factor. 
Maeda, in analysing the different clinical implications of ST 
depression and T inversion in 42 NQMI patients on the basis of 
ECG, coronary angiography and left ventriculography, suggested 
that, unlike T wave inversion which was frequently preceded by 
ST segment elevation and represented a recovery phase in a 
localised infarct within presumed one-vessel territory, ST 
segment depression indicated the presence of extensive 
ischaemia in the subendocardium of multivessel terri-
tories. (?O) In the GSH study, ST segment depression was 
associated with the presence of multivessel disease on 
angiography (p=0.045), and although it was shown to be 
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statistically linked to poor immediate outcome, it did not 
predict for subsequent increased mortality or recurrence of 
ischaemia. 
Further review of analysis .of risk factors for immediate 
outcome showed that smoking, alcohol and use of thrornbolytics 
were •negative' risks. The effect of smoking, at face value, 
is surprising. However, it is known that smokers who survive 
MI, frequently have a better outcome( 134 ) (l3S) (see discussion 
under smoking). Thrornbolytics, by saving myocardium, would be 
expected to improve the immediate outcome of patients if 
compared to QMI pa_tients, provided no complications from 
thrornbolysis itself occurred. That thrornbolytics appear to be 
associated with lower risk of immediate complications in the 
group of patients with NQMI, may be because of the strict 
criteria required for thrornbolytic administration -
particularly ST segment elevation. This therefore, excludes 
the group of patients with ST segment depression, which as 
noted, is associated with poor immediate outcome. 
Multivariate analysis confirmed that diabetes mellitus is a 
significant independent risk factor for immediate outcome. 
Comparison of immediate outcome with other studies is 
difficult. In the TIMI II Study, a combination of both 
various patient characteristics and also unfavourable findings 
after admission defined patients as being "not low risk" e.g. 
~10 years, anterior MI, crackles > 1 /3 of lung fields, systemic 
hypotension with sinus tachycardia, atrial flutter or 
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b) 
fibrillation, pulmonary oedema and cardiogenic shock. Thus, 
56% of NQMI patients were considered to be "not low risk". (22 ) 
A similar combination performed in this study revealed 51% 
(93) to be in a similar group. 
The two patients who died were undergoing emergency CABG. One 
did not come of bypass and the other died within hours of the 
operation. In both cases, surgery was performed following 
active investigation during the primary CCU admission. These 
were the only deaths among the 47 patients in total who had 
CABG (39 as a result of investigation during the primary 
admission and 8 following recurrence of ischaemia requiring 
active intervention). The CABG rate was therefore, 26%. The 
operative mortality rate was 4.3% and was related to emergency 
CABG procedures. These results compare well with other 
centres. Madigan et al reported a prospective study of 28 
patients treated with CABG within 3 months of NQMI with a 3.6% 
incidence of peri-operative death and a 10.7% incidence of 
peri-operative acute myocardial infarction. (l28 ) Furthermore, 
it is known that emergency procedures are associated with 
higher mortality. 
Late outcome - cardiac failure 
Excluding those who had a previous history of cardiac failure, 
24 patients were noted to develop cardiac failure during the 
total follow-up period. This cardiac failure rate of 13.6% 
compares favourably with the prognosis assessment in the 
Framingham Heart Study which showed an incidence of cardiac 
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failure following NQMI of 10.1% and 15 . 1% at 1 and 5 years 
respectively(lO). 
The development of late cardiac failure was statistically 
associated with an unstable immediate outcome and the use of 
inotropes during the primary admission. Recurrence of 
ischaemia within 12 months was also related. Surprisingly, no 
statistical significance could be achieved for past history of 
myocardial infarction/ischaemia. 
NQMI located inferiorly and also the use of beta-blockers 
after the index event, both correlated negatively with 
subsequent cardiac failure. However, it was only the beta-
blocker use that maintained significance following 
multivariate analysis . As the introduction of beta-blockers 
was considered routine practice, intolerance or failure of 
their use probably marked those patients with poorer left 
ventricular function (which was the most likely mechanism of 
the cardiac failure) (3 4). 
Cardiac failure after the index NQMI, itself, may be a 
predictor of mortality as 9 of these 24 patients died; a 
significantly higher proportion than those who did not develop 
failure (p=0.005) (OR= 4.23). 
2) Mortality 
Analysis and rates of mortality are traditionally divided 
into: 
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a ) Early or in-hospital mortality; and 
b ) Subsequent or post -discharge mortality; 
a ) 
usually on the presumption that the former is related to the 
acute "peri-infarction-related complications" and the latter 
to the long-term effects of MI . 
In-hospital mortality 
In this study there were no in-hospital deaths except for two 
patients who underwent emergency coronary artery bypass 
grafting (CABG) surgery and died intra-operatively or within 
the first day, post-operatively. 
Compared to generally published .figures, this is remarkable. 
Although meta-analyses of in-hospital mortality rates give an 
average of 10% (with a range from 3-32%) (24 ), this is for all 
types of NQM-infarcts and includes some studies with extra-
ordinarily high mortality rates. Select subsets of NQMI show 
different results, although the Worcester Heart Attack Study 
involving a large number of patients (2451) in one region in 
the USA, with or without previous infarcts, showed an in-
hospital mortality rate for NQMI of 0 . 9% only . (54 ) In a study 
of 148 first infarct NQMI patients, the incidence of in-
hospital deaths was 4.1%. (34 ) The TIMI II Study which 
included only those patients with ST segment elevation who 
were then given TPA, the 21-day mortality rate for NQMI was 
2.1% . (22 ) Further subgroup analysis in a study by Nicod et al 
showed that in-hospital mortality in patients with NQMI was 
significantly lower than QMI patients only in those older than 
70 years. (2l) 
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The reason for the low in-hospital mortality rate in the 
Groote Schuur Hospital Coronary Care Unit (CCU) may be due to 
inadvertent patient selection. Firstly, deaths among acute MI 
patients prior to admission to CCU may have been due to NQMI. 
Note must be made of the long delay between onset of chest 
pain and arrival at hospital in those who survived: 7.1 ± 8.8 
hours. (The time period for those who died prior to admission 
to CCU is not known.) Secondly, due to the low capacity of 
the CCU, many patients with IHD including acute MI are managed 
in the general medical wards and selection criteria need to be 
applied when patients in the Emergency Unit are referred for 
admission to the .CCU. Those patients managed elsewhere are 
not included in this study. These, however, are usually 
patients who are very stable with minor ECG changes only and 
who, should they become unstable, are usually re-referred to 
the CCU. Inevitably, there are those patients who due to 
multiple medical problems, are not considered candidates for 
intensive care and therefore are managed in the medical wards. 
Amongst acute MI patients in the CCU with previous QMI, there 
may have been NQMI. However, unless the acute MI was clearly 
evident to be in a previously non-infarct-related region, 
these patients were excluded from this study. Thirdly, the 
low in-hospital mortality rate reflects the management and 
range of support available in the CCU e.g. emergency 
angiography, intra-aortic balloon pumping and emergency 
revascularisation. 
Early ischaemia after acute MI has prognostic significance. 
The Ischaemia Residua Study Group, analysing low risk acute MI 
patients with an otherwise uncomplicated course, showed that 
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early recurrent ischaemia (defined as spontaneous, transient 
ST depression or elevation and/or T inversion) which occurred 
in 8% of their patients, was the only significant predictor of 
in-hospital cardiac events (deaths, reinfarctions and urgent 
revascularisations). (l36 ) . The GISSI-2 Trial showed that this 
was unrelated to gender, age, ECG location, thrombolysis or Q 
or NQMI. (ll3 ) (136 ) In a study of 93 patients with NQMI, Ogawa 
noted that 12 of 13 patients who died in hospital had ST 
segment depression on ECG and that at postmortem, 
circumferential subendocardial lesions with triple vessel 
disease were found in the majority. (l37 ) Based on data 
obtained from the. Diltiazem Reinfarction Study (DRS), it has 
been shown that 20% of NQMI patients experience one or more 
episodes of spontaneous post-infarct angina during the primary 
hospital admission. (48) 
This GSH Study, although it did not specifically identify 
those with ongoing pain separately, but rather grouped them 
under the unstable irmnediate outcome, showed no increase in 
mortality for this group, nor among an addit~onal 9 patients 
with post-infarct angina during the primary admission, in whom 
according to accepted policy, urgent angiography was 
considered to be indicated. 
Early recurrent infarction is an important risk factor for 
early mortality. Marmor et al found that among patients with 
NQMI, in-hospital mortality was 23% in those with early 
reinfarction and 8% for those without recurrence 
(p<0.05). (l38 ) Braunwald states that in-hospital mortality in 
patients with NQMI is approximately 50-60% that in QMI, unless 
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b) 
early recurrent infarction or infarct extension occurs, in 
which case mortality is similar. (l9) 
No patients were identified in the GSH Study as having 
reinfarction or extension of infarction during their primary 
admission. These may have been missed. Methods of various 
in-hospital re-infarct studies frequently define recurrence on 
a biochemical basis (re-elevation of CPK) following routine 
daily CPK measurement throughout the admission 
period. (142 ) (l43 ) This is not the routine at GSH. 
Post-discharge mortality 
The one-year mortality rate for all deaths was 9.6% with a 92% 
follow-up rate. (The Kaplan-Meir survival curve of all deaths 
in the first year after NQMI is shown in Figure No. 13.) The 
cardiac death rate for the same period was 7.8%. Of the 16 
deaths that occurred during the first year of follow-up, 13 
(81%) were due to cardiac causes and 9 (56%) had occurred by 
the third month. As was noted earlier, NQMI is associated 
with lower early and in-hospital mortality rates than QMI, but 
by one year the mortality rates are similar with possibly a 
higher rate among NQMI patients after the immediate in-
hospital period( 2l) resulting in a "catching up" with the QM! 
rates. Thus, the early advantage possessed by NQMI patients 
is soon lost. 
The cardiac mortality rate in the GSH Study is mid-way amongst 
those reported in various studies. The placebo arm of the 
beta-blocker Heart Attack Trial (BHAT), giving a natural 
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Figure No.13: Kaplan-Meier survival curve taking into account all deaths 
during the first year of follow-up after the index NQMI. 
history in NQMI, showed a one-year mortality of 3 . 1%. (51) 
Yet, a 30-month follow-up study on 148 NQMI patients was 
16%. (34) 
Low rates of mortality (2.4%) among 1473 patients with UAP and 
NQMI were noted at 6 weeks in the TIMI IIIB Trial. (68) 
Schechtman et al showed that the mortality rate decreased 
steadily for the first 3 months and then remained 
constant. (32 ) The GSH Study is in keeping with this as shown 
in the graph relating the number of deaths per month (Figure 
No. 14) . 
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Figure No.14: Monthly rates of deaths after the index NOMI. 
On analysis of the GSH data, for identifiable risk factors, 
univariate methods suggested numerous associations with 
mortality: age, diabetes, past history of ischaemia, 
peripheral vascular disease, hypercholesterolaemia, poor early 
outcome, early cardiac catheterisation, angiographic findings 
of triple vessel disease and early (<3 month) recurrence of 
ischaemia. However, only: 
past history of cardiac failure (p=0.002) 
hypotension at primary admission (p=0.01); and 
re-admission for symptomatic recurrence of ischaemia 
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Kaplan-Meier survival curves of cardiac deaths in the year 
after NQMI in patients who required re-admission for ischaemia 
within 3 months and those who did not. 
were identified as independent risk factors by multivariate 
analysis. 
Other studies have shown different risk factors for early 
mortality compared to late mortality. (32 ) Independent 
predictors of early mortality noted, include: 
ST segment depression persisting during hospitalisation 
(p<0.0001) 
in-hospital reinfarction (p=0.0006) 
history of CCF (p=0,0255) 
Risk factors for mortality may be apparent very early after 
admission. Late mortality (at one year) as reported by Boden 
from the DRS Study is associated with spontaneous ischaemia 
after NQMI and before hospital discharge. (96 ) It appears that 
even the admission ECG may be predictive of late events. 
Willich showed that not only does ST segment depression on 
admission bode poorly, with a higher cumulative one-year 
mortality, but also severe and multiple lead ST segment 
elevation is associated with an adverse prognosis. (l39) 
Independent variables predictive of occurrence of spontaneous 
pre-discharge ischaemia shown by Pierard et al in a study of 
953 patients surviving the first 3 days after acute MI, 
were: (l35 ) 
history of angina before MI 
NQMI 
absence of smoking 
higher age 
These variables: history of past infarction, no smoking and 
age, statistically could not be shown in the GSH Study to 
predict for post discharge mortality. Previous studies have 
shown excess mortality after acute MI in diabetics. (l40) The 
GSH Study showed some univariate association that did not 
reach significance on multivariate analysis. LVH in patients 
with NQMI has been associated with higher rates of mortality 
and reinfarction. (l4l) This was not examined for in this 
study. However, most of these variables are not specific for 
NQMI and are equally valid for QMI. (135) (32) (61) 
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3) 
The mortality findings and associations need to influence 
management both during the primary admission and subsequently. 
The TIMI IIIB Trial showed that a low incidence of 42-day 
mortality of 2.1% can be achieved in a relatively high risk 
group (all patients with ST segment depression} by inunediate 
hospitalisation, bedrest and vigorous use of anti-ischaemic 
treatment, IV heparin and oral aspirin. (68 > The TIMI II Trial 
showed that a low one-year mortality in NQMI patients of 3.4% 
can be achieved following administration of TPA to patients 
with ST segment elevation. (22 > 
The GSH Study sugsests that patients with previous cardiac 
failure and who were hypotensive on admission need to be 
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watched carefully . watched carefully. Since admission f 
of ischaemia within 3 months was a significant risk factor -
this itself must be addressed. Obviously ST segment 
depression pre-discharge, reflects more than just mechanical 
damage, but is an indication of ischaemia requiring active 
management . Prophylaxis against recurrence of ischaemia is 
therefore strongly indicated. 
Recurrence of Ischaemia 
Recurrence of ischaemia is important, not only because of 
considerable morbidity, but also because of, as seen 
previously, the strong association with post-infarct 
mortality( 9l} which applies even to that group of low risk 
patients with an otherwise uncomplicated course as shown by 
the Ischaemia Residua Study Group . (l36} 
In the GSH Study, recurrence refers to the earliest 
symptomatic recurrence of myocardial ischaemia after discharge 
from CCU, which may have required re-admission, or not. As 
noted in Study Methods, patients with acute MI at GSH do not 
routinely undergo tests to .provoke ischaemia e.g. exercise 
stress test, radionuclide stress testing or tests of silent 
ischaemia e.g. Holter ECG monitoring. Rather, recurrence of 
ischaemia is awaited by the spontaneous declaration of further 
symptoms. Since patients were included into this study by 
retrospective analysis of ECGs (looking specifically for non-
QMI) and admission findings, patients with ECGs that showed 
late development of Q waves not associated with recurrence of 
chest pain were excluded. NQMI extensions or in-hospital 
reinfarctions (by CPK iso-enzyme criteria) were not considered 
as separate events unless accompanied by chest pain and ECG 
changes. Definitions of extension vary and may include ECG 
and enzyme re-elevation above the preceding baseline _ 
only. (142 ) (l43) In addition, studies have shown that in 20% 
of patients with NQMI who have infarct extension, new Q waves 
develop when these were initially absent. (l43 ) (l44 ) If these 
developed during the primary admission, the patients would 
have been excluded from the GSH study. Furthermore, prior to 
discharge from the hospital, patients are mobilised in the 
general medical wards. Early recurrence of ischaemia may have 
occurred and may have remained unreported. Thus, the true 
frequency of both reinfarction and recurrence of ischaemia may 
be underestimated. Despite possible underestimation, a very 
high early recurrence rate was noted. (Early recurrence was 
defined as occurring within 3 months.) (Figure No. 16) 
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NQMI: MONTHLY RATE OF FIRST 
SYMPTOMATIC RECURRENCE OF ISCHAEMIA 
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Figure No.16: Monthly rate of the first symptomatic recurrence of ischaemia 
after the index NQMI. 
By one . year (with a follow-up of 92%), there was a recurrence 
of symptomatic ischaemia in 51.2% of patients. Of this group: 
46% had occurred within the first month, 
62% within the first 3 months and almost two thirds 
required re-admission. 
The monthly rate of recurrence, as shown in Figure No. 16, is 
particularly high in the first 2 months, falling off rapidly 
and remaining constant thereafter. Due to possible under-
estimation, the recurrence rate within the first month may 
actually have been higher. As these rates refer only to 
spontaneous symptomatic ischaemia, active search for inducible 
ischaemia (e.g. EST, radionuclide stress test or silent 
ischaemia), which usually is performed within one month to six 
weeks after discharge, may have elevated these early figures 
even more. 
The strikingly high recurrence rate coincides with the 
findings of other studies. A meta-analysis by Nixon showed a 
recurrent angina rate of 47% post NQMI. (24 ) If one 
extr~polated to include NQMI under the old classification of 
subendocardial MI, a study by Madigan et al found that 
unstable angina occurred in almost half the patients with NQMI 
during a follow-up period averaging 11 months. (l4S) 
Analysis of the GSH data to establish risk factors has been 
divided into: 
a) those predicting for recurrence of symptoms by three 
months, and 
b) those predicting for recurrence by 12 months . 
a ) Early symptomatic recurrence is statistically significantly 




hypertension and hypercholesterolaemia 
NQMI not localised in the inferior 
territory and interestingly lower CPK 
elevation and use of thrornbolytics 
no early catheterisation (i.e . 
conservative management and particularly 
no early revascularisation); also non-use 
of aspirin. 
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However, with multivariate analysis, only early revascu-
larisation remained a significant, but negative risk factor. 
It is interesting that lower CPK values and thrombolysis 
showed a trend to increased risk. One may speculate that this 
reflects smaller area of infarction and therefore more 
jeopardised or viable myocardium at risk. 
b) Analysis for symptomatic recurrence of ischaemia by 12 months 
again links thrombolysis, no early catheterisation and no 
early revascularisation with a higher recurrence rate. No 
smoking is also associated with a higher recurrence. 
Multivariate analysis singles out early revascularisation plus 
inferior territory infarcts as being significant independent 
negative risk factors. 
The mechanism of recurrence of ischaemia following 
thrombolysis can be readily explained. Viable, salvaged 
myocardium persists distal to the un- or partly resolved 
arterial stenotic lesion and is thus at risk of further 
recurrent episodes of ischaemia. However, why this subset of 
aborted QMI should be at a significantly higher risk than the 
rest of the NQMI group of patients (p=0.015) where the same 
mechanism exists, is not clear. It is noted statistically 
that significantly fewer thrombolysed patients underwent early 
catheterisation as compared to those who did not receive 
thrombolytic agents (p=0.005). 
That inferior infarction is associated with a lower risk is 
not surprising( 146 ) (G 3 ) (l47 ) and will be discussed more fully 
under NQMI Location. 
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4) 
The GSH data show that 12-month survival after NQMI without 
significant morbidity, is 46%. 
Commentators on other studies which have also shown that most 
recurrence occurs early, indicate that the main effort of 
physicians should not be spent on management of the acute 
event, but rather on the prevention of recurrence of 
myocardial ischaemia and infarction. (33) The retrospective 
analysis of the GSH data appears to be in keeping with this 
and suggests that early investigation by catheterisation for 
the purpose of early revascularisation reduces the risk of 
subsequent recurrence. 
Reinfarction 
Reinfarction is important because it not only re-exposes the 
patient to peri-infarct-related acute complications, but is, 
as has been discussed, associated with higher death rates and 
among those who survive further deterioration in ventricular 
function. (l43 ) 
In this GSH Study, the reinfarction rates were 2 . 9% and 9% at 
3 months and 12 months respectively. As usual, other studies 
give a wide scatter of rates from 4.7% at one year in the 
placebo arm of the BHA Trial (essentially a natural history 
study of NQMI) (5l) to 21% of NQMI, then called subendocardial 
MI in a study by Madigan. (145 ) 
There is greater discrepancy among studies with regard to 
early reinfarction rates. In the TIMI IIIB Trial, 
reinfarction by 6 weeks had occurred in 6.3%. (68) 
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Reinfarction rate at 2 weeks in the Diltiazem Reinfarction 
Study was 9.3%. (142 ) Yet, a prospective study of 
"subendocardial infarcts" by Marmor et al, showed that 43% had 
recurrent myocardial infarction within 10 ± 4 days after the 
initial episode and that this group's mortality rate 
doubled. (l43 ) The high figure relates to their definition of 
recurrent infarction as being a secondary rise iri plasma CPK-
MB levels. This criterion was not used in GSH; the!efore, if 
the second MI was silent or if it resulted in Q waves, these 
patients may have been excluded. 
Numbers in the GSH Study are small. Risk factors for 
reinfarction by univariate analysis appear to be recurrence of 
symptomatic ischaemia and re-admission by 3 months. Re-
infarction is less frequent in those patients with inferior MI 
and in those who had early investigation. Age and past 
history variables were of no significance. 
Risk factors for reinfarction in other studies are: 
spontaneous post-infarction angina(l03) as shown in the DRS 
Study and baseline hypertension (in the Framingham Heart 
Study). (lO) Associations have been noted with a history of 
previous MI, angina, congestive heart failure and diabetes and 
with triple vessel disease on coronary angiography in a study 
by Gilpin in a large population of 3666 acute MI patients. (6l) 
Angina pectoris, however, was the single most important factor 
related to reinfarction on multivariate analysis. This 
supports the practice of performing coronary angiography in 
patients with angina pectoris on follow-up after NQMI. 
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Figure No.17: Monthly rate of re-infarction after the index NOMI. 
Studies have also suggested that early reinfarction involves 
the same coronary artery and site of obstruction, as during 
the index NQMI in up to 90% of cases. (97 ) (l43) After about 6 
months, infarction occurs in the same area in only 50% of 
cases and in 50% randomly. Such analysis is not possible in 
the GSH study where infarct recurrence was not assessed by 
routine follow-up ECG, but refers either to symptomatic 
infarcts requiring admission or to infarcts reported in 
patients re-admitted to the medical wards, not specifically 
for MI, but for UAP or cardiac failure. 
5) Early Conservative Versus Early Active Management 
All the patients in this study were retrospectively divided 
into two groups: (The decision on management had been taken 
by the physician caring for the patient on a variety of 
clinical indications) 
a ) Early active management: 
This refers to management of NQMI patients during the primary 
admission by means of cardiac catheterisation and angiography 
with the prime objective of performing a revascularisation 
procedure (either coronary artery bypass grafting [CABG] or 
percutaneous transluminal coronary angioplasty [PTCA]) if 
coronary anatomy was suitable. 
b ) Early conservative management: 
This group consisted of those NQMI patients who did not have 
cardiac catheterisation during the primary admission to CCU. 
Their subsequent management was expectant and included cardiac 
catheterisation (again with view to revascularisation) if 
indicated by e . g. recurrence of ischaemia. Active search for 
inducible ischaemia by means of exercise or radionuclide 
stress testing post-acute myocardial infarction , was not the 
general policy of the GSH Cardiac Clinic as it was felt that 
recurrence of ischaemia would declare itself spontaneously, 
usually on mobilisation either in CCU or after transfer to the 
general medical ward before discharge from hospital . In 
either group, for the purpose of analysis of outcome of the 
management strategies, recurrence of symptomatic myocardial 
ischaemia (including re-admission with angina and/or 
reinfarction and cardiac deaths) was considered to be a 
failure . 
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(As stated in Study Methods, all patients admitted to the CCU 
received intravenous heparin, aspirin orally and Beta-blocker, 
unless contra-indicated or not tolerated.) 
Analysis of the study data reveals that 93 patients underwent 
cardiac catheterisation during the primary admission to CCU. 
(Follow-up data is available for 92 of the patients.) The 
indications, which have been listed, included all the well-
accepted ones: recurrence or ongoing chest pain and also, 
some patients purely for the reason that they were NQMI. 
Although it was difficult at times to determine retro-
spectively what the consultant cardiologist's primary 
intentions were, at least 24 patients had cardiac catheterisa-
tion for no reason other than they had had a NQMI. A further 
19 were actively managed because they had NQMI, plus an ECG 
that "looked ischaemic" with either ST segment depression or T 
inversion. 
In the group managed with active intervention, so patients 
were recommended to undergo a revascularisation procedure (13 
PTCA and 37 CABG). Furthermore, in 12 of the 43 patients who 
were advised to have medical treatment primarily, 
revascularisation was considered to be an alternative action 
if symptoms recurred. Thus, medical treatment ·as the only 
option was the outcome of active investigation in 33. 3.% of the 
patients. 
The conservatively managed group consisted of 88 patients, 
although follow-up data is only available on 82. In this 
group, none of the indications for cardiac catheterisation 
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Figure No.18: Recurrence of symptomatic ischaemia in the first year after NQMI 
in patients who were managed conservatively versus actively 
investigated during the primary admission. 
listed previously were present. Thus, in essence, this group 
was considered at low risk i.e. low risk of complications 
including recurrence of ischaemia. 
No statistically significant differences were noted in the 
demographic characteristics of the patients of both groups nor 
in the NQMI location. 
Analysis of these two retrospectively divided groups is 
sunnnarised in Figure No. 18. Of the 82 patients who were 
initially treated conservatively, there were 51 who had 
recurrence of symptomatic ischaemia within 12 months. In the 
actively managed group of 92, only 34 had similar recurrence. 
Statistical significance was P=0.0009 . Active management was 
associated with a 25% risk reduction of recurrent ischaemia. 
The difference at 3 months was just within acceptable limits 
of significance (p=0.047). Analysis also revealed signifi-
cantly lower re-admission and reinfarction rates, both at 3 
and 12 months in the actively managed group. However, no 
statistically significant difference was noted with regard to 
mortality. 
The results may, therefore, appear to justify active 
intervention. However, it must be remembered that this was 
not a natural history study or a randomised prospective trial, 
but a non-randomised retrospective analysis. Risk strati-
fication had inevitably taken place in the recommendation of 
active intervention/investigation. 
Bearing in mind the limitation of this study, it is worth 
noting that the conservatively managed group, despite being 
obviously low risk (otherwise the patients would have been 
catheterised) still had a higher recurrence rate than the 
early actively managed patients. 
The fact that no favourable effect on mortality was noted, is 
reminiscent of numerous other studies relating to cardiac 
disorders where significant improvement in symptoms has been 
noted, but no long-term survival benefi~ has been achieved. 
(The GSH experience appears to parallel that of a group in 
Israel who recently reported a retrospective study with an 
improved outcome in patients with a first anterior NQMI 
treated with an early invasive approach . (l48)) 
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6) Early Conservative Versus Early Active Management in NOMI 
Alone 
As mentioned in the previous section, 24 patients underwent 
early cardiac catheterisation purely for the reason that they 
had NQMI (to be called Group A). They were in all other 
respects, low risk and therefore equivalent to the group that 
was initially managed conservatively (Group B). In fact, 
Group A was a little different to the remainder of the early 
actively managed patients who were all clearly higher risk 
patients in whom there was also a trend to more revascu-
larisation - 41 of 68 patients (as opposed to 9 of 24 in 
Group A) (p=0.05). During the fol1ow-up period, 16 patients 
in Group B underwent cardiac catheterisation for recurrence of 
ischaemia. 
Thus, Group A and B represent what would have been the ideal 
if this study were randomised and prospective - all 
essentially low risk, with one group undergoing active 
intervention. 
This, however, is a retrospective study. Taking cognisance 
that such subanalysis tends to lose statistical significance, 
particularly with the low population numbers, and may also be 
considered 'dangerous' if routine practice and management 
should be significantly changed as a result of possibly 
suspect analysis, it is still interesting to speculate what 
the results of a study such as this would be - this if only to 
guide proposals for a future prospective randomised study. 
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Comparisons of the demographics, use of thrombolytics, 
previous MI, NQMI localisation and CPK levels revealed no 
statistically significant differences except for age with 
Group A having a mean age of 48.5 years and Group B, 57.3 
years (p<0.001). 
Analysis of differences in recurrence of cardiac events in 
these two groups showed no significance for recurrence of , 
symptomatic ischaemia nor for cardiac deaths. Significant 
differences in re-admission and reinfarction were noted 
between Group A and B, but only at 12 months after the index 
NQMI with lower rates in Group A (Figure No. 19) . (There were 
no significant differences in any of these respects between 
Group A and the rest of the early catheterised group). 
One may conjecture as to the meaning of such results. 
Firstly, the fact that there appeared to be no significant 
difference in symptomatic ischaemia indicates, provided it was 
not due to lack of numbers, how equivalent the two groups were 
regarding risk. Secondly, the statistical difference with 
lower rates of reinfarction and re-admission in Group A shows 
either that active investigation, even in a low risk group 
such as represented by Group A, has benefit or reflects the 
only other significant difference as mentioned before - the 
younger age in this group. However, why does this not affect 
cardiac mortality? Interpretation here becomes exceedingly 
tenuous as the numbers are small. 
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Figure No.19: Comparison of recurrence of symptomatic ischaemia, recurrence 
requiring re-admission and reinfarction by 12 months in patients managed 
conservatively (NQMI with no other indication for early catheterisation) vs patients 
who were catheterised early where the only indication was the index NQMI. 
The difficulty with interpretation of these results and those 
in the previ ous section is the lack of active search in the 
conservative group of inducible recurrence of ischaemia . Pre-
discharge exercise stress testing (and radionuclide stress 
testing) as discussed previously, is effective in NQMI, both 
in provoking ischaemia and marking individuals at higher risk 
of subsequent complications and risk stratifying a group with 
low risk . Only 9 patients underwent exercise stress testing 
in the GSH Study. 
Other studies have also tried to evaluate conservative and 
act i ve strategies. In the NQMI subanalysis of the TIMI II 
Study (patients with acute MI who presented with ST segment 
elevation and were given TPA), in the conservatively managed 
group (which did include EST in all patients) cardiac 
catheterisation (equivalent to treatment failure) was 
performed by day 42 after thrombolytic therapy in 47.5% and 
subsequent revascularisation in 27.6% of the patients. (22 ) 
The outcomes of conservative management and the invasive 
strategy showed no significant differences in death, fatal or 
non-fatal reinfarction 42 days after lytic therapy. Reported 
reasons for performing the catheterisation before hospital 
discharge in the conservative group were: 






The data would suggest that pre-discharge EST has little 
value. However, the published results do not tally as 71% 
(928) of all the analysed conservatively-managed infarct 
patients completed a hospital discharge exercise test. 
Thirty-three percent had a positive or equivocal result and 
32% went on to catheterisation. No data is available for the 
period between discharge and day 42. 
The TIMI IIIB Study evaluating conservative and active 
management in patients who presented with ST segment 
depression, also showed equally satisfactory clinical outcomes 
whether managed by either invasive or conservative 
strategies. (G 9) In this study, by day 42 after initial 
randomisation, 64% of the early conservative group had had 
catheterisation (with 90% occurring before discharge) and 49% 
had revascularisation. The mean time to catheterisation was 
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7.1 days. Review of the study publication does not reveal the 
number of patients in the conservative arm that underwent 
catheterisation for recurrence of symptoms or positive EST. 
Are these studies comparable to the GSH Study? There are 
three major differences: 
1. The conservative group in the retrospective GSH Study was 
a selected low risk group i.e. the remainder in whom no 
indication could be found for catheterisation during the 
primary admission. In both TIMI II and TIMI IIIB, the 
conservative groups were randomised on admission and were 
clearly not low risk, as noted by the mean time to 
catheterisation of 7.1 days in the TIMI IIIB Study. Yet, 
the GSH Study appeared to relate an unfavourable outcome 
to the otherwise low risk group. 
2. The GSH Study groups were highly heterogeneous including 
the whole spectrum of NQMI. These two TIMI studies had 
highly selected homogeneous groups of patients, with 
regard to ECG, yet were not purely NQMI, the diagnosis of 
which was made post-randomisation. Hence, these TIMI 
studies do not encompass the entire gamut of NQMI. 
3. Both TIMI studies performed pre-discharge EST in their 
conservatively managed patients, unless they had already 
reached the endpoint of a recurrent cardiac event. 
(However, it is not clear to what degree this altered 
management.) EST results from other studies show a 
considerable number to be positive. In a study of the 
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clinical and functional distinctions between Q and NQMI, 
Gibson reported that 55% of the NQMI patients had either 
angina or ST segment depression during the pre-discharge 
EST with 20% experiencing limiting angina resulting in 
test termination(SS). If this policy of a pre-discharge 
EST had been applied to the conservative strategy group in 
the GSH Study, it is possible that the majority of this 
already low risk group that subsequently had further 
complications, could have been identified. The result may 
then have shown that early conservative strategy (which in 
fact, was not as "early" as in either of the TIMI trials) 
was at least equivalent to early active intervention. 
After all in the GSH study, 48.8% of the total group of 
181 NQMI patients and 37.8% of the conservatively treated 
group of patients, did not have any recurrence in the 
first year after the index NQMI. If one performs good 
evidence based risk stratification, it is possible that 
the resulting group assessed as being of low risk, will 
coincide with these groups without any recurrence. 
lB. GENERAL RESULTS 
1) Demographic Characteristics: Age and Gender 
a) Age 
Since progressive coronary artery disease is associated with 
advancing years, the ages of patients included in any study 
within the spectrum of ischaemic heart disease, may play a 
major role in influencing the outcome. 
This has been seen in numerous studies. In a large patient 
study (n=2024) assessing the clinical outcome after Q and NQMI 
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AGE OF NQMI PATIENTS 
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Figure No.20a: The age frequency of patients admitted with NQMI 1990-1993. 
EARLY CATHETERISATION, EARLY REVASCULARISATION 
& SMOKING vs AGE 
25 45 65 85 
AGE 
Figure No.20b: Multiple boxplots giving mean, standard deviation and range with 
statistical significance in the comparison of those who had early catheterisation, 
early revascularisation and smoked versus those who did not. 
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where the mean age of the patients with NQMI was 65 years, the 
in-hospital mortality for NQMI was shown to be significantly 
lower than QMI, only in patients older than 70 years. On the 
other hand, patients s70 years with NQMI do not have increased 
risk of death at one year c.ompared to those with QMI. (2l) 
In-hospital mortality may not differ much between older and 
younger NQMI patients; one-year mortality, however, is 
significantly higher in the elderly. (26 ) Not only is long-
term prognosis poorer, but NQMI patients >70 years are more 
likely to develop atrial fibrillation and cardiac failure, and 
less likely to receive thrombolytic therapy, cardiac 
catheterisation and coronary angiography. (26) 
The higher mortality rate in these patients suggests that this 
subgroup of NQMI may benefit from more aggressive treatment. 
Data from the TIMI IIIB Trial supports this contention as 
patients >65 years presenting with UAP or NQMI appeared to 
derive significant benefit from early catheterisation and 
revascularisation if anatomically feasible. (68) 
In the GSH Study, the mean age of 55.3 ± 10.7 years, appears 
to be younger than other studies. (2l) (68 ) (22 ) Although age 
was statistically associated with poorer inunediate outcome 
following NQMI and mortality (particularly overall total 
mortality), in multivariate analysis, age was not found to be 
a significant or independent risk factor for either outcome or 
cardiac deaths by 12 months. Interestingly, age was not 
related to the recurrence of post NQMI symptomatic ischaemia. 
There was a significantly lower early catheterisation rate in 
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patients ~70 years (p=0.001), however, no differences in 
revascularisation rates among those catheterised, were noted. 
b) Gender 
Myocardial infarction in women has a similar clinical 
presentation as in men with the exception of increased 
incidence of NQMI. Differences between the genders in the 
period after any type of infarct become more evident, 
particularly with regard to mortality. 
Analysis of causes of higher in-hospital mortality in women 
after acute MI has shown that women are older, have more 
systemic hypertension, higher cholesterol levels and seek 
medical care later. Yet, coronary angiography has shown 
similar vessel involvement and severity of coronary artery 
disease. (l49 ) A study analysing this showed that 5 variables 
predicted for higher in-hospital mortality in women: age >65 
years, diabetes mellitus, shock, NQMI and not undergoing 
cardiac catheterisation. It concluded that the difference in 
hospital mortality between men and women is due to a 
combination of pre- and in-hospital factors in women and not 
due to differences in disease severity. (149) 
With regard to morbidity, Marmor et al implicated obesity and 
female gender as predisposing factors for reinfarction in post 
NQMI patients. (l3S) 
In this GSH study, females formed about one-third of the total 
number of NQMI patients (Figure No. 21). Although the average 
age of females was higher (57.3 ± 9.7 years) as compared to 
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Figure No.21 a: Analysis of NQMI patients 1990-1993 by gender. 
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SMOKING, REVASCULARISATION vs GENDER 
REVASCULARISATION: 
II YES 
[lli] NO p<0.001 
SMOKING: 
• YES 
[I NO p=0.006 
TOTAL 
Figure No.21 b: Comparison of the proportion of males and females presenting with 
with NQMI who smoked and who underwent revascularisation and 
the levels of statistical significance. 
males (54.2 ± 11.1 years), this was not statistically 
significant. 
Revascularisation as noted in other studies was also gender-
dependent. In total, 12 women (18 . 8%) versus 51 men (43.6%) 
underwent PTCA or CABG (p<0 . 001). 
2) Habits: Smoking and Alcohol Intake 
a ) In this study, smokers were shown to be statistically related 
to irrnnediate outcome and recurrence of ischaemia, although 
they were not shown to be independent variables on multi-
variate analysis . Remarkably, this was an inverse or negative 
relationship, i.e. smoking was associated with a lower 
incidence of irrnnediate instability or recurrence of ischaemia . 
Such a relationship has been shown in studies with smokers 
having an improved survival after MI compared to non-
smokers. (l50) (l34 ) Reasons for this were studied in 2955 
patients with acute MI, by Kelly et al, who found that both 
early (1 month) (p<0.0001) and late (12 months) (p<0 . 01) 
mortality rates were lower in the smoking population. The 
fact that smokers as compared to non-smokers were 10 years 
younger (p<0.001), had lower prevalence of hypertension 
(p<0.01), CCF (p<0.00001), angina pectoris (p<0.01) and 
diabetes mellitus (p<0 . 0001), appeared to explain this. When 
adjusted for age and the other variables, they eliminated the 
differences in late mortality rates, suggesting that not 
smoking at the time of acute MI does not appear to be an 
independent predictor of death during the first year after 
acute MI. (l34 ) 
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In the GSH Study, the mean age of non-smokers was 61 . 4 ± 2.4 
years and of smokers 52.0 ± 1.8 years (p<0.0001). Differences 
may, however, not only be attributable to the younger age of 
smokers. Smokers have been shown to differ in their site of 
infarction compared to non-smokers. (l49 ) In addition, it is 
possible that smokers may have more sudden death or pre-
hospital admission deaths related to their acute MI and thus, 
only the survivors have selected themselves out. 
The GSH Study data reflects the use of tobacco in the South 
African society, not only with 65% of the total patients, but 
also in the breakdown by gender, with 52% of the females and 
72% of the males (p=0.007) admitted with NQMI, being smokers. 
b) In a similar way to smoking, alcohol use was related to a 
better inunediate outcome although by multivariate analysis it 
did not independently predict for this . Alcohol has 
cardioprotective effects and may beneficially alter serum 
lipoprotein concentrations and promote coronary-artery 
vasodilatation. This may account for the approximately 30% 
reduction in the relative risk of fatal and non-fatal coronary 
heart disease among moderate drinkers as compared with non-
drinkers, as shown in other studies. (l5l) However, this GSH 
Study took note of heavy users of alcohol of whom there was 
only a small number (7%). The beneficial effects of alcohol 
may be partly neutralised in the heavy drinkers by increases 
in blood pressure and sympathetic over-stimulation. (152) 
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3) Cardiac Catheterisation and Coronary Anqioqraphic Findings 
121 cardiac catheterisation procedures in total were 
performed, of which 93 were early (i.e. the indication 
occurring during the primary CCU admission and performed 
before discharge from hospital), giving an early 
catheterisation rate of 51.3%. Despite an expectant strategy 
of management with the option of active intervention, only 28 
late cardiac catheterisations were done (i.e. the indication 
occurring only after discharge from CCU). This late 
catheterisation rate of 16.1% is noticeably lower than the 43% 
in the conservative strategy group of TIMI II which had a 
similar stated expectant management protocol as in the GSH 
Study, except that patients were randomised to this group on 
admission and underwent exercise stress testing before 
discharge. (22 ) 
Complications related to catheterisation were unconunon, with 
no deaths, 2 aortic dissections (which were considered to be 
minor and successfully managed conservatively) and the 
requirement of one intra-aortic balloon pump following the 
provocation of ischaemic chest pain. This compares well with 
the previously reported 2-11% complication rate of coronary 
angiography performed early in NQMI. (75) 
The coronary angiographic findings showed that occlusive 
coronary artery disease was present in 58% of patients who 
were catheterised. The culprit vessel or infarct-related 
artery (IRA), defined as the vessel that was most likely 
responsible for the regional wall motion abnormality (taken as 
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Figure No.22: Frequency of involvement of coronary arteries as culprit vessels or infarct-ro;;. , 
arteries. (CIRC = circumflex, LAD = left anterior descending, RCA = right 
cor.artery, OM = obtuse marginal, MAIN = mainstem, DIAG = diagonal artery) 
angiogram, was found to be occluded in 60.2% of the early and 
32,1% of the late angiograms (p=0.009). (Occlusion was taken 
as functional occlusion or TIMI grades O or 1.) The left 
anterior descending arter (LAD), followed by the right 
coronary arter (RCA) and circumflex were most frequently 
involved (Figure No. 22). 
IRA occlusion rates in NQMI are significantly lower than in 
QMI as discussed in the Introduction: Differences between QMI 
and NQMI. Results of individual studies vary from 23%(45) to 
a 48%( 38 ) rate of IRA occlusion in NQMI. Extrapolation from 
nontransmural infarct studies show an occlusion rate of up to 
51%. (43 ) No study compares exactly with another because of 
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Figure No.23: Collateral vessels observed on analysis of early coronary angiograms. 
(Grades of collaterals as defined by Rentrop et al.(IBl) 
NQMI. Even so, the IRA occlusion rate in the GSH Study is 
high. Among patients who had been given thrombolytics, the 
rate was 20%,whereas the TIMI II Study showed an equivalent 
occlusion rate of 11 . 1% in patients with NQMI. (22 ) 
Collaterals in the GSH Study were present in 60.2% of all 
angiograms analysed: 60.4% of the early catheterisation and 
75% of the late catheterisation group of patients had 
collaterals (Figure No. 23). 
In an elaborate cross-sectional study by De Wood et al, of 
coronary angiographic findings soon after NQMI (341 patients) 
with catheterisation variably performed at <24 hours after 
peak symptoms, between 24-72 hours and between 72 hours and 7 
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days, total occlusion of the IRA was found in 26% (49 of 192), 
37% (35 of 94) and 42% (23 of 55) of the patients respectively 
(p<0.05) and a parallel increase in the presence of visible 
collateral vessels in 27, 34 and 42% respectively 
(p<0.05). <75 ) A similar parallel, but with higher figures of 
60% occlusion of IRA and 60% presence of collaterals, was 
noted in the GSH Study. It therefore appears that complete 
failure of perfusion is infrequent in NQMI. 
Eighty-four percent of all angiograms analysed showed that 
perfusion was maintained by either collateral vessels or a 
patent IRA. Seventy percent of those with IRA occlusion had 
collaterals. This compares with De Wood's report that 85% of 
patients with NQMI and an occluded coronary artery, had 
collateral flow to the area distal to the occlusion. (75 ) 
Another study showed residual perfusion in 79% of patients 
during the first 6 hours of NQMI. (40) 
The high IRA occlusion rate in the early catheterisation group 
of patients in the GSH Study may partly be explained by the 
timing of the angiography. Although indicated during the 
primary admission with the index NQMI to the CCU, and usually 
performed within 3-4 days, some of these procedures were only 
done into the second week of admission. De Wood's study 
showed an increasing total occlusion rate with time. A study 
by Gibson et al reported an occlusion rate of 53% in NQMI 
patients studied 11 ± 3 days after NQMI. (l44 ) Also the GSH 
Study was heterogeneous, including first NQMI and previous MI, . 
and not only asymptomatic patients, but those with ongoing or 
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recurrent chest pain/post-infarct angina in whom a higher 
occlusion rate may have been expected. 
Despite these possible explanations, the findings still seem 
to be at odds with the belief that NQMI are due to transient 
occlusion (equivalent to QMI with thrombolysis). However, 
even when total occlusion was observed, perfusion of the 
distal vessel was almost always maintained by collateral 
vessels. The occlusion is not the important issue, the 
collaterals are . The essential finding of this study is that 
some degree of perfusion (either antegrade or by collaterals) 
is present soon after NQMI, sufficient to limit the extent o~ 
the initial necrosis. 
The occlusion rate in patients in whom coronary angiography 
was indicated subsequent to discharge from CCU, had a lower 
rate of IRA occlusion. Unlike the two TIMI studies, where the 
majority of patients in the conservative strategy groups had 
what was considered failure of therapy and thereby reached the 
study endpoint soon after the index event (in TIMI IIIB the 
average time to catheterisation in the early conservative 
group was 7.1 days(GS)), the patients in the GSH Study who had 
late catheterisation, had this procedure much later, (an 
average of 2.2 months). It is possible that they therefore 
represented a different type of coronary artery disease. NQMI 
has been shown to occur in patients with either minimal 
stenosis with an unstable plaque or in severe stenoses in 
multiple vessels. (4l) In the latter, NQMI may simply 
represent a severe imbalance between supply and demand in the 
presence of a patent, but severely narrowed coronary 
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Figure No.24: Coronary artery disease by number of vessels involved on analysis 
of coronary angiograms. 
artery. ( 75 ) The more acute recurrences noted in the TIMI 
studies may reflect the acute unstable plaque complications, 
whereas the late catheterisation group of the GSH Study may be 
due to progressive coronary artery narrowing in patients with 
severe multiple vessel stenoses. Unfortunately, such a theory 
is difficult to prove as angiographic data of the late 
catheterisations were not evaluated. 
Assessment of coronary disease in the GSH patients showed that 
72% had double-vessel coronary artery disease or more (Figure 
No . 24) . (A similar assessment by Parikh et al of NQMI was 
52% . (l53)) The most frequently involved coronary artery was 
the left anterior descending artery (LAD). When culprit 
vessels were related to NQMI location, posterior and infero-
. ,. 
posterior NQMI were most frequently caused by circumflex, and 
inferior NQMI by right coronary artery lesions. In the TIMI 
II Study, the circumflex artery was classified as the infarct-
related artery, more commonly in patients who evolved NQMI 
than in those with QMI: 
NQMI 20.6% versus QMI 9.9% (p<O. 001) (22 ) 
Left ventricular angiographic findings revealed some wall 
motion abnormality in 85% of the GSH patients. Dyskinesia was 
noted in 6 patients and LV aneurysm in 4 patients. Bearing in 
mind the inclusion criteria in this study, it was inevitable 
that some patients undergoing cardiac catheterisation would 
have had previous MI. An angiographic study comparing NQMI 
and QMI showed that apical aneurysms occurred exclusively in 
patients with QMI. (49 ) Analysis of the 4 patients with LV 
aneurysm in the GSH Study revealed that they had all had 
previous MI. 
4) Thrombolysis and Incidence of NOMI 
Twenty-nine of the patients admitted to GSH over the 4 years, 
covered by this study, were given thrombolytic agents (28 
streptokinase and 1 TPA). From 1990 through to 1993, the 
percentage of NQMI patients receiving thrombolytics increased 
progressively (9.4%, 11,6%, 15.4% and 24.1% in each of the 
successive years) (Figure No. 25). 
Analysis of the annual number of acute MI eligible for 
inclusion in this study also shows a steady increase over this 
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Figure No.25: The number of patients given thrombolysis per total NQMI 
admissions per year. 
time period . A possible explanation for this may be the 
observed, more frequent use of thrombolytics. 
In a study by Goldberg on changes in the occurrence and 
prognosis of NQMI, in the Worcester metropolitan area (USA), 
it was shown that there was an increase in attack rates of 
NQMI from 46 per 100 000 in 1975 to 89 per 100 000 in 1981 
(p<0.001), a relative increase of 93% for NQMI, whereas the 
concurrent increase for QMI was 29%. (54 ) The increased 
frequency of NQMI was thought to be due to greater awareness 
of the diagnosis, patient education, better treatment of 
chronic IHD and modification of risk factors. (24 ) The 
increase in NQMI, especially those of small size, also 
reflected the improvement in sensitivity of MI detection. 
.. 
Using the standard ECG algorithm, no increase in attack rates 
of NQMI between 1970 and 1980 was shown. However, when CPK 
and CP~-MB were considered, NQMI (or rather recognition of 
these infarcts} had increased. (l54 > Now it is the therapeutic 
interventions (Beta-blockers, nitrates and anti-thrombotics) 
capable of limiting MI extension, that seem to be responsible 
for the true increasing incidence of NQMI. (l3} An alternative 
view of this, as proposed by Boden, is that thrombolytic 
therapy may be contributing to the expanding pool of patients 
with incomplete infarcts. (35 > 
The use of thrombolytics in NQMI patients may be criticised. 
The TIMI IIIB Trial assessing the effects of TPA in UAP and 
NQMI stated that the addition of a thrombolytic agent is not 
beneficial and may be harmful . (68 > This study, however, was 
limited to patients presenting with ST segment depression. 
The recommendation, therefore, cannot be applied to patients 
who present with ST segment elevation. The beneficial effect 
of thrombolytic in acute QMI is well proved, and even though 
ST segment elevation is not an invariable harbinger of 
subsequent Q waves (in the TIMI II Study, 29% of patients 
presenting with ST segment elevation and given TPA sustained 
NQMI( 22 )}, thrombolytics are strongly indicated. 
5) NOMI Location 
Location of NQMI, as determined by LV angiography, echo-
cardiography, nuclear imaging, ECG characteristics of ST 
segment elevation or T inversion and coronary angiography, in 
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Figure No.26: Location of NQMI as determined by ECG and LV imaging. 
(Anterior includes anterolateral and lateral; Inferior includes 
i nferoposteri or) 
diminishing order of preference or certainty, was (Figure 
No. 26): 
44% inferior, 40% anterior, 7% posterior and 9% non-
localisable. 
Localisation just on the basis of ECG showed that: 
34% were inferior, 40% anterior, 2% posterior and 22% non-
localisable. 
Although the "non-localisable by ECG" incidence at GSH 
approximates the rates in other studies (e.g. 19.3% in a study 
-
by Schechtman et a1( 146 )), the GSH incidence of anterior NQMI 
is lower than the 51-65% of these reports. (l46) (l47 ) 
The significance of this localisation is prognostic. (l55 ) 
Using data from the Multicenter Investigation of Limitation of 
Infarct Size (MILIS) (l46 ), Stone et al( 156 ) suggest that long-
term mortality among patients with anterior NQMI is more than 
twice the rate in inferior NQMI regardless of infarct size. 
The reason may be the major association between LV function 
and outcome after acute MI . Lower LV ejection fractions have 
been observed in anterior infarcts as opposed to inferior 
MI. ( 63 ) Hence the prognostic implication of infarct location 
remains valid even adjusted for infarct size or type of 
infarction. (34 ) It has however, been suggested that such data 
applies more specifically to the first infarct, (88 ) since in 
patients. with previous MI, a new infarct in any location, 
superimposed on extensive previous infarction, may be enough 
to tip the balance regarding LV function and poor prognosis. 
The study of Schechtman et al showed that infarct 
localisability implied increased risk. In the GSH study, non-
localisable infarcts (even when LBBB was excluded) did not 
show lower mortality. This is not entirely out of keeping 
with Schechtman's view that non-localised NQMI defines a 
heterogeneous population, and although in his study these 
patients were associated with a lower mortality, they could 
not be assigned to a low risk stratum( 146 ) (i.e. they may 
require an active interventional strategy). 
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Accumulated data does not favour the prognosis of inferior 
infarction over the anterior variety in QMI alone, but also in 
NQMI. Thus, inferior NQMI carries the "best survival". The 
Schechtman Study showed that the 1-year mortality was: 
inferior NQMI 2.8% versus anterior group 17%. (l46) 
Patients with inferior MI have a prognosis that is generally 
so good that even the issue of thrornbolytic therapy remains 
unsettled. ( 14 7) 
In the GSH Study, survival benefits could not be shown for 
inferiorly located NQMI. However, a statistically significan~ 
association was made with a lower incidence of early 
recurrence of symptomatic ischaemia. 
In view of the high post hospitalisation risks and increasing 
frequency of NQMI, it is important that characteristics such 
as infarct location distinguishing low and high risk patients 
be defined. Accurate risk stratification is the basis for 
differential, yet successful post-infarct management. 
2. ECG LOCALISATION OF NQMI 
The importance, especially with regard to prognosis, of 
establishing the site of location of a NQMI, has been discussed. 
In the previous section, the method of infarct localisation was by 
imaging of the LV invasively (e.g. LV angiography) or by echo-
cardiography or radionuclide scanning. Knowledge of the accuracy 
of ECG method of localisation is crucial before suggesting that 
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NQMI infarct location as determined by the 12-lead ECG, should be 
used as a major risk stratification factor. If the ECG method is 
found to be unreliable, use of the other modalities of localisation 
may be warranted. These would add to patient management costs and 
strengthen the argument in favour of invasive investigation/ 
intervention in all NQMI as being the most cost-effective method in 
the long-term. 
Difficulties exist in correlating pathological/anatomical location 
with ECG location as postmortem studies have shown a high incidence 
of multiple/previous infarcts in NQMI patients that have died after 
the acute event. (43 ) Furthermore, NQMI presenting in a relatively 
silent way and especially first time NQMI, which has been shown 
usually to be a small infarction with good LV function, is unlikely 
to cause death or come to postmortem. Therefore, in order to 
assess the value of 12-lead ECGs in localising NQMI, only first 
infarcts can be evaluated and other reliable methods of 
localisation for comparison, are required. For this, angiography 
has been used as a gold standard. Unfortunately, it too has 
drawbacks. As has been shown in this GSH Study, regional wall 
motion abnormality, seen on LV angiography and used to identify the 
location of the NQMI, is not seen in 15% of patients undergoing 
this investigation. This is not unexpected as it reflects small 
infarction that is not detectable by this method. This is not a 
significant problem, as these types of infarct probably do not 
affect prognosis. 
2A. ECG FOR LOCALISING NOMI TERRITORY 
Using the most severe electrocardiographic changes (as described 
previously in Study Methods, with ST segment elevation, and T wave 
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inversion in order of decreasing validity), NQMI locations as 
determined by ECG in this study were (in groups): 




In applying various epidemiological tests comparing 12-lead ECG and 
angiography (which is taken as being the gold standard despite 
minor reservations) for the localisation of only first time NQMI, 
the above-mentioned methods (ST segment elevation or T inversion) 
of localisation of infarcts that do not have Q waves show an 
overall positive predictive value of 61% for all NQMI infarcts or 
70% if only localisable NQMI are considered. (This positive 
predictive value of ECG varied, from 87% for the inferior group of 
NQMI, 63% for the anterior and 19% for ECG non-localisable 
infarcts.) The overall sensitivity for any of the specific 4 
groups of locations was 56% and the specificity 88% (i . e. 
specificity in defining the location within the total NQMI group 
and not NQMI versus non-NQMI). The sensitivity of 18% in 
diagnosing posterior MI, confirms previous findings that the ECG is 
an extremely non-specific localiser of posterior infarction. (lS?) 
2B. ECG FOR DETERMINING SPECIFIC NOMI LOCATION 
More specific localisation of infarction (within groups), e.g. 
inferior, infero-posterior, infero-lateral, anterior, anteroseptal, 
anterolateral, is described in ECG texts by Schamroth( 129 ) and 
Rowlands. (l)O) Various NQMI studies including the TIMI II Study 
determine this specific location by the extrapolation of the rigid 
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electrocardiographic criteria set down in the WHO categorisation 
(1959) and the Minnesota Code (1969), despite the fact that these 
criteria originally required 2 contiguous Q waves for the ECG 
diagnosis of acute infarction. (74 ) The Multicenter Post-Infarction 
Programme (MPIP) has set specific NQMI criteria for all locations 
(obviously except for posterior NQMI because ST - T changes in Vi -
v2 in the absence of a tall R wave are considered to be 
anterior). (74 ) The GSH Study shows that this more specific 
localisation of NQMI is of poor value. Although for infero-
posterior infarcts the ECG had a positive predictive value of 100% 
for angiographic evidence of this location of infarct, the 
sensitivity was very low at 7%. The overall, positive predictive 
value (for all specific locations) was 29% and specificity 25%. 
2C. SPECIFIC COMPONENTS OF ECG FOR LOCALISATION OF NOMI 
Fuchs investigated the accuracy of the 12-lead ECG in localising 
the site of the coronary artery narrowings as documented with 
single vessel disease on angiography. (l3l) Q waves, ST segment 
elevation and T wave inversion in leads I, aVL and Vi to V4 were 
all highly correlated with LAD disease and in leads II, III, aVF 
with right coronary artery (RCA) or circumflex disease (p<0.001). 
The location of new T wave inversions on the resting ECG during MI 
was found to be useful in predicting the site of coronary artery 
disease. ST segment depression did not accurately reflect the site 
of ischaemia because it occurred frequently both as a primary 
change due to "subendocardial" ischaemia or infarction and as a 
secondary "reciprocal change" as substantiated by animal 
experiments. Fuchs showed that: 
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Q waves identified the location of coronary artery disease in 
98% of cases 
ST elevation in 91% 
T inversion in 84% 
ST depression in 60% 
Review of his data shows that 37 of the 42 patients with ST segment 
depression had simultaneous ST elevation in other leads. Hence the 
statistics do not really assess the value of ST segment depression 
alone. Other studies have also shown the only moderate value of 
the ECG repolarisation changes. De Wood found that about 50% of 
patients with NQMI had anterior ST-T changes even though the LAD 
was not involved. (30) 
In analysing the GSH data, the overall (positive predictive) value 
of the specific components of the 12-lead ECG in predicting 
angiographic location of NQMI was: 
ST segment elevation 79% 
T wave inversion 50% 
ST segment depression 48% 
Thus, only ST segment elevation in either the anterior or inferior 
leads and possibly T wave inversion combined with ST segment 
depression (in the inferior leads only) have any value in 
localisation of NQMI by 12-lead ECG. ST segment depression alone 
is confirmed to be of no value. 
These figures are worse than in Fuch's Study( 131 ) which may have 
been expected to show poorer correlation given the interpatient 
197 
variability in coronary artery supply against which the ECG was 
being evaluated in his study. In addition, these results question 
the validity of studies (e.g. those assessing the mortality and 
NQMI location( 146 ) and sites of NQMI reinfarction( 93 )) where 
infarct location is determined by ST segment shifts (either way). 
Other methods of ECG analysis which emphasize the presence of 
diagnostic information outside the initial part of the QRS and/or 
signal processing using T waves and QRS voltages which have been 
shown to be useful in differentiating between Q and NQMI, (l58 ) have 
not yet been evaluated with regard to localisation . 
2D. SIGNIFICANCE OF COMPONENTS OF ECG IN NOMI 
Analysis of the ECGs of the patients included in the GSH NQMI Study 
showed: 
ST segment elevation in 97 patients (54%) 
ST segment depression in 52 patients (29%) 
T inversion (excluding ST segment 
elevation) in 62 patients (34%) 
ST segment depression (excluding 
T inversion) in 11 patients (6%) 
Other NQMI studies have shown that the prevalence of early ST 
segment elevation in NQMI is 30-43%. (41) (46) (35) 
Although ST-T changes, particularly ST depression, are inaccurate 
for locating NQMI, they may be useful for prognostic purposes. 
Ogwawa et al, who studied the ECGs obtained within 12 hours of the 
onset of NQMI, found that patients with ST segment depression in 
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any leads had a higher rate of multivessel disease and 
mortality. (137 ) Not only ST segments, but T waves provide very 
early and valuable prognostic information. In a study of 911 men 
with UAP or NQMI, the ECG during the initial hospitalisation was 
associated with the following prognosis: (82 ) 
Normal ECG: 8% 1 year risk of MI or death 
Isolated negative T waves: 14% (p<0.05) 
ST segment elevation: 16% {p<0.05) 
ST segment depression: 18% {p<0.01) 
Combination of ST elevation 
and depression: 26% {p<0.001) 
Changes noted in serial ECGs {not just on one-off ECG analysis as 
above) may be even more valuable. Using the Diltiazem Reinfarction 
Study database, it was shown that persistent ST segment depression 
appeared to be the marker for poor outcome. Patients with ST 
segment depression on admission and at discharge experienced a 22% 
1-year mortality. Those without ST segment depression had a 5.5% 
mortality. (l0 8 ) ST segment depression predicts more than just 
mortality. LV function has been noted to be significantly lower in 
NQMI patients with ST segment depression. (l8 ) This may be due to 
the higher frequency of previous MI in these patients( 159 ) and the 
reason for their higher mortality. 
In the GSH Study, widespread ST segment depression was associated 
with greater instability in the immediate outcome of the patients 
admitted with NQMI. No statistical association was noted in 
relation to recurrence of ischaemia or mortality, even on 
subanalysis (previous/first NQMI). 
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Figure No.27: The relative frequency of QMI versus NQMI admitted in 1990 and 1993 
and the gender distribution among NQMI. 
The greatest value of the ECG in risk stratification is therefore 
in determining the lower risk categories: viz. normal ECG, no ST 
segment depression and inferior location of NQMI as determined by 
ST segment elevation alone. 
3. COMMENTS ON GSB CCU STATISTICS 
3A. NOMI VERSUS QMI RATE 
The NQMI rate for the GSH CCU was determined for 1991 and 1993 and 
found to be 13% and 17% respectively (Figure No. 27). 
The reported rate of NQMI is very variable - from 29% in the 
Multicenter Diltiazem Post-Infarct Trial(SO) to 52% amongst 921 
patients with acute MI admitted to Goteborg Hospital in Sweden. (25) 
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Figure No.28: The total number of NQMI patients admitted to CCU per year 
Much of this variation is dependent on the time of the ECG used to 
classify acute MI into either Q or NQ. Most classifications in the 
past were done at the time of discharge from hospital, giving ample 
time for Q waves to evolve. It was assumed that Q waves appearing 
late were all part of the initial assault on the heart. This 
assumption may be incorrect. Other studies have used the admission 
ECG e.g. TIMI IIIB. TIMI II used the day 2 ECG since this was 
considered the time most physicians made clinical decisions 
concerning the necessity for catheterisation in stable 
patients. (22 ) 
In the GSH Study, all records from the CCU were studied 
retrospectively. These included the series of ECGs on admission to 
determine NQMI location and also the pre-hospital discharge ECG 
(provided that the patient remained stable in the interim) to 
exclude the presence of Q waves. If these had evolved late 
(without any evidence from history and ECG of recurrence of 
ischaemia), the patients were excluded from this study. In a study 
of patients with NQMI by Kleiger, analysis of the ECG at 50 ± 10 
hours after the acute event showed subsequent late evolution of ·Q 
waves in 14% of patients. (66 ) This group was more likely to 
exhibit ST segment elevation ~lnun and have higher CPK values. This 
progression to QMI appears to involve two different mechanisms: 
1. temporal lag in ECG; and 
2. actual extension. 
Another study in patients who received thrombolytics relating the 
timing of Q wave evolution to prognosis, showed that delayed Q 
development (>3 hours after starting thrombolytic therapy) was 
similar to NQMI with respect to lower CPK peak, better LVEF, less 
cardiac failure by discharge and lower in-hospital mortality than 
the QMI group. (73 ) Thus, excluding all those patients with even 
later Q wave extension in the GSH study, may have been incorrect. 
The numbers of patients thus affected was not determined. 
Eisenberg et al reported that progression of NQMI to QMI occurred 
only in 1.5% of patients treated with thrombolytic therapy in the 
period from 24 hours after the onset of the index event to hospital 
discharge. ( 73 ) 
3B. TIME DELAY: ONSET TO TREATMENT 
In a study determining the clinical features of patients given 
streptokinase and developing either NQMI or QMI which occurred in 
43% and 57% respectively, the time from symptoms to thrombolytic 
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treatment averaged less than 3 hours. (46 ) This contrasts quite 
markedly with the time delay, from onset of chest pain to arrival 
at hospital, which averages to 7.1 hours for the GSH patients. 
This does not include substantial delays which do occur in the 
emergency unit and before any treatment is given. This may also 
account for the relatively small number of NQMI patients, 
especially in the thrornbolytic era, as Q waves may have developed 
during this long time delay, well before any thrornbolytic is 
administered . Also of note is that the duration of chest pain on 
average is 4 hours and that this therefore is frequently no longer 
present by the time the patient arrives at hospital. 
In a review by Jenkins et al, of the causes of higher in-hospital 
mortality in women than in men after acute MI, the times (in the 
early 1990s in Missouri, USA) from chest pain to emergency room 
were 5.3 ± 12.7 hours for men and 8.9 ± 19.9 hours for women 
(p=0.03). (l49 ) In the GSH Study, this male to female ratio was 
reversed, with the time for men being 8.25 ± and 10.4 hours and for 
women being 4.73 + 3.3 hours (p=NS). There is no obvious medical 
or sociological reason for this. No statistical difference could 
be found between male and females in mortality or immediate post-
infarct course. One may, therefore speculate whether, in the GSH 
Study, the earlier arrival of women was somehow associated with the 
neutralisation of their usually worse outcome. 
The duration of admission of NQMI patients to the GSH CCU was for a 
mean of 3.66 days (range 1-11 days). This, with the 1993 total 
admission reaching 791 in a unit with just 10 beds, reflects a high 
turnover of patients. Despite this, the incidence of poor 
immediate outcome and in-hospital mortality was low. 
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3C. ASPIRIN 
Aspirin {daily, in antiplatelet/antithrombotic doses) was . being 
used by 14.9% of the GSH patients prior to the index MI. This 
contrasts with the TIMI IIIB Study where half the patients had 
taken aspirin within 24 hours of admission. {GS) Eighty-five 
percent of the patients in the GSH Study were discharged from CCU 
on aspirin which leaves a larger number than expected not on 
aspirin. The most frequent reason for this appeared to be aspirin 
intolerance. Aspirin use after infarction was associated 
statistically with, but was not an independent predictor of lower, 
early recurrence of symptomatic ischaemia. 
3D. BETA-BLOCKER 
Beta-blockers were used by 24% of patients before and by 70% after 
the primary admission with the NQMI. The relatively high pre-index 
MI use of beta-blockers reflects the 48% prevalence of hypertension 
and 50% of previous ischaemic heart disease in this study 
population. As shown in the section Results, the prior use of 
beta-blockers before the index NQMI did not influence significantly 
the outcome or subsequent mortality. Beta-blocker use after the 
index NQMI was statistically associated with a reduced total and 
cardiac mortality. 
Another interesting association is that of reduced total subsequent 
mortality in the group of patients who were unstable immediately 
post - infarct and given beta-blockers as compared to those not on 
this drug {p=0.014). No direct effect can be inferred from this as 
the tolerance of beta-blockers may be a marker for improved 
survival. 
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Review of the presence of pre-admission risks shows that the 
prevalence of certain factors is, as expected, higher in NQMI 
patients than is usually found in the general population e.g. 
hypertension in 48%, diabetes mellitus 19.3%, known previous 
hypercholesterolaemia 12%, but on admission 8%, and smoking 65%. 
3E. CPK ENZYME 
The median CPK value was 688. No significant difference was noted 
between the patients given thrombolytics and the group not given 
these agents. The results of CPK-MB isoenzyme testing were only 
available in 13 patients (7.2%). Although this is reportedly done 
on all admissions, the results did not appear to have been 
transcribed into the patients' notes. Since the diagnosis of NQMI 
required the triad of: symptoms, ECG changes and CPK elevation, 
the unavailability of the CPK-MB fraction, which is then mainly 
used in diagnostically doubtful cases, is unlikely to have changed 
much. It has been shown that CPK-MB isoenzyme may be elevated in 
the presence of normal serum CPK levels in NQMI. (142 ) Since the 
GSH chemical pathology laboratory does not give absolute 
measurements of MB isoenzyme and only calculates a fraction or 
percent of the total CPK if the latter is raised, these types of 
patients would not have been picked up at GSH. Furthermore, it has 
been reconunended that blood samples for CPK levels be taken at 4-6 
hour intervals for 18-24 hours, especially in NQMI( 88 ) because the 
rise may be low and short-lived( 33 ) because of early "washout". At 
GSH, CPK levels were done either at 12 or 24 hour intervals, thus 
non-sustained elevations in CPK would not have been detected and 
NQMI in such patients would have been missed. These patients would 
then have been labelled as having UAP. This too may account for 
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the somewhat lower proportion of NQMI among all infarcts at GSH as 
compared to other studies. 
4 . GSH CCU MANAGEMENT OF NQMI 
Criticism of the CCU management of NQMI, as an audit of the 
practised management strategies, is valuable. However, it must be 
constructive as the achievements of the CCU in managing unstable 
patients and maintaining an almost negligible in-hospital mortality 
are commendable. 
The routine management of patients admitted with the "acute 
coronary syndrome" (i.e. acute MI or UAP) follows generally 
accepted strategy, viz. bedrest and monitoring, oral aspirin, IV 
heparin and beta-blockers were possible. Heparin was administered 
in 89% of the patients. As to why this was not higher is unclear. 
Bleeding disorders may have accounted for a proportion of these. 
The protocol itself, of the administration of heparin, can also be 
criticised. The failure to monitor anticoagulation levels achieved 
by the standard dose of 25 OOOu of heparin per 24 hours and failure 
to give a bolus dose of heparin on admission as was the practice 
during the 4 years of this study, may have resulted in poor 
antithrombotic activity in all the patients in the first few hours 
after admission probably the most unstable and crucial time period, 
and in some of the patients in the succeeding 48-72 hours. This 
may have resulted in the extension of the acute MI. Bearing in 
mind the pivotal role of platelet aggregation in the pathogenesis 
of NQMI, the new antiplatelet agents may have a significant role 
during this initial time period. (79 > 
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In the TIMI IIIB Trial studying patients with UAP and NQMI, all 
patients were given beta-blockers (metoprolol 50mg bd), a calcium 
antagonist (diltiazem 30mg 6 hourly) and a long-acting nitrate 
(isosorbide dinitrate ~lOmg 8 hourly). (68 ) This is unlike the GSH 
practice where only beta-blockers are given routinely. Since the 
practice of medicine at GSH is guided by the principles of 
evidence-based medicine, calcium antagonists are generally not used 
in acute infarct patients. None of this study's patients were 
given diltiazem. The result of giving nitrates and diltiazem to 
all patients in the TIMI IIIB Study may have been to mask some 
initially unstable patients. Alternatively in the GSH Study, since 
these drugs were not routinely given, it is more likely that 
patients with ongoing ischaemia became evident in hospital, during 
the primary admission, and were investigated. Thus the group of 
patients who ended up being treated conservatively, were completely 
"unmasked", and hence, of lower risk. Yet, with regard to 
recurrence of ischaemia, this lower risk, conservatively managed 
group was shown to have a result worse than the actively intervened 
patients. 
The major criticism of the CCU management is the minimal use of the 
exercise stress test (EST) in patients admitted with NQMI. This 
test is often considered to be a routine pre-discharge procedure 
and an important method of risk-stratifying the potentially 
unstable group of NQMI patients. Only 9 of the GSH patients 
underwent EST, which was positive in 6. The use also, in the 
majority of these patients, was not to assess risk and thus 
determine subsequent conservative/active management, but to 
establish whether revascularisation was to be recommended in 
patients who had already undergone active investigation with 
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majority of these patients, was not to assess risk and thus 
determine subsequent conservative/active management, but to 
establish whether revascularisation was to be recommended in 
patients who had already undergone active investigation with 
cardiac catheterisation with equivocal stenoses on angiography. 
EST in the group managed conservatively may have altered the final 
outcome in this GSH Study, giving no advantage with regard to 
reduced recurrence of ischaemia to the initially active strategy 
and therefore a result similar to the two TIMI studies discussed 
previously. Thus, in the GSH Study, patients retrospectively 
categorised as having received conservative treatment, were truly 
managed conservatively. 
5. LIMITATIONS/SHORTCOMINGS OF THE STUDY 
The most obvious limitation of this study and therefore, of its 
conclusions is the fact that it is a retrospective/observational 
analysis . However, even this type of review has some value, 
particularly as an audit of management practice and as grounds on 
which a prospective trial could be based. 
A shortcoming may be the patient population studied. Some 
selection bias inevitably took place for admission to the CCU 
rather than to the medical wards. Thus, this group of patients 
included in this study may not be truly representative of the 
entire spectrum of NQMI patients. Even though these study patients 
may have been relatively more unstable, the in-hospital mortality 
rate remained low. Deaths prior to admission to CCU may have been 
due to NQMI, but were excluded from this analysis possibly also 
making this in-hospital mortality rate falsely low. Any 
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prospective study on NQMI patients, in order to reflect the entire 
heterogeneous group, should therefore include all such patients 
admitted to the hospital. 
Including all patients admitted to hospital with NQMI in a study 
may overcome the other shortcoming of the total number of patients 
in the study. To achieve some statistical significance, sufficient 
patients had to be included in this analysis. This could only be 
done by including patients over the relatively long period of 4 
years. This poses difficulties with the rapidly changing practices 
and advances in management of modern cardiology. 
Results and conclusions of a study such as this are limited by the 
non-uniformity within groups compared. The various or non-uniform 
indications for active intervention limit the interpretation of 
this strategy being generally recommended. Perhaps uniformity in 
a group of patients as heterogeneous as NQMI is an impossible goal. 
6. STUDY 
It has been said that until it is broadly accepted that low-risk 
subgroups can be prospectively and non-invasively identified, the 
suggestion that all patients with NQMI should undergo coronary 
angiography will retain wide acceptance. (l46} 
The results of this retrospective GSH Study, justify the conduction 
of a randomised study. Such randomised clinical trials are 
particularly important when the plausible effect is only moderate 
e.g. 15-25% reduction in the risk of developing a major adverse 
outcome such as death or reinfarction in NQMI patients. (l04} 
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Since the incidence of subsequent coronary events is high among 
NQMI patients, an opportunity is provided for objective assessment 
of the efficacy of various treatment. Moreover, studying a high 
risk subset such as this has the advantage of being able to show 
benefits after a relatively short time period and having clearly 
identifiable endpoints. 
Such a proposed study would be similar to the TIMI IIIB i.e. a 
comparison not of invasive versus non-invasive, but rather of 2 
management strategies: routine early coronary angiography and 
revascularisation versus conservative treatment with angiography 
available if medical management fails. 
By means of statistical formulas, the number of patients needed for 
such a study on NQMI can be calculated based on this study's 
retrospective findings of a 37% occurrence of recurrent ischaemia 
in the active strategy group versus a 62% occurrence in the 
conservatively managed patients (as summarised in Figure No. 18). 
The total number of patients needed in a 1:1 randomised study to 
show a risk reduction of 25% with various significance/confidence 
levels and statistical powers, is as follows: (l60) 
Confidence Power Sample Size Test 
90% 80% 110 
95% 80% 136 
99% 80% 176 
95% 90% 176 
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Obviously, larger trials would be needed to show survival benefit 
as the mortality rate is low in NQMI patients. 
A prospective study looking precisely at the question of NQMI 
management, in a way similar to the GSH review, has been embarked 
on. The Veterans Affairs Non-Q Wave Infarction Strategies In-
Hospital (VANQWISH) Trial is a prospective, multicentre clinical 
trial which is testing invasive versus conservative strategy 
(cardiac catheterisation only for post MI angina or significant 
inducible ischaemia) in the early post-NQMI period, the purpose of 
which will be to compare the effects of these management strategies 
on long-term (minimum follow-up: 1 year; median follow-up 2.4 
years) clinical outcome (all-cause mortality; recurrent non-fatal 
infarction). (lOS) Over 900 patients are to be recruited. The Data 
Safety and Monitoring Board has recently (August 1995) approved 
that the study, begun in May 1993, be continued until completion. 
This may indicate that on the basis of cumulative data available on 
over 800 patients so far recruited, there may be no significant 
differences, although to date, there appear to be more events in 
the invasive arm. Interestingly, only approximately 30% of the 
patients who have been randomised to the conservative arm have 
undergone a protocol-eligible cardiac catheterisation (personal 
conununication: Boden - Chairman VANQWISH Trial). This is in 
contrast to the TIMI IIIB NQMI subset which showed that high 
percentage of conservatively managed patients (64% by 6 weeks) had 
crossed over to cardiac catheterisation and revascularisation. (68) 
An abstract submitted to the 68th Scientific Sessions of the 
American Heart Association in November 1995 by the VANQWISH Trial 
investigators, analysing 726 patients, reveals clinical variables 
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similar to the GSH Study: 40% of the NQMI patients have ECG ST 
segment depression, 32% had anterior NQMI, 44% prior MI and 13% 
received thrombolysis. The result of the VANQWISH Study is 
therefore eagerly awaited. A more limited prospective single 
centre study may also give valuable information. 
7. RECOMMENDATION: CONSERVATIVE VERSUS INVASIVE 
The results of the GSH Study, albeit a retrospective one, appear to 
justify a more aggressive diagnostic approach. With this may be 
included a careful non-invasive search for ischaemia and often 
coronary angiography even in the asymptomatic, but selected 
patient. 
1) Medical therapy: 
2) 
In patients with NQMI, the only therapy of proven benefit for 
short-term cardioprotection is aspirin and perhaps 
diltiazem. <62 ) 
Stress Testing: 
Exercise stress testing should be performed at discharge and 
should probably be symptom limited. Since the recurrence rate 
early post-MI is so high in the first two months, it is not 
appropriate to delay the EST until a follow-up clinic 
appointment 4-6 weeks after the index NQMI. Symptom-limited 
exercise tests performed before hospital discharge after 
uncomplicated MI have been shown to provide significantly 
greater cardiovascular stress than do low level tests and are 
associated with an ischaemic response nearly twice as 
frequently, and are safe. (ll 6) (The prognostic significance 
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of a positive response at higher work loads has not been 
identified.) EST use can also be selective. It has been 
shown to be particularly useful in patients with clinical 
markers of higher risk (e.g. pulmonary congestion) and of a 
more limited role in uncomplicated NQMI. (ll9) 
3) Alternative non-invasive tests: 
4) 
In those patients who have not had recurrence of ischaemic 
symptoms or angina at low levels of activity (i.e. where there 
has been no conventional indication for cardiac catheterisa-
tion), or who are unable to exercise additional means of risr 
identification may be required to predict future prognosis a , 
intervene if the risk is considered unacceptable. Such tests 
include: thallium and sestamibi exercise tests and dobutamine 
stress echocardiography. Gibson et al suggest that 
asymptomatic patients who are then shown by these tests to 
have residual myocardial ischaemia especially in the area 
supplied by the LAD, should be considered for early coronary 
angiography. (l44 ) However, no prospective study has yet 
demonstrated a reduction in the risk of MI. 
There may be uncertainty regarding positive results. On the 
other hand, patients with negative maximum thallium exercise 
tests are, according to a prospective study, at very low risk 
of cardiac events in the 12-15 months post NQMI. (161) 
Invasive investigation and revascularisation: 
According to guidelines for early management of patients with 
acute MI set out by the American College of Cardiology/ 
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American Heart Association Task Force, NQMI should be 
identified and studied during days 2-5 (phase 2) after 
admission. (162 ) Patients with jeopardised myocardium must be 
identified for revascularisation to try to improve survival. 
The problem with this is that any recommendation in favour of 
catheterisation of asymptomatic post-infarction patients 
assumes that prophylactic revascularisation will prolong life 
or prevent reinfarction. The evidence-based policy followed 
by GSH, is that in QMI and angina pectoris patients, (l63 ) if a 
lesion is demonstrated, action is indicated only if symptoms 
occur. This should probably apply to NQMI also. 
Routine cardiac catheterisation after 18-48 hours of anti-
thrombotic therapy has a number of advantages: (68 ) 
rapid establishment of definitive anatomic diagnosis 
the ability to stratify prognosis 
a therapeutic plan can be developed. 
One would therefore, be able to identify rapidly, either 
patients without critical obstruction who will not need 
revascularisation and should have a favourable prognosis, or 
patients with left mainstem or triple-vessel disease with LV 
dysfunction, in whom CABG has been shown to prolong 
life. (164 ) (122 ) Revascularisation of other patients with 
critical stenosis, while not necessarily life-prolonging, may 
reduce the need for an anti-anginal medication and early re-
hospitalisation. Thus, the definitive diagnosis and often 
definitive therapy, can be completed within several days of 
admission. 
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Routine catheterisation must be balanced against the 
following: 
NQMI has a more unstable pathology which is dynamically 
changing. The angiographic result is therefore, not 
definitive. 
Clinical features and EST should be able to identify most 
patients with prognostically important residual ischaemia. 
Many unnecessary revascularisation procedures may be 
performed if the cardiac catheterisation is used alone to 
determine the need for myocardial revascularisation. 
NQMI is a highly heterogeneous group with only some having 
an "incomplete infarction". A large minority (30-40%) 
have a very good prognosis subsequently. (62 ) 
5) Conservative treatment: 
Since trials, such as the TIMI IIIB, showed that the more 
conservative approach is equally acceptable and does not 
increase the risk of death, and results of definitive 
prospective studies(lOS) are not yet available, the 
conservative strategy cannot be regarded as incorrect 
management. However, it requires careful observation of the 
patient, identification of patients with residual ischaemia 
and the ability to go on to invasive management if medical 
treatment fails. This conservative strategy may require more 
medication, non-invasive testing and hospital admission. (68) 
Thus, in effect, it is not conservative treatment, but rather 
expectant. A substantial group of the GSH conservatively 
managed patients remained perfectly stable. This raises the 
issue of the cost/benefit ratio. If aggressive/interventional 
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6) 
management was the general routine policy, these patients 
would have all be catheterised, with cost, possible morbidity 
and complications. 
Final recommendations; NQMI management policy: <165 > 
a) Antiplatelet therapy (and possibly short-term diltiazem) as 
soon as the diagnosis is established (probably excluding the 
patients with LV dysfunction). 
b) Patients who develop early recurrent ischaemia on therapy 
(i.e. angina with associated ST-T wave changes) should undergo 
prompt cardiac catheterisation and myocardial 
revascularisation. 
c) Patients with an entirely uncomplicated hospital course and 
who are asymptomatic require pre-discharge risk 
stratification. If they cannot be stratified by clinical or 
ECG characteristics (e.g~ non-inferior NQMI), EST is required 
(preferably with an imaging study). If a high risk is shown, 
pre-discharge cardiac catheterisation is required. 
The important consideration in management of NQMI is that this 
group is highly heterogeneous. The separation into Q and NQ 
following first MI may be artificial as studies have shown no real 
differences in mortality and reinfarction (in the longer term). 
Reconunendations with regard to cardiac catheterisation and EST may 
at face value apply equally to both Q and NQMI patients, and this 
is regardless of whether patients receive thrombolytic therapy. (63 ) 
However, even this generalisation is "dangerous" as NQ myocardial 
infarcts form too heterogeneous a group to attempt to characterise, 




* NQMI managed at Groote Schuur Hospital Coronary Care Unit 
showed low mortality rates (particularly early in-hospital). 
* Mortality is linked to recurrence of ischaemia requiring early 
re-admission. 
* There is a high recurrence of ischaernic events after NQMI with 
the majority occurring within 3 months. 
* If no recurrence of ischaemia occurs by 3 months, the 
likelihood of later recurrence is small. 
* Retrospective analysis appears to relate active interventional 
management with a reduction in overall recurrence of 
symptomatic ischaemia. 
* NQMI not localised in the inferior territory is associated 
with higher risk. 
* ECG is of limited use in localising NQMI - ST segment 
depression is confirmed to have no localising value. 
These findings may therefore, justify further risk stratification 
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